<SEC-DOCUMENT>0001104659-23-022869.txt : 20230216
<SEC-HEADER>0001104659-23-022869.hdr.sgml : 20230216
<ACCEPTANCE-DATETIME>20230216170526
ACCESSION NUMBER:		0001104659-23-022869
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20230216
DATE AS OF CHANGE:		20230216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267891
		FILM NUMBER:		23639275

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm236507-3_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html>
  <head>
    <title>tm236507-3_424b3 - none - 8.6875339s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Filed pursuant to Rule&#160;424(b)(3)</font>&#8203;</div>
        <div style="margin-top:2.1pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Registration No. 333-267891</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SUPPLEMENT DATED FEBRUARY 16, 2023 </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(TO PROXY STATEMENT/PROSPECTUS DATED JANUARY 19, 2023)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;margin-left:20pt;margin-top:14pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="height:68pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:202pt;">
              <div style="position:relative;text-align:center;">
                <img src="lg_sesenbio-4c.jpg" alt="[MISSING IMAGE: lg_sesenbio-4c.jpg]" height="70" width="118" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:202pt;">
              <div style="position:relative;text-align:center;">
                <img src="lg_carismatherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_carismatherapeutics-4c.jpg]" height="64" width="240" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.1pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AMENDED MERGER PROPOSAL</font>
          <br >
          <font style="letter-spacing:-0.2pt;">YOUR VOTE IS VERY IMPORTANT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the stockholders of Sesen Bio, Inc. and CARISMA Therapeutics Inc.: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On or about January&#160;24, 2023, Sesen Bio, Inc., or Sesen Bio, mailed you a proxy statement/prospectus dated January&#160;19, 2023, or the proxy statement/prospectus, relating to a special meeting of Sesen Bio stockholders, or the Sesen Bio special meeting, to be held at 10:00&#160;a.m., Eastern Time, on Thursday, March&#160;2, 2023, unless postponed or adjourned to a later date, for the purpose of considering and voting upon the matters set forth in the Notice of Special Meeting of Stockholders in the proxy statement/prospectus. The Sesen Bio special meeting will be a virtual meeting held exclusively via live webcast. Sesen Bio stockholders will be able to attend the meeting online, vote during the meeting until polls are closed, and submit questions during the meeting by registering in advance at www.proxydocs.com/SESN. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since the mailing of the proxy statement/prospectus, Sesen Bio, CARISMA Therapeutics Inc., or Carisma, and Seahawk Merger Sub, Inc., or Merger Sub, entered into the Second Amendment to Agreement and Plan of Merger and Reorganization dated as of February&#160;13, 2023, or the Second Merger Agreement Amendment, which amends the Agreement and Plan of Merger and Reorganization dated as of September&#160;20, 2022, or the Original Merger Agreement, as amended by the First Amendment thereto dated as of December&#160;29, 2022, or the First Merger Agreement Amendment, which is referred to herein collectively with the Original Merger Agreement and the First Merger Agreement Amendment as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio, which transaction is referred to herein as the merger. We refer to the surviving corporation following the merger as the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is furnishing this supplement to the proxy statement/prospectus, or the supplement, to provide supplemental disclosures regarding the Second Merger Agreement Amendment and certain related matters. The Second Merger Agreement Amendment, among other things, (i)&#160;decreases the minimum net cash of Sesen Bio required at the closing of the merger from $75.0&#160;million to $70.0&#160;million, (ii)&#160;increases the amount of the special cash dividend expected to be paid to Sesen Bio stockholders from approximately $70.0&#160;million to $75.0&#160;million, subject to the terms and conditions set forth in the Merger Agreement, and (iii)&#160;includes Michael Torok, an approximately 4.1% stockholder of Sesen Bio, as the Sesen Bio designee to the combined company&#8217;s board of directors in place of Dr.&#160;Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors. The special cash dividend remains contingent upon Sesen Bio stockholder approval of Proposal Nos. 1 and 2, as described in the proxy statement/prospectus, and the closing of the merger following satisfaction or waiver of the applicable conditions to the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, on February&#160;13, 2023, as part of the Second Merger Agreement Amendment, the parties thereto amended and restated the Contingent Value Rights Agreement, or the amended CVR agreement, that Sesen Bio will enter into at or prior to the effective time of the merger. The amended CVR agreement extends the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, would be paid to holders of contingent value rights, or CVRs, from December&#160;31, 2023 to March&#160;31, 2027. The amended CVR agreement does not alter the contractual right of CVR holders to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., or collectively, Roche, if any, pursuant to the Asset Purchase Agreement by and among Sesen Bio and Roche, or the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement. </font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the execution of the Second Merger Agreement Amendment, on February&#160;13, 2023, Sesen Bio and Carisma entered into a voting and support agreement with Bradley L. Radoff and Michael Torok, or, together with their affiliates, the Investor Group, pursuant to which the Investor Group agreed to vote their shares of Sesen Bio common stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and all related proposals. As of January&#160;17, 2023, the record date for the Sesen Bio special meeting, the Investor Group beneficially owned approximately 8.5% of the outstanding shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, each outstanding share of Carisma capital stock (including shares of Carisma common stock issued in connection with the Carisma pre-closing financing) will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 172 of the proxy statement/prospectus, as supplemented by this supplement. Also at the effective time of the merger, each outstanding option to purchase shares of Carisma common stock will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the exchange ratio. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 40.0154 shares of Sesen Bio common stock for each share of Carisma capital stock, which exchange ratio does not give effect to the proposed reverse stock split described in the proxy statement/prospectus. The final exchange ratio is subject to adjustment prior to the closing of the merger based on Sesen Bio&#8217;s net cash at the closing of the merger and the aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each share of Sesen Bio common stock, each option to purchase Sesen Bio common stock and each Sesen Bio restricted stock unit that is outstanding at the effective time of the merger will remain outstanding in accordance with its terms and such shares of common stock, options and restricted stock&#160;units, subject to the proposed reverse stock split, will be unaffected by the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 24.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, are expected to own approximately 75.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of closing of the merger being at least $70.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After careful consideration, each of the Sesen Bio and Carisma boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the merger. The Sesen Bio board of directors has approved the proposals described in the proxy statement/prospectus and unanimously recommends that its stockholders vote &#8220;FOR&#8221; the proposals described in the proxy statement/prospectus, as supplemented by this supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">More information about Sesen Bio, Carisma, the Merger Agreement and the transactions contemplated thereby and the proposals being considered at the Sesen Bio special meeting is contained in the proxy statement/prospectus. Sesen Bio urges you to read the proxy statement/prospectus carefully and in its entirety. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER THE SECTION ENTITLED &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 26 OF THE PROXY STATEMENT/PROSPECTUS, AS SUPPLEMENTED BY THIS SUPPLEMENT BEGINNING ON PAGE S-9.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Your vote is important. If you have already submitted a proxy, you may still change your vote and revoke your proxy by: (1)&#160;submitting a new proxy via the internet or telephone by following the instructions on your proxy card that was previously mailed to you with the proxy statement/prospectus; (2)&#160;signing another proxy card and arranging for delivery of that proxy card by mail by 11:59&#160;p.m., Eastern Time, the day before the Sesen Bio special meeting; (3)&#160;giving Sesen Bio&#8217;s Corporate Secretary written notice before the Sesen Bio special meeting that you want to revoke your proxy; or (4)&#160;voting during the Sesen Bio special meeting. Your attendance at the Sesen Bio special meeting alone will not revoke a previously submitted proxy. Sesen Bio will count your vote in accordance with the last instruction Sesen Bio receives from you prior to the closing of the polls, whether your instruction is received by internet, telephone, mail, or at the Sesen Bio special meeting.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma are excited about the opportunities the proposed merger brings to both Sesen Bio&#8217;s and Carisma&#8217;s stockholders, and thank you for your consideration and continued support. </font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:40pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">
              <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">
              <font style="letter-spacing:0.2pt;">Steven Kelly </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;">
              <font style="letter-spacing:0.2pt;">Sesen Bio, Inc. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;">
              <font style="letter-spacing:0.2pt;">CARISMA Therapeutics Inc.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this supplement. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">This supplement is dated February&#160;16, 2023, and is first being mailed to Sesen Bio stockholders on or about February&#160;17, 2023.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXNO">&#8203;</a><a name="tRTAI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPLANATORY NOTE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This supplement to the proxy statement/prospectus of Sesen Bio, Inc., dated January&#160;19, 2023, which was first mailed on or about January&#160;24, 2023 to Sesen Bio stockholders who were record holders of Sesen Bio common stock as of January&#160;17, 2023, is being provided to you because the parties thereto have entered into the Second Amendment to Agreement and Plan of Merger and Reorganization dated as of February&#160;13, 2023, or the Second Merger Agreement Amendment, by and among Sesen Bio, Inc., CARISMA Therapeutics, Inc., and Seahawk Merger Sub, Inc. The Second Merger Agreement Amendment, among other things (i)&#160;decreases the minimum net cash of Sesen Bio required at the closing of the merger from $75.0&#160;million to $70.0&#160;million, (ii)&#160;increases the amount of the special cash dividend expected to be paid to Sesen Bio stockholders from approximately $70.0&#160;million to $75.0&#160;million, subject to the terms and conditions set forth in the Merger Agreement, and (iii)&#160;includes Michael Torok, an approximately 4.1% stockholder of Sesen Bio, as the Sesen Bio designee to the combined company&#8217;s board of directors in place of Dr.&#160;Thomas&#160;R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors. In addition, on February&#160;13, 2023, as part of the Second Merger Agreement Amendment, the parties thereto amended and restated the Contingent Value Rights Agreement, or the amended CVR agreement, that Sesen Bio will enter into at or prior to the effective time of the merger. The amended CVR agreement extends the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, would be paid to holders of contingent value rights, or CVRs, from December&#160;31, 2023 to March&#160;31, 2027. In connection with the execution of the Second Merger Agreement Amendment, on February&#160;13, 2023, Sesen Bio and Carisma entered into a voting and support agreement, or the Investor Group support agreement, with Bradley L. Radoff and Michael Torok or, together with their respective affiliates, the Investor Group, pursuant to which the Investor Group agreed to vote their shares of Sesen Bio common stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and all related proposals. As of January&#160;17, 2023, the record date for the Sesen Bio special meeting, the Investor Group beneficially owned approximately 8.5% of the outstanding shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This supplement and the annexes hereto should be read in conjunction with the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, the annexes to the proxy statement/prospectus and the documents referred to in the proxy statement/prospectus and this supplement, each of which should be read in its entirety. </font></div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise described in this supplement and the annexes to this supplement, the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, the annexes to the proxy statement/prospectus and the documents referred to in the proxy statement/prospectus and this supplement, are not otherwise modified, supplemented or amended. To the extent that information included in this supplement differs from, updates or conflicts with information included in the proxy statement/prospectus, the information in this supplement shall supersede or supplement the information in the proxy statement/prospectus. </font></div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Capitalized terms used and not defined in this supplement have the meanings set forth in the proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This supplement revises all of the references in the proxy statement/prospectus to the &#8220;merger agreement&#8221; to refer to the Agreement and Plan of Merger and Reorganization dated as of September&#160;20, 2022, as amended by the First Amendment to Agreement and Plan of Merger and Reorganization dated as of December&#160;29, 2022, and as further amended by the Second Merger Agreement Amendment. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">REFERENCES TO ADDITIONAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This supplement incorporates important business and financial information about Sesen Bio that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission, or the SEC, website (www.sec.gov) or upon your written or oral request by contacting the Corporate Secretary of Sesen Bio, Inc., 245 First Street, Suite 1800, Cambridge, MA 02142 or by calling (617) 444-8550. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To ensure timely delivery of these documents, any request should be made no later than February&#160;23, 2023 to receive them before the Sesen Bio special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For additional details about where you can find information about Sesen Bio, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Where You Can Find More Information</font><font style="letter-spacing:0.2pt;">&#8221; on page <a href="#tWYCF">S-42</a> of this supplement.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:626.34pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXNO"><font style="letter-spacing:0.2pt;">EXPLANATORY NOTE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXNO">i</a></font> <a href="#tEXNO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.4pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRTAI"><font style="letter-spacing:0.2pt;">REFERENCES TO ADDITIONAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.4pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.4pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRTAI">i</a></font> <a href="#tRTAI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.4pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTQA"><font style="letter-spacing:0.2pt;">UPDATE TO QUESTIONS AND ANSWERS ABOUT THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.4pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.4pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTQA">S-1</a></font> <a href="#tUTQA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTPS"><font style="letter-spacing:0.2pt;">UPDATE TO PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTPS">S-5</a></font> <a href="#tUTPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tTHME"><font style="letter-spacing:0.2pt;">The Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHME">S-5</a></font> <a href="#tTHME"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tOOTM"><font style="letter-spacing:0.2pt;">Overview of the Merger Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOOTM">S-5</a></font> <a href="#tOOTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tVASA"><font style="letter-spacing:0.2pt;">Voting and Support Agreements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tVASA">S-6</a></font> <a href="#tVASA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMFTM"><font style="letter-spacing:0.2pt;">Management Following the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMFTM">S-7</a></font> <a href="#tMFTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tIOSB"><font style="letter-spacing:0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.39pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOSB">S-7</a></font> <a href="#tIOSB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">Material U.S. Federal Income Tax Consequences of Receipt of the Special Cash Dividend </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">S-7</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLRTT"><font style="letter-spacing:0.2pt;">Litigation Related to the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLRTT">S-8</a></font> <a href="#tLRTT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTMP"><font style="letter-spacing:0.2pt;">UPDATE TO MARKET PRICE AND DIVIDEND INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTMP">S-9</a></font> <a href="#tUTMP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTRF"><font style="letter-spacing:0.2pt;">UPDATE TO RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTRF">S-10</a></font> <a href="#tUTRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTTS"><font style="letter-spacing:0.2pt;">UPDATE TO THE SPECIAL MEETING OF SESEN BIO STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTTS">S-14</a></font> <a href="#tUTTS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTTM"><font style="letter-spacing:0.2pt;">UPDATE TO THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.38pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTTM">S-15</a></font> <a href="#tUTTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tBOTM"><font style="letter-spacing:0.2pt;">Background of the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBOTM">S-15</a></font> <a href="#tBOTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tOOSB"><font style="letter-spacing:0.2pt;">Opinion of Sesen Bio&#8217;s Financial Advisor </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOOSB">S-18</a></font> <a href="#tOOSB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tIOSB1"><font style="letter-spacing:0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOSB1">S-18</a></font> <a href="#tIOSB1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMCAE"><font style="letter-spacing:0.2pt;">Merger Consideration and Exchange Ratio </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMCAE">S-18</a></font> <a href="#tMCAE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tAAT"><font style="letter-spacing:0.2pt;">Anticipated Accounting Treatment </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tAAT">S-19</a></font> <a href="#tAAT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLRTT1"><font style="letter-spacing:0.2pt;">Litigation Related to the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.37pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLRTT1">S-19</a></font> <a href="#tLRTT1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTTM1"><font style="letter-spacing:0.2pt;">UPDATE TO THE MERGER AGREEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTTM1">S-21</a></font> <a href="#tUTTM1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tEXRA"><font style="letter-spacing:0.2pt;">Exchange Ratio </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXRA">S-21</a></font> <a href="#tEXRA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tDAOO"><font style="letter-spacing:0.2pt;">Directors and Officers of Sesen Bio Following the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDAOO">S-21</a></font> <a href="#tDAOO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tPRDI"><font style="letter-spacing:0.2pt;">Pre-Closing Dividend </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRDI">S-21</a></font> <a href="#tPRDI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTAR"><font style="letter-spacing:0.2pt;">UPDATE TO AGREEMENTS RELATED TO THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTAR">S-23</a></font> <a href="#tUTAR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCVAG"><font style="letter-spacing:0.2pt;">CVR Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.36pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCVAG">S-23</a></font> <a href="#tCVAG"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tVASA1"><font style="letter-spacing:0.2pt;">Voting and Support Agreements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tVASA1">S-23</a></font> <a href="#tVASA1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.3pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tUTMB"><font style="letter-spacing:0.2pt;">UPDATE TO MATTERS BEING SUBMITTED TO A VOTE OF SESEN BIO </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.3pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTMB">S-25</a></font> <a href="#tUTMB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTSB"><font style="letter-spacing:0.2pt;">UPDATE TO SESEN BIO BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTSB">S-26</a></font> <a href="#tUTSB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLEPR"><font style="letter-spacing:0.2pt;">Legal Proceedings </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEPR">S-26</a></font> <a href="#tLEPR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTMF"><font style="letter-spacing:0.2pt;">UPDATE TO MANAGEMENT FOLLOWING THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.35pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTMF">S-28</a></font> <a href="#tUTMF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.3pt 0pt 0.5pt 0pt; width:419.11pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tUTUP"><font style="letter-spacing:0.2pt;">UPDATE TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.3pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTUP">S-29</a></font> <a href="#tUTUP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUTPS1"><font style="letter-spacing:0.2pt;">UPDATE TO PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUTPS1">S-39</a></font> <a href="#tUTPS1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">S-42</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.34pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ANNEXES</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Annex S-A&#8201;&#8212;&#8201;Second Amendment to Agreement and Plan of Merger and Reorganization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">S-A-1 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; width:419.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Annex S-B&#8201;&#8212;&#8201;Form of Contingent Value Rights Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.34pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">S-B-1 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.007pt 0pt 0.5pt 0pt; width:419.11pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; text-align:left; width:63pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Annex S-C&#8201;&#8212;&#8201;</font>
                <br >
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:63pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">Voting and Support Agreement by and among the Radoff Family Foundation, Bradley L. Radoff, JEC II Associates, LLC, the K. Peter Heiland 2008 Irrevocable Trust, Michael Torok, CARISMA Therapeutics, Inc. and Sesen Bio, Inc. </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.007pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.007pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">S-C-1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTQA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO QUESTIONS AND ANSWERS ABOUT THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following information supplements and, where applicable, replaces, the information in the section entitled &#8220;Questions and Answers About The Merger&#8221; beginning on page 1 of the proxy statement/prospectus. You should read this supplement and the proxy statement/prospectus carefully, including the attached annexes. For more information, see the section entitled &#8220;Where You Can Find More Information&#8221; on page <a href="#tWYCF">S-42</a> of this supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">Why am I receiving this supplement to the proxy statement/prospectus?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You are receiving this supplement to the proxy statement/prospectus because Sesen Bio and Carisma have entered into the Second Merger Agreement Amendment, which is included as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex S-A</font><font style="letter-spacing:0.2pt;"> to this supplement. This supplement provides information about the Second Merger Agreement Amendment and supplements the proxy statement/prospectus that was previously mailed to you. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">What are the significant changes in the Second Merger Agreement Amendment?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Second Merger Agreement Amendment further amends the Original Merger Agreement, as amended by the First Merger Agreement Amendment, to, among other things, (i)&#160;decrease the minimum net cash of Sesen Bio required at the closing of the merger from $75.0&#160;million to $70.0&#160;million, (ii)&#160;increase the amount of the special cash dividend expected to be paid to Sesen Bio stockholders from approximately $70.0&#160;million to $75.0&#160;million, subject to the terms and conditions set forth in the Merger Agreement, and (iii)&#160;include Michael Torok, an approximately 4.1% stockholder of Sesen Bio, as the Sesen Bio designee to the combined company&#8217;s board of directors in place of Dr.&#160;Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors, who was formerly designated as such. The special cash dividend remains contingent upon Sesen Bio stockholder approval of the merger and the satisfaction or waiver of the applicable closing conditions to the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, as part of the Second Merger Agreement Amendment, the parties thereto amended and restated the CVR Agreement, or the amended CVR Agreement, to extend the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, would be paid to holders of CVRs from December&#160;31, 2023 to March&#160;31, 2027. The amended CVR Agreement does not alter the contractual right of CVR holders to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement. A copy of the form of the amended Contingent Value Rights Agreement is attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex S-B</font><font style="letter-spacing:0.2pt;"> to this supplement and shall replace in entirety the form of Contingent Value Rights Agreement attached to the proxy statement/prospectus as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex F</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">What will Sesen Bio stockholders receive in the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consistent with the description on page 2 of the proxy statement/prospectus, following the Second Merger Agreement Amendment, at the effective time Sesen Bio stockholders will continue to own and hold their existing shares of Sesen Bio common stock and Sesen Bio intends to declare (i)&#160;a dividend payable to Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time with respect to the receipt of one CVR for each outstanding share of Sesen Bio common stock held by such stockholders on such date and (ii)&#160;the special cash dividend. Applying the estimated exchange ratio as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 24.2% of the outstanding shares of capital stock of the combined company rather than 25.2% (subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $70.0&#160;million) and each CVR will be entitled to the proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, through March&#160;31, 2027, rather than through December&#160;31, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">What will Carisma stockholders and Carisma optionholders receive in the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">What Carisma stockholders will receive in the merger, as described on page 3 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, remains unchanged by the Second Merger Agreement Amendment, except that, applying the estimated exchange ratio as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, immediately after the merger, pre-merger Carisma stockholders are expected to own approximately 75.8% of the outstanding shares of capital stock of the combined company rather than 74.8% (subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $70.0&#160;million). </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">Who will be the directors of the combined company following the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The combined company&#8217;s board of directors as described beginning on page 4 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus remains unchanged by the Second Merger Agreement Amendment, except that Michael Torok will be the Sesen Bio designee to the combined company board of directors following the closing of the merger rather than Thomas R. Cannell. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">As a Sesen Bio stockholder, how does the Sesen Bio board of directors recommend that I vote in light of the Second Merger Agreement Amendment?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">After careful consideration of the Second Merger Agreement Amendment, the Sesen Bio board of directors continues to recommend that Sesen Bio stockholders vote &#8220;FOR&#8221; all of the proposals described in the proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">Has there been any change to the time and location of the Sesen Bio special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No. As stated in the proxy statement/prospectus, the Sesen Bio special meeting will be a virtual meeting held exclusively via live webcast at 10:00&#160;a.m., Eastern Time, on March&#160;2, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to attend the Sesen Bio special meeting, you must register in advance at www.proxydocs.com/</font>&#8203;<font style="letter-spacing:0.2pt;">SESN. After completing your registration, you will receive further instructions via email, including a unique link that will allow you to access the Sesen Bio special meeting and to vote and submit questions during the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your proxy card. </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If your shares are held in &#8220;street name&#8221; by a broker, bank or other nominee, you are also invited to attend and vote your shares at the Sesen Bio special meeting. After completing your registration in advance at www.proxydocs.com/SESN, you will receive further instructions via email, including a unique link to access the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your voting instruction form. You will also need to provide the registered name on your account and the name of your broker, bank or other nominee as part of the registration process. You may be instructed to obtain a legal proxy from your broker, bank or other nominee and to submit a copy in advance of the meeting. Further instructions will be provided to you as part of your registration process. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if you plan to attend the Sesen Bio special meeting, Sesen Bio requests that you sign and return the enclosed proxy card or voting instruction form to ensure that your shares will be represented at the Sesen Bio special meeting if you become unable to attend. Please be sure to follow the instructions found on your proxy card or voting instruction form. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">What do I do if I have already submitted a proxy or provided proxy instructions?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders of record may change or revoke their vote at any time before their proxy is voted at the Sesen Bio special meeting by doing any one of the following things: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">submitting a new proxy via the internet or telephone by following the instructions on the enclosed proxy card; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">signing another proxy card and arranging for delivery of that proxy card by mail by 11:59&#160;p.m., Eastern Time, the day before the Sesen Bio special meeting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;min-height:677.72pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">giving Sesen Bio&#8217;s Corporate Secretary a written notice before the Sesen Bio special meeting that you want to revoke your proxy; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">voting during the Sesen Bio special meeting. Your attendance at the Sesen Bio special meeting alone will not revoke a previously submitted proxy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a Sesen Bio stockholder who owns shares of Sesen Bio common stock in &#8220;street name&#8221; has instructed a broker to vote its shares of Sesen Bio common stock, the stockholder must follow directions received from its broker to change those instructions. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Your vote will be counted in accordance with the last instruction received prior to the closing of the polls, whether your instruction is received by internet, telephone, mail or at the Sesen Bio special meeting. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">What risks should I consider in deciding whether to vote in favor of the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You should carefully review the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 26 of the proxy statement/prospectus, as amended and supplemented by this supplement, which sets forth certain risks and uncertainties related to the merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of Sesen Bio and Carisma, as independent companies, are subject. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">What do I need to do now?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Sesen Bio urges you to read the proxy statement/prospectus and this supplement carefully, including the annexes thereto and hereto, and to consider how the merger affects you. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder of record, you may provide your proxy instructions in one of three ways prior to the Sesen Bio special meeting: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Over the internet.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares over the internet by following the instructions in the enclosed proxy card. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">By telephone.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares by telephone by following the instructions in the enclosed proxy card. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">By mail.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares by completing, dating and signing the proxy card and promptly mailing it in the postage-paid envelope provided. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please provide your proxy instructions only once, unless you are revoking a previously delivered proxy instruction, and as soon as possible so that your shares can be voted at the Sesen Bio special meeting. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">Who can help answer my questions?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">If you would like to request documents from Sesen Bio or Carisma, please send a request in writing or by telephone to either Sesen Bio or Carisma at the following addresses: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;margin-bottom:5pt;margin-left:40pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">Sesen Bio, Inc.</font>
                <br >
                <font style="letter-spacing:0.2pt;">245 First Street, Suite 1800</font>
                <br >
                <font style="letter-spacing:0.2pt;">Cambridge, Massachusetts 02142</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (617) 444-8550</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: ir@sesenbio.com </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">CARISMA Therapeutics Inc.</font>
                <br >
                <font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200</font>
                <br >
                <font style="letter-spacing:0.2pt;">Philadelphia, PA 19104</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (267) 491-6422</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: info@carismatx.com</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8.1pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder and would like additional copies, without charge, of the proxy statement/prospectus or this supplement, or if you have questions about the merger, including the procedures for voting your shares, you should contact Sesen Bio&#8217;s proxy solicitor: </font>
        </div>
        <div style="position:relative;margin-left:20pt; margin-top:10.1pt; text-align:center; width:436pt;">
          <img src="lg_mackenziepartners-bw.jpg" alt="[MISSING IMAGE: lg_mackenziepartners-bw.jpg]" height="57" width="192" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:568pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">MacKenzie Partners, Inc. 1407</font>
          <br >
          <font style="letter-spacing:0.2pt;">Broadway, 27th Floor </font>
          <br >
          <font style="letter-spacing:0.2pt;">New York, New York 10018 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(800) 322-2885 </font>
          <br >
          <font style="letter-spacing:0.2pt;">proxy@mackenziepartners.com</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTPS">&#8203;</a><a name="tTHME">&#8203;</a><a name="tOOTM">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">UPDATE TO PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The following information amends as described, supplements and, where applicable, replaces, the information in the section entitled &#8220;Prospectus Summary&#8221; beginning on page 11 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. You should read this supplement and the proxy statement/prospectus carefully, including the annexes attached hereto and thereto, respectively. For more information, see the section entitled &#8220;Where You Can Find More Information&#8221; on page <a href="#tWYCF">S-42</a> of this supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The section &#8220;Prospectus Summary&#8201;&#8212;&#8201;The Merger&#8221; on pages 11 and 12 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If the merger is completed, Merger Sub will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio. After the completion of the merger, Sesen Bio will change its corporate name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; as contemplated by the Merger Agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, each outstanding share of Carisma capital stock will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 172 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 40.0154 shares of Sesen Bio common stock for each share of Carisma capital stock, which exchange ratio does not give effect to the proposed reverse stock split. The final exchange ratio is subject to adjustment prior to the closing of the merger based on Sesen Bio&#8217;s net cash at the closing of the merger and the aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company. </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Also at the effective time, each outstanding Carisma option will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with the number of shares and exercise price being appropriately adjusted to reflect the exchange ratio between Sesen Bio common stock and Carisma common stock determined in accordance with the Merger Agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Each share of Sesen Bio common stock, each Sesen Bio option and each Sesen Bio RSU that is outstanding at the effective time will remain outstanding in accordance with its terms and each such share of Sesen Bio common stock, Sesen Bio option and Sesen Bio RSU, subject to the proposed reverse stock split, will be unaffected by the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 24.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of the Carisma convertible note, are expected to own approximately 75.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $70.0&#160;million. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview of the Merger Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Merger Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Overview of the Merger Agreement&#8201;&#8212;&#8201;Merger Consideration&#8221; on page 14 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, each outstanding share of Carisma capital stock will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 172 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 40.0154 shares of Sesen Bio common stock for each share of Carisma capital stock, which exchange ratio does not give effect to the proposed reverse stock split. The final exchange ratio is subject to </font></div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tVASA">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:0.289999999999964pt; margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">adjustment prior to the closing of the merger based on Sesen Bio&#8217;s net cash at the closing of the merger and the aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Also at the effective time, each outstanding Carisma option will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with the number of shares and exercise price being appropriately adjusted to reflect the exchange ratio between Sesen Bio common stock and Carisma common stock determined in accordance with the Merger Agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Each share of Sesen Bio common stock, each Sesen Bio option and each Sesen Bio RSU that is outstanding at the effective time will remain outstanding in accordance with its terms and each such share of Sesen Bio common stock, Sesen Bio option and Sesen Bio RSU, subject to the proposed reverse stock split, will be unaffected by the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 24.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, are expected to own approximately 75.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $70.0&#160;million. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Conditions to the Completion of the Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Overview of the Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger&#8221; on page 15 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">To complete the merger, Sesen Bio stockholders must approve Proposal Nos. 1 and 2 and Carisma stockholders must adopt the Merger Agreement and approve the merger and the related transactions. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived (including Sesen Bio having net cash as of the closing of the merger greater than or equal to $70.0&#160;million). </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The following section is added following the section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Support Agreements and Written Consents&#8221; on page 16 of the proxy statement/prospectus:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Voting and Support Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In connection with the execution of the Second Merger Agreement Amendment, on February&#160;13, 2023, Sesen Bio and Carisma entered into the Investor Group voting and support agreement, pursuant to which, among other things, the Investor Group agreed to vote all of their shares of Sesen Bio common stock (i)&#160;in favor of (a)&#160;the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (b)&#160;the issuance of shares of Sesen Bio common stock to Carisma stockholders in connection with the Merger Agreement and the transactions contemplated thereby, (c)&#160;the change of control of Sesen Bio resulting from the merger pursuant to Nasdaq rules, (d)&#160;an amendment to the Sesen Bio Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock, at a ratio of 1-for-20, and a reduction of the number of authorized shares of Sesen Bio common stock to 100,000,000, (e)&#160;the approval of the equity plan amendment proposals, and (f)&#160;a waiver of any notice that may have been or may be required relating to the merger or any other transactions contemplated thereby, and (ii)&#160;against any competing acquisition proposal and any action in furtherance of any such competing acquisition proposal. The Investor Group support agreement contains restrictions on the transfer of Sesen Bio common stock held by the Investor Group, subject to certain exceptions. In addition, the Investor Group support agreement provides that from the effective time of the Merger until the expiration of a standstill period, the Investor Group will vote all of its shares of Sesen Bio common stock in accordance with the recommendations of the combined company&#8217;s board of directors, subject to certain exceptions, and includes certain standstill restrictions applicable to the Investor Group. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMFTM">&#8203;</a><a name="tIOSB">&#8203;</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Management Following the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Management Following the Merger&#8221; on page 18 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following table lists the names, ages as of February&#160;13, 2023 and positions of the individuals who are expected to serve as executive officers and directors of the combined company following completion of the merger. </font>
          </div>
          <table style="width:456pt;height:173.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:207.5pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:17pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Age </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:207.5pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Position </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:-0.2pt;">Executive Officers</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:207.5pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Steven Kelly </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">57 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Richard Morris </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">49 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">33 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:207.5pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">66 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Director, Chair of the Board </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">53 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">63 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">64 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">40 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Michael Torok </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">44 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.5pt;">
                <font style="letter-spacing:0.2pt;">Director</font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:12.1pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The last paragraph of the section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Interests of Sesen Bio Directors and Executive Officers in the Merger&#8221; on page 19 of the proxy statement/prospectus is replaced with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the Second Merger Agreement Amendment, Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors, is no longer expected to continue as a member of the combined company&#8217;s board of directors following the merger. Instead, Michael Torok, an approximately 4.1% stockholder of Sesen Bio, is expected to be the Sesen Bio designated director on the combined company&#8217;s board of directors. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of Receipt of the Special Cash Dividend</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of Receipt of the Special Cash Dividend&#8221; on page 20 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In connection with the merger, the Sesen Bio board of directors will declare and pay a special cash dividend to Sesen Bio stockholders of record prior to the effective time in an aggregate amount of $75.0&#160;million, assuming Sesen Bio&#8217;s net cash as of closing of the merger is at least $70.0&#160;million. The U.S. federal income tax consequences of the Sesen Bio U.S. holders&#8217; receipt of such special cash dividend generally should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining amount. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of the special cash dividend to be treated as other than a dividend for U.S. federal income tax purposes. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">See the section entitled &#8220;</font><font style="letter-spacing:0.2pt;">The Merger&#8201;&#8201;&#8212;&#8201;&#8201;Material U.S. Federal Income Tax Consequences of the Special Cash Dividend</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; beginning on page 162 of the proxy statement/prospectus for a general description of the tax consequences of the special cash dividend that Sesen Bio will pay in connection with the </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLRTT">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">consummation of the merger, subject to Sesen Bio having net cash as of the closing of the merger greater than or equal to $70.0&#160;million. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The tax consequences to you of the special cash dividend will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Litigation Related to the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The proxy statement/prospectus describes certain pending litigation related to the merger agreement up to and including January&#160;19, 2023, the date of the proxy statement/prospectus. The discussion below supplements that description up to and including the date of this supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On February&#160;3, 2023, a purported Sesen Bio stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Plumley&#160;v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:23-cv-00131 (D. Del.), or the Plumley Complaint. The Plumley Complaint asserts claims under Section&#160;14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus and under Section&#160;20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the merger and an award for plaintiff&#8217;s fees and costs. On February&#160;7, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Franchi v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, 1:23-cv-01041 (S.D.N.Y.), or the Franchi Complaint. The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. On February&#160;8, 2023, Sesen Bio received a demand letter on behalf of a purported Sesen Bio stockholder, or the Rosenblatt demand letter, alleging omissions of material information with respect to the merger from the proxy statement/prospectus, including information regarding the financial projections with respect to Carisma, the financial analyses performed by SVB Securities in support of its fairness opinion, potential conflicts of interest involving SVB Securities, and the background and process leading to the execution of the Merger Agreement, and demanding that Sesen Bio promptly provide stockholders with additional disclosure. Additionally, on February&#160;9, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Menzer v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, 1:23-cv-01119 (S.D.N.Y.), or the Menzer Complaint. The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. On February&#160;13, 2023, Sesen Bio received a demand letter on behalf of a purported Sesen Bio stockholder, or the Markman demand letter. The Markman demand letter contains substantially similar allegations and claims and seeks substantially similar relief as the Rosenblatt demand letter. On February&#160;15, 2023, Sesen Bio received an updated demand letter on behalf of a purported Sesen Bio stockholder who had previously sent a demand letter on November&#160;4, 2022, or the updated McKinley demand letter. The updated McKinley demand letter contains substantially similar allegations and claims and seeks substantially similar relief as the Rosenblatt demand letter. Sesen Bio believes that the claims asserted in the Plumley Complaint, the Franchi Complaint, the Rosenblatt demand letter, the Menzer Complaint, the Markman demand letter, and the updated McKinley demand letter are without merit. At this time, no assessment can be made as to the likely outcomes or whether the outcomes will be material to Sesen Bio.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTMP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:420pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO MARKET PRICE AND DIVIDEND INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;Market Price and Dividend Information&#8201;&#8212;&#8201;Dividends&#8221; on page 25 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has never declared or paid any cash dividends on the Sesen Bio common stock and does not anticipate paying cash dividends on the Sesen Bio common stock for the foreseeable future, other than the special cash dividend that Sesen Bio will pay to Sesen Bio stockholders in connection with the consummation of the merger, subject to Sesen Bio having net cash as of the closing of the merger greater than or equal to $70.0&#160;million. Carisma has never declared or paid any cash dividends on the Carisma common stock and does not anticipate paying cash dividends on the Carisma common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the merger will be at the discretion of the combined company&#8217;s then-current board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;Risk Factors&#8221; of the proxy statement/prospectus is hereby revised as follows:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The third risk factor on page 28 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio stockholders and Carisma stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the merger as compared to their current ownership and voting interest in the respective companies.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is completed, the current Sesen Bio stockholders and Carisma stockholders will own a smaller&#160;percentage of the combined company than their ownership in their respective companies prior to the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 24.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, are expected to own approximately 75.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of closing being at least $70.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The fourth risk factor on page 30 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If existing Sesen Bio stockholders and Carisma stockholders sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after the merger, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, and taking into account the consummation of the Carisma pre-closing financing, the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note and an assumed exchange ratio of 40.0154, the combined company is expected to have outstanding a total of approximately 922,677,434 shares of common stock (prior to giving effect to the proposed reverse stock split) immediately following the completion of the merger. Not all shares of Sesen Bio common stock will be freely tradable, without restriction, in the public market. For example, an aggregate of 462,853,942 shares of the combined company&#8217;s common stock will be subject to the lock-up agreements required under the Merger Agreement as of the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The second risk factor on page 31 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lawsuits have been filed, and additional lawsuits may be filed in the future, against Sesen Bio, the members of the Sesen Bio board of directors, Carisma and/or the members of the Carisma board of directors arising out of the merger, which may delay or prevent the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additional putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Sesen Bio, the Sesen Bio board of directors, Carisma, and/or the Carisma board of directors in connection with the transactions contemplated by the Merger Agreement. For example, Sesen Bio has received several letters from purported Sesen Bio stockholders demanding that it amend the proxy statement/prospectus to provide additional disclosures that such stockholders allege were improperly omitted. Additionally, several complaints have been filed asserting claims against Sesen Bio and the Sesen Bio board of directors under Section&#160;14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus, and under Section&#160;20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements. The outcome of litigation is uncertain, and Sesen Bio and Carisma may not be successful in defending against any such future claims. Lawsuits that may be filed against Sesen Bio, the Sesen Bio board of directors, Carisma, and/or the Carisma board of directors could delay or prevent the merger, divert the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">attention of the management teams and employees of Sesen Bio and Carisma from day-to-day business and otherwise adversely affect the business and financial condition of Sesen Bio, Carisma or the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The second risk factor on page 34 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio has never paid and, other than in connection with the merger, does not intend to pay any cash dividends in the foreseeable future.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has never paid cash dividends on any of its capital stock. Pursuant to the terms of the Merger Agreement, Sesen Bio will, in addition to the CVRs, declare and pay a special cash dividend to its stockholders of record prior to the merger, which would be contingent upon Sesen Bio stockholder approval of Proposal Nos. 1 and 2 and the satisfaction or waiver of the applicable customary closing conditions to the merger. The amount of the special cash dividend expected to be paid to Sesen Bio stockholders is $75.0&#160;million, assuming Sesen Bio&#8217;s net cash as of closing of the merger is at least $70.0&#160;million. Other than such special cash dividend in connection with the closing of the merger, Sesen Bio does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first risk factor on page 54 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio and certain of its officers have been, and may in the future be, named as defendants in lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert Sesen Bio management&#8217;s time and attention from Sesen Bio&#8217;s business, and have a material adverse effect on Sesen Bio&#8217;s results of operations. Any other lawsuits to which Sesen Bio is subject may be costly to defend and are uncertain in their outcome.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;19, 2021, August&#160;31, 2021 and October&#160;7, 2021, three substantially identical securities class action lawsuits were filed against Sesen Bio and certain of its officers, alleging violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder based on statements made by Sesen Bio concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October&#160;29, 2021, the court consolidated the three cases. On December&#160;6, 2021, the plaintiffs filed an amended class action complaint, alleging the same violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder on the same theory as the prior complaints. On July&#160;19, 2022, the parties reached an agreement in principle to settle the securities litigation. On September&#160;28, 2022, the court issued an order granting preliminary approval of the proposed settlement, and on January&#160;31, 2023, the court issued an order granting final approval. Accordingly, this matter is now resolved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2021 and September&#160;24, 2021, two substantially similar derivative lawsuits were filed against Sesen Bio and certain of its officers. On January&#160;12, 2022, a third derivative complaint was filed against the Sesen Bio board of directors and certain of its officers. The three derivative complaints alleged breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by Sesen Bio concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. One of the complaints further alleged unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints sought unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On July&#160;19, 2022, the parties reached an agreement in principle to settle the derivative litigation and other potential related derivative claims. On August&#160;22, 2022, the parties entered into a Stipulation of Settlement to settle the derivative litigation. On September&#160;2, 2022, the court issued an order granting preliminary approval of the Stipulation of Settlement, and on November&#160;8, 2022, the court issued an order granting final approval. Accordingly, this matter is now resolved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;28, 2022, a purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:22-cv-10085 (S.D.N.Y.), or the Original Keller Complaint, asserting claims under Section&#160;14(a) of the Exchange Act and Rule&#160;14a-9 promulgated </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">thereunder for allegedly false and misleading statements in the proxy statement/prospectus and under Section&#160;20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and sought, among other relief, an order enjoining the merger and an award for plaintiff&#8217;s fees and costs. On December&#160;20, 2022, the purported Sesen Bio stockholder voluntarily dismissed the Original Keller Complaint and on December&#160;21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022), or the New Keller Complaint. Along with the complaint, the purported Sesen Bio stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Special Meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint, and seek, among other relief, an order enjoining the merger and an award for plaintiff&#8217;s fees and costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;3, 2023, a purported Sesen Bio stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Plumley&#160;v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:23-cv-00131 (D. Del.), or the Plumley Complaint. The Plumley Complaint asserts claims under Section&#160;14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus and under Section&#160;20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the merger and an award for plaintiff&#8217;s fees and costs. On February&#160;7, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Franchi v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, 1:23-cv-01041 (S.D.N.Y.), or the Franchi Complaint. The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February&#160;9, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Menzer v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, 1:23-cv-01119 (S.D.N.Y.), or the Menzer Complaint. The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may be the target of similar litigation in the future. The market price of its common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert Sesen Bio management&#8217;s attention from other business concerns, which could seriously harm its business. Sesen Bio maintains liability insurance; however, if any costs or expenses associated with the pending lawsuits or any other litigation exceed Sesen Bio&#8217;s insurance coverage, Sesen Bio may be forced to bear some or all costs and expenses directly, which could adversely affect its business, financial condition, results of operations or stock price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first risk factor on page 55 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio is unable to regain compliance with the listing requirements of the Nasdaq Capital Market, Sesen Bio common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on Sesen Bio&#8217;s business and could make it more difficult for Sesen Bio stockholders to sell their shares of Sesen Bio common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio common stock is listed on the Nasdaq Capital Market, and Sesen Bio is therefore subject to Nasdaq&#8217;s continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders&#8217; equity, among others, and requirements relating to board and committee independence. If Sesen Bio fails to satisfy one or more of the requirements, it may be delisted from the Nasdaq Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;25, 2023, Sesen Bio was notified by the Listing Qualifications Department, or the Staff, of Nasdaq that, based upon its non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule&#160;5550(a)(2), or the Rule, Sesen Bio common stock will be delisted from Nasdaq unless Sesen Bio timely requests a hearing before a Nasdaq Hearings Panel, or the Panel. Sesen Bio requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured Sesen Bio common stock remains listed and eligible for trading on Nasdaq pending a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">determination by the Panel. The hearing has been scheduled for March&#160;16, 2023. At the hearing, Sesen Bio will present its plan to evidence compliance with all applicable Nasdaq listing criteria. To that end, in connection with the merger, Sesen Bio is seeking approval for the implementation of a reverse stock split at the Special Meeting. There can be no assurance, however, that the Panel will grant Sesen Bio&#8217;s request for continued listing or that Sesen Bio will evidence compliance with all applicable criteria for listing within any extension period that may be granted by the Panel following the hearing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As previously disclosed, on January&#160;24, 2022, Sesen Bio received written notice from the Staff indicating that, based upon the closing bid price for Sesen Bio common stock for the previous 30 consecutive business days, Sesen Bio no longer satisfied the Rule and, in accordance with the Nasdaq Listing Rules, was afforded an initial grace period of 180 calendar days, through July&#160;25, 2022, and a second 180-calendar day period, through January&#160;23, 2023, to regain compliance with the Rule. Sesen Bio did not regain compliance with the Rule by January&#160;23, 2023, which resulted in the Staff&#8217;s January&#160;25, 2023, determination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Delisting from the Nasdaq Capital Market would adversely affect Sesen Bio&#8217;s ability to consummate the merger and may adversely affect Sesen Bio&#8217;s ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors to trade Sesen Bio common stock, or negatively affect the value and liquidity of Sesen Bio common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio is delisted from Nasdaq and Sesen Bio is not able to list Sesen Bio common stock on another exchange, Sesen Bio common stock could be quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, Sesen Bio could face significant adverse consequences including, among others: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a limited availability of market quotations for Sesen Bio common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a determination that Sesen Bio common stock is a &#8220;penny stock&#8221; which will require brokers trading in Sesen Bio common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for Sesen Bio&#8217;s securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a limited amount of news and little or no analyst coverage for Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Sesen Bio would no longer qualify for exemptions from state securities registration requirements, which may require Sesen Bio to comply with applicable state securities laws; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3) or obtain additional financing in the future. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The second risk factor on page 116 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">After completion of the merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of the merger, and giving effect to the issuance of the shares of common stock of Carisma prior to the closing of the merger pursuant to the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately 58.21% of the combined company&#8217;s outstanding shares of common stock, subject to certain assumptions, including, but not limited to, Sesen Bio&#8217;s net cash as of closing being at least $70.0&#160;million. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTTS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:168pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO THE SPECIAL MEETING OF SESEN BIO STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;The Special Meeting of Sesen Bio Stockholders&#8201;&#8212;&#8201;Purposes of the Sesen Bio Meeting&#8221; on page 121 of the proxy statement/prospectus, is amended and restated as follows (with new text in bold and deleted text in strikeout font):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purposes of the Sesen Bio Special Meeting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The purposes of the Sesen Bio special meeting are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Original Merger Agreement, as amended by the Merger Agreement Amendment </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and the Second Merger Agreement Amendment</font><font style="letter-spacing:0.2pt;">, copies of which are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annexes A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">A-2</font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">, respectively,</font><font style="letter-spacing:0.2pt;"> to </font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">this</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;letter-spacing:-0.2pt;">the</font><font style="letter-spacing:0.2pt;"> proxy statement/ prospectus </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and as </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Annex S-A</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> to this supplement</font><font style="letter-spacing:0.2pt;">, and the change of control of Sesen Bio resulting from the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment to the Sesen Bio Certificate of Incorporation, to (a)&#160;effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock at a ratio of 1-for-20, with the implementation and timing of the reverse stock split to be determined in the discretion of the Sesen Bio board of directors and as agreed to by Carisma at or prior to the closing of the merger, or in the sole discretion of the Sesen Bio board of directors if Proposal No. 1 is not approved, and (b)&#160;if and when the reverse stock split is effected, reduce the number of authorized shares of Sesen Bio common stock, in the form attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex&#160;G</font><font style="letter-spacing:0.2pt;"> to the proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment and restatement of the 2014 Incentive Plan to, among other things, (a)&#160;increase the number of shares of Sesen Bio common stock reserved for issuance under the 2014 Incentive Plan, and (b)&#160;extend the term of the 2014 Incentive Plan to the tenth (10th) anniversary of the closing of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment to the 2014 ESPP to increase the number of shares of Sesen Bio common stock reserved for issuance under the 2014 ESPP to 6,568,655 shares of Sesen Bio common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an adjournment of the Sesen Bio special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 or 2; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to transact such other business as may properly come before the Sesen Bio special meeting or any adjournment or postponement thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTTM">&#8203;</a><a name="tBOTM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Background of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first full, non-bulleted paragraph in the section entitled &#8220;The Merger&#8201;&#8212;&#8201;Background of the Merger&#8221; on page 127 of the proxy statement/prospectus, is amended and restated as follows (with new text in bold):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Also during this period, Sesen Bio entered into confidentiality agreements with 18 of the companies that submitted indications of interest. 17 of the 18 confidentiality agreements, including those of Carisma, Party A, Party B, Party C and Party D, contained standstill provisions that expired 24&#160;months after their execution. The remaining confidentiality agreement contained a standstill provision that expires 12&#160;months after its execution. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">All of the confidentiality agreements contained a provision prohibiting the participants in the strategic process from making any request that Sesen Bio waive the standstill provisions, known as a &#8220;don&#8217;t ask/</font>&#8203;<font style="font-weight:bold;letter-spacing:-0.2pt;">don&#8217;t waive&#8221; provision.</font><font style="letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following paragraph is added following the third full paragraph in the section entitled &#8220;The Merger&#8201;&#8212;&#8201;Background of the Merger&#8221; on page 131 of the proxy statement/prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise disclosed in the proxy statement/prospectus, prior to entry into the Original Merger Agreement, there was no material agreement, arrangement or understanding between Sesen Bio or any of its executive officers or directors, on the one hand, and Carisma or any of its executive officers or directors, on the other hand, regarding post-closing employment for Sesen Bio&#8217;s executive officers or directors, nor were there any material negotiations regarding the same. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The fourth paragraph in the section entitled &#8220;The Merger&#8201;&#8212;&#8201;Background of the Merger&#8221; beginning on page 133 of the proxy statement/prospectus, is amended and restated as follows (with new text in bold):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;29, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells and SVB Securities were present. Sesen Bio&#8217;s directors met in executive session with representatives of Hogan Lovells to review, among other things, the Sesen Bio board of directors&#8217; previous evaluation of strategic alternatives, including liquidation, that the Sesen Bio board of directors conducted before approving the merger. The Sesen Bio board of directors confirmed that it continues to believe such transaction maximizes stockholder value and is in the best interest of the Sesen Bio stockholders. Following the executive session, Ms.&#160;Clark provided an update on engagement with the Investor Group, including the Investor Group&#8217;s continued demand for an approximate $100.0&#160;million special cash dividend to Sesen Bio stockholders, which the Sesen Bio board of directors agreed would make the merger unfeasible (including that Carisma advised that such special cash dividend would be unacceptable) and potentially introduce significant risk to Sesen Bio. Ms.&#160;Clark then reviewed the draft merger agreement amendment which would (i)&#160;reduce the minimum net cash of Sesen Bio required at the closing of the merger from $100.0&#160;million to $75.0&#160;million, (ii)&#160;increase the amount of the special cash dividend to be paid to Sesen Bio stockholders to the amount of cash available after Sesen Bio meets the $75.0&#160;million net cash minimum as of the closing of the merger, which was estimated to be approximately $70.0&#160;million, and (iii)&#160;amend the form of CVR Agreement to also include potential proceeds from any sale of Sesen Bio&#8217;s legacy assets (including Vicineum), in addition to any proceeds from the milestone payment under the Roche Asset Purchase Agreement, as part of the CVR. Representatives of SVB Securities reviewed SVB Securities&#8217; financial analysis of the proposed transaction with Carisma pursuant to the terms of the Merger Agreement. Following discussion with the Sesen Bio directors, SVB Securities then rendered to the Sesen Bio board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&#160;29, 2022, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion, the exchange ratio to be paid by Sesen Bio pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Sesen Bio. Ms.&#160;Clark reviewed with the Sesen Bio board of directors the prior discussions from December&#160;21, 2022 that in the event the merger is not completed, a court-managed liquidation would likely provide greater value to Sesen Bio stockholders compared to other potential strategic alternatives available to Sesen Bio. Ms.&#160;Clark reviewed that, if the Sesen Bio board of directors were to approve and recommend, and Sesen Bio stockholders were to approve, a liquidation of Sesen Bio, Sesen Bio would be required under Delaware corporate law to notify potential claimants and pay its outstanding obligations, as well as to make reasonable provision for contingent and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">unknown obligations, which may be sizeable, prior to making any distributions in liquidation to Sesen Bio stockholders. Ms.&#160;Clark noted that as a result of such requirement, a portion of Sesen Bio&#8217;s assets would need to be reserved pending the resolution of such obligations, the timing of any such resolution would be uncertain, and Sesen Bio may become subject to litigation or other claims related to a dissolution and liquidation of Sesen Bio. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">The Sesen Bio board of directors also reviewed an analysis prepared by Sesen Bio management estimating that Sesen Bio stockholders would only receive approximately $0.40 to $0.60 per share in an initial distribution to stockholders upon a dissolution and liquidation, assuming stockholder approval of the dissolution and liquidation in the second quarter of 2023 and a cash balance of approximately $140.0 million at the time of initial distribution and based on approximately 60% to 90% of Sesen Bio&#8217;s estimated cash balance being available for an initial distribution to stockholders upon a dissolution and liquidation.</font><font style="letter-spacing:0.2pt;"> Representatives of Hogan Lovells reviewed with the Sesen Bio board of directors the Investor Group&#8217;s Schedule&#160;13D filings and opposition to the merger, engagement with the Investor Group to date and other matters related to the Investor Group, including potential responses and related considerations. A discussion ensued regarding engagement with the Investor Group, the terms of the Merger Agreement Amendment and the potential for a court-managed liquidation in the event the merger is not completed. Following discussion, the Sesen Bio board of directors unanimously (i)&#160;determined that the Merger Agreement Amendment and the transactions contemplated thereby are advisable and in the best interests of Sesen Bio and its stockholders, and (ii)&#160;approved and declared advisable the Merger Agreement Amendment and the transactions contemplated by the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The proxy statement/prospectus describes the background of the merger up to and including January&#160;17, 2023. The discussion below supplements that description up to and including the date of this supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;18, 2023, the Investor Group contacted representatives of SVB Securities and communicated that the Investor Group would consider supporting the merger if Sesen Bio and Carisma agreed to increase the special cash dividend to $0.45 per share, or approximately $92.0&#160;million, and reimburse the Investor Group&#8217;s legal fees and expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between January&#160;19, 2023 and January&#160;20, 2023, members of Sesen Bio management and members of Carisma management discussed the status of engagement with the Investor Group, including the Investor Group&#8217;s indication that it would consider supporting the merger if the special cash dividend was increased to approximately $92.0&#160;million, or approximately $0.45 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;20, 2023, representatives of SVB Securities contacted the Investor Group and communicated that Sesen Bio would be willing to discuss an advisory role for the two principals of the Investor Group as additional CEO advisors, a role that was established at Sesen Bio in 2020, and reimbursement of legal fees and expenses as part of a settlement agreement with the Investor Group. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;2, 2023, the Investor Group contacted representatives of SVB Securities and indicated that the Investor Group would consider supporting the merger if Sesen Bio and Carisma agreed to increase the special cash dividend to $0.40 per share, or approximately $80.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between February&#160;2, 2023 and February&#160;7, 2023, members of Sesen Bio management, members of Carisma management and their respective advisors discussed the status of engagement with the Investor Group, including the Investor Group&#8217;s indication that it would consider supporting the merger if the special cash dividend was increased to approximately $80.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;8, 2023, Sesen Bio entered into a confidentiality agreement with the Investor Group to facilitate the sharing of certain information with the Investor Group. The confidentiality agreement required Sesen Bio to notify the Investor Group, by the earlier of February&#160;12, 2023 and two business days following the Investor Group&#8217;s agreement to vote in favor of the merger, that the information shared with the Investor Group does not constitute material, non-public information as of such date. Later on February&#160;8, 2023, representatives of SVB Securities and representatives of Evercore contacted the Investor Group and indicated that Sesen Bio and Carisma were willing to increase the special cash dividend to approximately $73.5&#160;million and extend the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, if any, would be paid to holders of CVRs from December&#160;31, 2023 to March&#160;31, 2027, on the terms and conditions set forth in the CVR Agreement. During this call, representatives of SVB Securities and representatives of Evercore agreed to schedule a call with the Investor Group and Steven Kelly, Carisma&#8217;s Chief Executive Officer, to discuss the merger and long-term value potential of the Carisma platform. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;9, 2023, representatives of SVB Securities, representatives of Evercore, Mr.&#160;Kelly and the Investor Group held a call to discuss the merger, the amount of the potential special cash dividend and minimum net cash condition and the long-term value potential of the Carisma platform. Later on February&#160;9, 2023, the Investor Group contacted representatives of SVB Securities and indicated that the Investor Group would consider supporting the merger if Sesen Bio and Carisma agreed to (i)&#160;increase the special cash dividend to $75.0&#160;million, with Sesen Bio&#8217;s minimum net cash adjusted accordingly, (ii)&#160;extend the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, would be paid to holders of CVRs from December&#160;31, 2023 to March&#160;31, 2027, (iii)&#160;include Mr.&#160;Torok as the only Sesen Bio designee on the combined company&#8217;s board of directors, and (iv)&#160;reimburse the Investor Group&#8217;s legal fees and expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;10, 2023, members of the Sesen Bio board of directors reviewed the terms proposed by the Investor Group and, following discussion with members of Sesen Bio management, authorized an increase to the amount of the expected special cash dividend in connection with the merger from approximately $70.0&#160;million to $75.0&#160;million and the other terms proposed by the Investor Group. Also on February&#160;10, 2023, members of Carisma management advised members of Sesen Bio management that the Carisma board of directors had authorized a decrease to the minimum net cash requirement from $75.0&#160;million to $70.0&#160;million, an increase to the amount of the expected special cash dividend from approximately $70.0&#160;million to $75.0&#160;million, as well as the other terms proposed by the Investor Group. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Between February&#160;10, 2023 and February&#160;13, 2023, representatives of Hogan Lovells and representatives of WilmerHale negotiated the terms of the second merger agreement amendment, which would (i)&#160;increase the amount of the special cash dividend to be paid to Sesen Bio stockholders to $75.0&#160;million, (ii)&#160;decrease Sesen Bio&#8217;s minimum net cash required at the closing of the merger to $70.0&#160;million, (iii)&#160;include Michael Torok, a member of the Investor Group, as the Sesen Bio designee on the combined company&#8217;s board of directors, and (iv)&#160;revise the CVR Agreement to extend the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, would be paid to holders of CVRs to March&#160;31, 2027. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Between February&#160;11, 2023 and February&#160;13, 2023, representatives of Hogan Lovells, representatives of WilmerHale and representatives of Olshan negotiated the terms of a voting and support agreement among Sesen Bio, Carisma and the Investor Group, including the Investor Group&#8217;s voting obligations, including the obligation to vote in favor of the merger, as well as customary standstill restrictions. Representatives of Hogan Lovells, WilmerHale and Olshan also finalized the terms of the Second Merger Agreement Amendment and amended CVR Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;12, 2023, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. Ms.&#160;Clark reviewed recent engagement with the Investor Group, including the Investor Group&#8217;s indication that it would consider supporting the merger if Sesen Bio and Carisma agreed to (i)&#160;increase the special cash dividend to approximately $75.0&#160;million, with Sesen Bio&#8217;s minimum net cash adjusted accordingly, subject to the terms and conditions set forth in the Merger Agreement, as amended, (ii)&#160;extend the date through which proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, if any, would be paid to holders of CVRs to March&#160;31, 2027, (iii)&#160;include Mr.&#160;Torok as the Sesen Bio designee on the combined company&#8217;s board of directors, and (iv)&#160;reimburse the Investor Group&#8217;s legal fees and expenses. A discussion ensued regarding engagement with the Investor Group and the terms of the Second Merger Agreement Amendment, the amended CVR Agreement and a voting and support agreement for the Investor Group. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;13, 2023, the Sesen Bio board of directors, acting by unanimous written consent, (i)&#160;determined that the Second Merger Agreement Amendment, the amended CVR Agreement, the Investor Group support agreement and the consummation of the transactions contemplated thereby are advisable and in the best interests of Sesen Bio and its stockholders, and (ii)&#160;approved and declared advisable the Second Merger Agreement Amendment, the amended CVR Agreement, the Investor Group support agreement and the transactions contemplated thereby. Later on February&#160;13, 2023, Sesen Bio and Carisma executed the Second Merger Agreement Amendment and the Investor Group support agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;14, 2023, Sesen Bio and Carisma issued a press release announcing the execution of the Second Merger Agreement Amendment and the Investor Group support agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tOOSB">&#8203;</a><a name="tIOSB1">&#8203;</a><a name="tMCAE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first paragraph in the section entitled &#8220;The Merger&#8201;&#8212;&#8201;Opinion of Sesen Bio&#8217;s Financial Advisor&#8221; on page 145 of the proxy statement/prospectus, is amended and restated as follows (with new text in bold):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and financial advisory services. In the ordinary course of business, SVB Securities and its affiliates currently are providing and may in the future provide investment banking and commercial banking services to Sesen Bio, Carisma or their respective affiliates and would expect to receive customary fees for the rendering of such services. In the past two&#160;years, SVB Securities has not </font><font style="font-weight:bold;letter-spacing:-0.2pt;">provided investment banking services to Carisma or its affiliates or</font><font style="letter-spacing:0.2pt;"> received any fees for investment banking services from Carisma </font><font style="font-weight:bold;letter-spacing:-0.2pt;">or its affiliates. During this period, SVB Securities&#8217; affiliates have provided commercial banking services to Carisma, which services consisted of holding deposits and investments and providing lines of credit, and for which SVB Securities&#8217; affiliates received compensation under $25,000.</font><font style="letter-spacing:0.2pt;"> In the ordinary course of business, SVB Securities and its affiliates have in the past and may in the future hold positions, for their own account or the accounts of their customers, in equity, debt or other securities of Sesen Bio, Carisma or their respective affiliates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Positions Following the Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;The Merger&#8201;&#8212;&#8201;Interests of Sesen Bio Directors and Executive Officers in the Merger&#8221; on page 150 of the proxy statement/prospectus, is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Second Merger Agreement Amendment, Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors, is no longer expected to remain a member of the board of directors of the combined company. Instead, Michael Torok, an approximately 4.1% stockholder of Sesen Bio, is expected to be the Sesen Bio designated director on the combined company&#8217;s board of directors. As a result, and pursuant to the terms of the Merger Agreement, effective upon the effective time, all then-current Sesen Bio directors will resign. Upon the resignation of the Sesen Bio directors, all unvested Sesen Bio options and Sesen Bio RSUs held by such directors will be vested in full. All out-of-the money Sesen Bio options will be canceled for no consideration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger Consideration and Exchange Ratio</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exchange Ratio</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first two paragraphs in the section entitled &#8220;The Merger&#8201;&#8212;&#8201;Merger Consideration and Exchange Ratio&#8201;&#8212;&#8201;Exchange Ratio</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; </font><font style="letter-spacing:0.2pt;">on pages 156 and 157 of the proxy statement/prospectus are replaced in their entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exchange ratio is calculated using a formula intended to allocate existing Sesen Bio and Carisma stockholders a&#160;percentage of the combined company. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 40.0154 shares of Sesen Bio common stock. This estimate is subject to adjustment prior to the closing of the merger for net cash at the cash determination time and aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing (and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the estimates set forth above, and certain other assumptions, Sesen Bio stockholders would own approximately 24.2% of the common stock of the combined company post-merger, and Carisma stockholders would own approximately 75.8% of the common stock of the combined company post-merger, of which the shares issued in the Carisma pre-closing financing and the shares issued upon the conversion of the Carisma convertible note are expected to represent approximately 8.5% and 11.4%, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tAAT">&#8203;</a><a name="tLRTT1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">respectively, of the common stock of the combined company post-merger. For more information on the Carisma pre-closing financing, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Subscription Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 198 of the proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anticipated Accounting Treatment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Anticipated Accounting Treatment&#8221; on page 166 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The merger is expected to be accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Sesen Bio are cash, cash equivalents and marketable securities. For financial reporting purposes, Carisma has been determined to be the accounting acquirer based upon the terms of the merger including: (i)&#160;Carisma stockholders and holders of securities convertible into Carisma common stock are expected to own approximately 75.8% of the combined company (based on estimates made at the time of the signing of the Merger Agreement), (ii)&#160;Carisma will hold the majority (six of seven) of board seats of the combined company and (iii)&#160;Carisma management will hold all key positions in the management of the combined company. Accordingly, the merger is expected to be treated as the equivalent of Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the merger, the net assets of Sesen Bio will be recorded at their acquisition-date fair value in the consolidated financial statements of Carisma and the reported operating results prior to the merger will be those of Carisma. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Unaudited Pro Forma Condensed Combined Financial Information</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 372 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for additional information. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Litigation Related to the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The proxy statement/prospectus describes certain pending litigation related to the merger agreement up to and including January&#160;19, 2023, the date of the proxy statement/prospectus. The discussion below supplements that description up to and including the date of this supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;3, 2023, a purported Sesen Bio stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Plumley&#160;v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:23-cv-00131 (D. Del.), or the Plumley Complaint. The Plumley Complaint asserts claims under Section&#160;14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus and under Section&#160;20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the merger and an award for plaintiff&#8217;s fees and costs. On February&#160;7, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Franchi v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, 1:23-cv-01041 (S.D.N.Y.), or the Franchi Complaint. The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Sesen Bio received a demand letter on February&#160;8, 2023, sent on behalf of a purported Sesen Bio stockholder, or the Rosenblatt demand letter, alleging omissions of material information with respect to the merger from the proxy statement/prospectus, including information regarding the financial projections with respect to Carisma, the financial analyses performed by SVB Securities in support of its fairness opinion, potential conflicts of interest involving SVB Securities, and the background and process leading to the execution of the Merger Agreement, and demanding that Sesen Bio promptly provide stockholders with additional disclosure. Additionally, on February&#160;9, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Menzer v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, 1:23-cv-01119 (S.D.N.Y.), or the Menzer Complaint. The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. On February&#160;13, 2023, Sesen Bio received a demand letter on behalf of a purported Sesen Bio stockholder, or the Markman demand letter. The Markman demand letter contains substantially similar allegations and claims and seeks substantially similar relief as the Rosenblatt demand letter. On February&#160;15, 2023, Sesen Bio received an updated demand letter on behalf of a purported Sesen Bio stockholder who had previously sent a demand letter on November&#160;4, 2022, or the updated McKinley demand letter. The updated McKinley demand letter contains substantially similar allegations and claims and seeks substantially similar relief as the Rosenblatt demand letter. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio believes that the claims asserted in the Plumley Complaint, the Franchi Complaint, the Rosenblatt demand letter, the Menzer Complaint, the Markman demand letter and the updated McKinley demand letter are without merit. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders and Carisma stockholders may serve additional demands and/or file additional lawsuits challenging the merger, which may name Sesen Bio, Carisma, members of the Sesen Bio board of directors, members of the Carisma board of directors and/or others as defendants. No assurance can be made as to the outcome of such additional demands, lawsuits, the Plumley Complaint, the Franchi Complaint, the Rosenblatt demand letter, the Menzer Complaint or the Markman demand letter, including the amount of costs associated with defending, settling, or any other liabilities that may be incurred in connection with the litigation or settlement of, such claims. If any additional demands are served and/or any additional lawsuits filed, absent new or different allegations that are material, Sesen Bio will not necessarily announce such additional demands and/or complaints. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTTM1">&#8203;</a><a name="tEXRA">&#8203;</a><a name="tDAOO">&#8203;</a><a name="tPRDI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO THE MERGER AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exchange Ratio</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first two paragraphs in the section entitled &#8220;The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; </font><font style="letter-spacing:0.2pt;">on page 172 of the proxy statement/prospectus are replaced in their entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The exchange ratio is calculated using a formula intended to allocate existing Sesen Bio and Carisma stockholders a&#160;percentage of the combined company. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of February&#160;13, 2023, the date the Second Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 40.0154 shares of Sesen Bio common stock. This estimate is subject to adjustment prior to the closing of the merger for net cash at the cash determination time and aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing (and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the estimates set forth above, and certain other assumptions, Sesen Bio stockholders would own approximately 24.2% of the common stock of the combined company post-merger, and Carisma stockholders would own approximately 75.8% of the common stock of the combined company post-merger, of which the shares issued in the Carisma pre-closing financing and the shares issued upon the conversion of the Carisma convertible note are expected to represent approximately 8.5% and 11.4%, respectively, of the common stock of the combined company post-merger. For more information on the Carisma pre-closing financing, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Subscription Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 198 of the proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors and Officers of Sesen Bio Following the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;The Merger Agreement&#8201;&#8212;&#8201;Directors and Officers of Sesen Bio Following the Merger&#8221; on page 175 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, none of the current directors of Sesen Bio will continue as directors of Sesen Bio or the combined company following the consummation of the merger and all such directors will resign effective as of the closing of the merger. Additionally, pursuant to the Merger Agreement, the employment and service of each officer of Sesen Bio will terminate. Effective as of the effective time, the Sesen Bio board of directors is expected to be comprised of seven directors, to serve in the class assigned to director. Pursuant to the terms of the Merger Agreement, one such director will be designated by Sesen Bio, and six such directors will be designated by Carisma. Pursuant to the Second Merger Agreement Amendment, it is no longer anticipated that Thomas R. Cannell will continue as a member of the combined company&#8217;s board of directors following the merger. Instead, Michael Torok, an approximately 4.1% stockholder of Sesen Bio, is anticipated to be the Sesen Bio designated director on the combined company&#8217;s board of directors. Carisma will appoint the remaining directors to the Sesen Bio board of directors to fill the resulting vacancies. It is anticipated that Sanford Zweifach, Regina Hodits, Briggs Morrison, Bj&#246;rn Odlander, Chidozie Ugwumba, and Steven Kelly will be appointed to the board of directors of the combined company by Carisma. Sanford Zweifach is expected to be appointed as chair of the board of directors of the combined company. It is anticipated that Sesen Bio&#8217;s executive officers upon the closing of the merger will be Steven Kelly, Richard Morris and Michael Klichinsky. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Closing Dividend</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;The Merger Agreement&#8201;&#8212;&#8201;Pre-Closing Dividend&#8221; on page 179 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will declare a dividend to its common stockholders of record consisting of (a)&#160;one CVR for each outstanding share of Sesen Bio common stock held by such stockholder as of such date, representing the right to receive contingent payments upon the occurrence of certain events as well as proceeds from any sale of Sesen Bio&#8217;s non-cash assets, as set forth in, and subject to and in accordance with the terms and conditions of, the amended CVR Agreement, in the form attached to this supplement as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex S-B</font><font style="letter-spacing:0.2pt;">, and (b)&#160;cash in an amount of $75.0&#160;million in the aggregate, subject to Sesen Bio&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:508pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">estimated net cash as of the closing of the merger being greater than or equal to $70.0&#160;million and subject to the satisfaction of certain obligations of Sesen Bio under the Merger Agreement. The record date for the pre-closing dividend shall be a date agreed upon by Carisma and Sesen Bio prior to the day on which the effective time occurs and the payment date for which shall be three business days after the effective time; provided, that the payment of such dividend may be conditioned upon the occurrence of the effective time. In connection with the pre-closing dividend, Sesen Bio shall cause the amended CVR Agreement to be duly authorized, executed and delivered by Sesen Bio and a rights agent selected by Sesen Bio with Carisma&#8217;s prior approval (such approval not to be unreasonably withheld, delayed or conditioned). For more information related to the CVRs, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 192 of the proxy statement/prospectus, as supplemented by this supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTAR">&#8203;</a><a name="tCVAG">&#8203;</a><a name="tVASA1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO AGREEMENTS RELATED TO THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CVR Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The fourth and fifth paragraphs in the section entitled &#8220;Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8221; on page 192 of the proxy statement/prospectus are replaced in their entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The sole right of the holders of the CVRs is to receive cash from Sesen Bio, if any, through the rights agent in accordance with the amended CVR Agreement. The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading on any exchange. The CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in Sesen Bio or its subsidiaries, and interest will not accrue on any amounts payable on the CVRs. The amended CVR Agreement will be effective prior to the closing of the merger and will continue in effect until the earlier of (i)&#160;March&#160;31, 2027 and (ii)&#160;the payment of all amounts payable thereunder, unless and until earlier terminated upon termination of the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the amended CVR Agreement does not purport to be complete and is qualified in its entirety by the full text of the form of amended CVR Agreement, which is included in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex&#160;S-B</font><font style="letter-spacing:0.2pt;"> to this supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following section is added following the section entitled &#8220;Agreements Related to the Merger&#8201;&#8212;&#8201;Support Agreements and Written Consents&#8221; beginning on page 197 of the proxy statement/prospectus:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting and Support Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Second Merger Agreement Amendment, on February&#160;13, 2023, Sesen Bio and Carisma entered into the Investor Group support agreement. Pursuant to the Investor Group support agreement, the Investor Group has agreed to vote their shares of Sesen Bio common stock (i)&#160;in favor of (a)&#160;the adoption and approval of the Merger Agreement and the transactions contemplated thereby; (b)&#160;the issuance of shares of Sesen Bio common stock to Carisma stockholders in connection with the Merger Agreement and the transactions contemplated thereby; (c)&#160;the change of control of Sesen Bio resulting from the merger pursuant to Nasdaq rules; (d)&#160;an amendment to the Sesen Bio Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock, at a ratio of 1-for-20, and a reduction of the number of authorized shares of Sesen Bio common stock to 100,000,000; (e)&#160;the approval of the equity plan amendment proposals; and (f)&#160;a waiver of any notice that may have been or may be required relating to the merger or any other transactions contemplated thereby and (ii)&#160;against any competing acquisition proposal and any action in furtherance of any such competing acquisition proposal. The Investor Group support agreement also contains restrictions on the transfer of Sesen Bio common stock held by the Investor Group, subject to certain exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, pursuant to the Investor Group support agreement, the Investor Group has agreed that from the effective time of the Merger until the expiration of the standstill restrictions, the Investor Group will vote all of their shares for all directors nominated and recommended for election by the combined company&#8217;s board of directors and otherwise in accordance with the recommendations of the combined company&#8217;s board of directors at any annual or special meeting of stockholders, subject to certain exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Investor Group support agreement also includes certain standstill restrictions applicable to the Investor Group pursuant to which the Investor Group is restricted from, among other things, (i)&#160;engaging in any solicitation of proxies or consents with respect to the securities of Sesen Bio or Carisma, (ii)&#160;forming or joining a group (within the meaning of Section&#160;13(d)(3) of the Exchange Act) with respect to shares of Sesen Bio common stock, (iii)&#160;seeking or submitting, or knowingly encouraging other persons to seek or submit, nominations in furtherance of a contested solicitation for the appointment, election or removal of directors or taking any other action with respect to the appointment, election or removal of any directors, in each case in opposition to the recommendation of the board of directors, (iv)&#160;making or participating in any extraordinary transaction, (v)&#160;seeking, alone or in concert with others, representation on the combined company&#8217;s board of directors, except as otherwise permitted by the Second Merger Agreement Amendment, and (vi)&#160;making any stockholder proposal, subject to customary exceptions. These restrictions apply until the later of (A)&#160;the earlier of (1)&#160;15&#160;days prior to the deadline under Sesen Bio&#8217;s amended and restated bylaws </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:320pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">for director nominations and stockholder proposals for Sesen Bio&#8217;s 2024 annual meeting of stockholders, (2)&#160;100&#160;days prior to the first anniversary of Sesen Bio&#8217;s 2023 annual meeting of stockholders, and (3)&#160;such date that is ten business days after Sesen Bio&#8217;s or Carisma&#8217;s receipt of notice from any member of the Investor Group specifying a material breach of the Investor Group support agreement that is not cured within such period, and (B)&#160;the date when Mr.&#160;Torok is no longer on the combined company&#8217;s board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Investor Group support agreement provides that in the event Sesen Bio or Carisma has not obtained the requisite stockholder vote under the Merger Agreement by April&#160;1, 2023, Sesen Bio will (a)&#160;provide the Investor Group at least 70&#160;days advance notice of the date of Sesen Bio&#8217;s 2023 annual meeting of stockholders, (b)&#160;deem otherwise compliant proposals or director nominations received from the Investor Group within ten days of such notice as timely received in accordance with Sesen Bio&#8217;s amended and restated bylaws, and (c)&#160;not hold such meeting fewer than 70&#160;days after such notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Investor Group support agreement terminates upon the earliest to occur of (i)&#160;the valid termination of the Merger Agreement, (ii)&#160;any amendment to the Merger Agreement that reduces the amount, or changes the form of any consideration payable to the Investor Group in the merger or otherwise materially and adversely affects the Investor Group, (iii)&#160;the expiration of the standstill period, (iv)&#160;solely in the event that either Sesen Bio or Carisma has not obtained the requisite stockholder vote under the Merger Agreement by April&#160;1, 2023, and (v)&#160;the termination of the Investor Group support agreement by written agreement of all parties thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of January&#160;17, 2023, the record date for the Sesen Bio special meeting, the Investor Group beneficially owned approximately 8.5% of the shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the Investor Group support agreement does not purport to be complete and is qualified in its entirety by the full text of the Investor Group support agreement, which is attached hereto as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex S-C</font><font style="letter-spacing:0.2pt;"> to this supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTMB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:152pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO MATTERS BEING SUBMITTED TO A VOTE OF SESEN BIO STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 1: Approval, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The second paragraph in the section entitled &#8220;Matters Being Submitted to a Vote of Sesen Bio Stockholders&#8201;&#8212;&#8201;Proposal No. 1: Approval, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger&#8221; beginning on page 201 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 24.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of the Carisma convertible note, are expected to own approximately 75.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including, Sesen Bio&#8217;s net cash as of closing being at least $70.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The third paragraph in the section entitled &#8220;Matters Being Submitted to a Vote of Sesen Bio Stockholders&#8201;&#8212;&#8201;Proposal No. 1: Approval, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger&#8221; beginning on page 201 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, is amended and restated as follows (with new text in bold and deleted text in strikeout font):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The terms of, reasons for and other aspects of the Merger Agreement, the merger and the issuance of Sesen Bio common stock in the merger are described in detail in the other sections in </font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">this</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;letter-spacing:-0.2pt;">the</font><font style="letter-spacing:0.2pt;"> proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. A copy of the Original Merger Agreement</font><font style="font-weight:bold;letter-spacing:-0.2pt;">,</font><font style=" text-decoration:line-through;letter-spacing:0.2pt;"> and</font><font style="letter-spacing:0.2pt;"> the Merger Agreement Amendment </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and the Second Merger Agreement Amendment</font><font style="letter-spacing:0.2pt;"> are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annexes A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">A-2</font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">, respectively,</font><font style="letter-spacing:0.2pt;"> to </font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">this</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;letter-spacing:-0.2pt;">the</font><font style="letter-spacing:0.2pt;"> proxy statement/prospectus </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and as </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Annex S-A</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> to this supplement, respectively</font><font style="letter-spacing:0.2pt;">. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The sixth paragraph in the section entitled &#8220;Matters Being Submitted to a Vote of Sesen Bio Stockholders&#8201;&#8212;&#8201;Proposal No. 1: Approval, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger&#8221; beginning on page 201 of the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, is amended and restated as follows (with new text in bold and deleted text in strikeout font):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The terms of, reasons for and other aspects of the Merger Agreement, the merger and the issuance of Sesen Bio common stock in the merger are described in detail in the other sections in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. A copy of the Original Merger Agreement</font><font style="font-weight:bold;letter-spacing:-0.2pt;">,</font><font style=" text-decoration:line-through;letter-spacing:0.2pt;"> and</font><font style="letter-spacing:0.2pt;"> the Merger Agreement Amendment </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and the Second Merger Agreement Amendment</font><font style="letter-spacing:0.2pt;"> are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annexes A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">A-2</font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">, respectively,</font><font style="letter-spacing:0.2pt;"> to </font><font style=" text-decoration:line-through;letter-spacing:0.2pt;">this</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;letter-spacing:-0.2pt;">the</font><font style="letter-spacing:0.2pt;"> proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and as </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Annex S-A</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> to this supplement, respectively</font><font style="letter-spacing:0.2pt;">. </font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTSB">&#8203;</a><a name="tLEPR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO SESEN BIO BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Current Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The first paragraph in the section entitled &#8220;Sesen Bio Business&#8201;&#8212;&#8201;Current Strategy&#8201;&#8212;&#8201;The Merger&#8221; beginning on page 230 of the proxy statement/prospectus is amended and restated as follows (with new text in bold and deleted text in strikeout font):</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2022, Sesen Bio announced that it had commenced a process to explore and evaluate strategic alternatives to enhance stockholder value, and had engaged a financial advisor to assist Sesen Bio in this process. Sesen Bio then commenced an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic acquisition or other transaction as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Background of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 125 of the proxy statement/prospectus. On September&#160;21, 2022, Sesen Bio announced that it had entered into the Original Merger Agreement, which was subsequently amended on December&#160;29, 2022 </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and on February&#160;13, 2023</font><font style="letter-spacing:0.2pt;">. Although Sesen Bio has entered into the Original Merger Agreement</font><font style="font-weight:bold;letter-spacing:-0.2pt;">,</font><font style=" text-decoration:line-through;letter-spacing:0.2pt;"> and</font><font style="letter-spacing:0.2pt;"> the Merger Agreement Amendment </font><font style="font-weight:bold;letter-spacing:-0.2pt;">and the Second Merger Agreement Amendment</font><font style="letter-spacing:0.2pt;"> and intends to consummate the merger, there is no assurance that it will be able to successfully consummate the merger on a timely basis, or at all. If, for any reason, the merger does not close, the Sesen Bio board of directors may elect to, among other things, attempt to complete another strategic transaction like the merger, attempt to sell or otherwise dispose of the various assets of Sesen Bio, resume its research and development activities and continue to operate the business of Sesen Bio or dissolve and liquidate its assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The proxy statement/prospectus describes certain pending litigation related to the merger agreement up to and including January&#160;19, 2023, the date of the proxy statement/prospectus. The discussion below supplements that description up to and including the date of this supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;3, 2023, a purported Sesen Bio stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Plumley v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:23-cv-00131 (D. Del.), or the Plumley Complaint. The Plumley Complaint asserts claims under Section&#160;14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus and under Section&#160;20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the merger and an award for plaintiff&#8217;s fees and costs. On February&#160;7, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Franchi v. Sesen Bio, Inc.</font><font style="letter-spacing:0.2pt;">, et al., 1:23-cv-01041 (S.D.N.Y.), or the Franchi Complaint. The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Sesen Bio received a demand letter on February&#160;8, 2023, sent on behalf of a purported Sesen Bio stockholder, or the Rosenblatt demand letter, alleging omissions of material information with respect to the merger from the proxy statement/prospectus, including information regarding the financial projections with respect to Carisma, the financial analyses performed by SVB Securities in support of its fairness opinion, potential conflicts of interest involving SVB Securities, and the background and process leading to the execution of the Merger Agreement, and demanding that Sesen Bio promptly provide stockholders with additional disclosure. Additionally, on February&#160;9, 2023, another purported Sesen Bio stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Menzer v. Sesen Bio, Inc.</font><font style="letter-spacing:0.2pt;">, et al., 1:23-cv-01119 (S.D.N.Y.), or the Menzer Complaint. The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. On February&#160;13, 2023, Sesen Bio received a demand letter on behalf of a purported Sesen Bio stockholder, or the Markman demand letter. The Markman demand letter contains substantially similar allegations and claims and seeks substantially similar relief as the Rosenblatt demand letter. On February&#160;15, 2023, Sesen Bio received an updated demand letter on behalf of a purported Sesen Bio stockholder who had previously sent a demand </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:536pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">letter on November&#160;4, 2022, or the updated McKinley demand letter. The updated McKinley demand letter contains substantially similar allegations and claims and seeks substantially similar relief as the Rosenblatt demand letter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio believes that the claims asserted in the Plumley Complaint, the Franchi Complaint, the Rosenblatt demand letter, the Menzer Complaint, the Markman demand letter and the updated McKinley demand letter are without merit. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to Sesen Bio. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTMF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:89.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO MANAGEMENT FOLLOWING THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The second paragraph and following table in the section entitled &#8220;Management Following the Merger&#8201;&#8212;&#8201;Executive Officers and Directors&#8221; on page 342 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the name, age as of February&#160;13, 2023 and position of each of the individuals who are expected to serve as executive officers and directors of the combined company. </font>
        </div>
        <table style="width:456pt;height:173.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:209.37pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:209.37pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Steven Kelly </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">57 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer, Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Richard Morris </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">49 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">33 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:209.37pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">66 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director, Chair </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">53 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">63 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">64 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">40 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:0.2pt;">Michael Torok </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;">
              <font style="letter-spacing:0.2pt;">44 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The second paragraph in the section entitled &#8220;Management Following the Merger&#8201;&#8212;&#8201;Executive Officers and Directors&#8201;&#8212;&#8201;Non-Employee Directors&#8221; on page 343 of the proxy statement/prospectus is deleted in its entirety.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following paragraph is added following the seventh paragraph in the section entitled &#8220;Management Following the Merger&#8201;&#8212;&#8201;Executive Officers and Directors&#8201;&#8212;&#8201;Non-Employee Directors&#8221; on page 343 of the proxy statement/prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Michael Torok</font><font style="letter-spacing:0.2pt;"> currently serves as the co-founder and managing director of JEC Capital Partners, LLC, an investment company with offices in the United States and Germany, since 2008, and Manager of JEC II Associates, LLC, an investment company, since 2008. Prior to that, he served as Chief Financial Officer for Integrated Dynamics Engineering Inc, a semiconductor equipment technology company that was acquired by Aalberts Industries (AMS: AALB). Earlier in his career, Mr.&#160;Torok served in various positions for PricewaterhouseCoopers LLP, a multinational professional services network of firms. Mr.&#160;Torok currently serves on the board of directors of Liberated Syndication, Inc. (formerly NASDAQ: LSYN), a podcasting platform for creators and advertisers, since December&#160;2022. He previously served on the board of directors of Photon Control Inc. (formerly TSX: PHO), which designs, manufactures and distributes a wide range of optical sensors and systems to measure temperature and position, from 2016 to May&#160;2018, and Symbility Solutions Inc., a software company focused on the insurance industry, from 2015 to January&#160;2018. Mr.&#160;Torok received a B.S. in Finance and a Master in Finance from Boston College.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTUP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, Sesen Bio, Merger Sub, and Carisma entered into the Original Merger Agreement (as amended by the Merger Agreement Amendment dated as of December&#160;29, 2022 and the Second Merger Agreement Amendment dated as of February&#160;13, 2023, the Merger Agreement) pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of Sesen Bio and the surviving corporation of the merger. At the effective time of the merger, Sesen Bio will change its name to &#8220;Carisma Therapeutics Inc.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to the execution and delivery of the Original Merger Agreement, Carisma entered into a subscription agreement in connection with the Carisma pre-closing financing, pursuant to which certain investors agreed to purchase shares of Carisma common stock at an aggregate purchase price of $30.6&#160;million. The closing of the Carisma pre-closing financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger set forth in the Merger Agreement. The shares of Carisma common stock issued in the Carisma pre-closing financing will be converted into shares of Sesen Bio common stock in the merger in accordance with the exchange ratio. As of immediately after the effective time of the merger, the Carisma convertible note will automatically convert into a number of shares of Sesen Bio common stock calculated in accordance with the terms of the Carisma convertible note and based on the exchange ratio for the conversion of Carisma capital stock into Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will enter into the CVR Agreement with a rights agent pursuant to which Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time will receive one CVR for each outstanding share of Sesen Bio common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes. The CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in Sesen Bio or its subsidiaries, and interest will not accrue on any amounts payable on the CVRs. Prior to the effective time, Sesen Bio will declare a pre-closing dividend to its common stockholders of record consisting of (a)&#160;one CVR for each outstanding share of Sesen Bio common stock held by such stockholder as of such date, representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement and (b)&#160;a special cash dividend expected to be $75.0&#160;million in the aggregate, subject to Sesen Bio&#8217;s estimated net cash as of the closing of the merger being greater than or equal to $70.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, each outstanding share of Carisma capital stock, including shares of Carisma common stock issued in connection with the Carisma pre-closing financing, will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio. The exchange ratio was estimated at the time of the execution of the Second Merger Agreement Amendment on February&#160;13, 2023 to be 40.0154 shares of Sesen Bio common stock for each share of Carisma capital stock and is subject to adjustment prior to the closing for, among other things, Sesen Bio&#8217;s net cash at the cash determination time. Because Sesen Bio&#8217;s final net cash will not be determined until the closing, and because the number of shares of Sesen Bio common stock issuable to Carisma stockholders is determined based on, among other things, Sesen Bio&#8217;s final net cash, Sesen Bio stockholders cannot be certain of the exact number of shares that will be issued to Carisma stockholders when Sesen Bio stockholders vote on the proposals at the Sesen Bio special meeting. The exchange ratio referenced above is an estimate only and the final exchange ratio will be determined pursuant to a formula described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Merger Consideration</font><font style="letter-spacing:0.2pt;">&#8221; in the proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following selected unaudited pro&#160;forma condensed combined financial data gives effect to the (i)&#160;merger, (ii)&#160;the Carisma pre-closing financing, (iii)&#160;the automatic conversion of the Carisma convertible note, and (iv)&#160;the pre-closing dividend. Additionally, the unaudited pro&#160;forma condensed combined balance sheet reflects the proceeds received by Sesen Bio in connection with the Roche Asset Purchase Agreement in July&#160;2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Sesen Bio are cash, cash equivalents, and marketable securities. For financial reporting purposes, Carisma has been determined to be the accounting acquirer based upon the terms of the merger and other factors including: (i)&#160;Carisma stockholders and other persons holding securities that are convertible into Carisma common stock are expected to own approximately 75.8% of the fully diluted closing Sesen Bio common stock immediately following the effective time of the merger (based on estimates made at the time of the execution of the Merger Agreement), (ii)&#160;Carisma will hold the majority (six of seven) of board seats of the combined company, and (iii)&#160;Carisma&#8217;s management will hold all key positions in the management of the combined company. The &#8220;fully diluted closing Sesen Bio common stock&#8221; as used herein means (x)&#160;the number of outstanding shares of Sesen Bio common stock, which amount excludes the shares of Sesen Bio common stock available for issuance under the 2014 Incentive Plan and the 2009 Incentive Plan, as well as inducement grants made outside of the Sesen Bio stockholder-approved plans and out-of-the-money Sesen Bio options, </font><font style="font-style:italic;letter-spacing:0.2pt;">plus</font><font style="letter-spacing:0.2pt;"> (y)&#160;the number of outstanding shares of Carisma common stock, which amount includes the shares of Carisma common stock available for issuance under the Carisma Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial information was prepared in accordance with Article&#160;11 of Regulation&#160;S-X. The Sesen Bio and Carisma unaudited pro&#160;forma condensed combined balance sheet data assume that the merger took place on September&#160;30, 2022, and combines the Sesen Bio and Carisma historical balance sheets at September&#160;30, 2022. The Sesen Bio and Carisma unaudited pro&#160;forma condensed combined statements of operations data assume that the merger took place as of January&#160;1, 2021 and combines the historical results of Sesen Bio and Carisma for the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. The historical financial statements of Sesen Bio and Carisma, which are included in the proxy statement/prospectus, have been adjusted to give pro&#160;forma effect to events that are (i)&#160;directly attributable to the merger, (ii)&#160;factually supportable, and (iii)&#160;with respect to the statements of operations, expected to have a continuing impact on the combined results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements are based on the assumptions and adjustments that are described in the accompanying notes. The unaudited pro&#160;forma condensed combined financial statements and pro&#160;forma adjustments have been prepared based on preliminary estimates of fair value of assets acquired and liabilities assumed. A final determination of these estimated fair values will be based on the actual net tangible assets of Sesen Bio that exist as of the date of completion of the merger. Differences between these preliminary estimates and the final fair value of assets and liabilities acquired may occur and these differences could have a material impact on the accompanying unaudited pro&#160;forma condensed combined financial statements and the combined company&#8217;s future results of operations and financial position. The actual amounts recorded as of the completion of the merger may differ materially from the information presented in these unaudited pro&#160;forma condensed combined financial statements as a result of the amount of cash used by Sesen Bio&#8217;s operations between the signing of the Merger Agreement and the closing of the merger; the timing of the closing of the merger; and other changes in Sesen Bio&#8217;s assets and liabilities that occur prior to the completion of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the merger. The unaudited pro&#160;forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had Sesen Bio and Carisma been a combined company during the specified period. The unaudited pro&#160;forma condensed combined financial statements, including the notes thereto, should be read in conjunction with the separate historical audited financial statements of Sesen Bio and Carisma for the year ended December&#160;31, 2021 and the unaudited condensed financial statements of Sesen Bio and Carisma for the nine&#160;months ended September&#160;30, 2022 included elsewhere in the proxy statement/prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Condensed Combined Balance Sheet</font>
          <br >
          <font style="letter-spacing:-0.2pt;">As of September&#160;30, 2022</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:597pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transactions</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Combined </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Current assets</font><font style="font-weight:normal;letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">28,943</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">71,107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(67,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">A</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">32,257</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">41,705</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">106,427</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">148,132</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">14,297</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">14,297</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current</font>
                <br >
                <font style="letter-spacing:0.2pt;">assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">2,290</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">527</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">2,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">72,938</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">192,358</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(67,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">197,503</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,677</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,677</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Right of use assets&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">6,121</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">6,121</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.75pt 0pt; width:209.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">87,736</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">199,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(67,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">219,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">LIABILITIES, CONVERTIBLE PREFERRED </font>
                <br >
                <font style="letter-spacing:-0.2pt;">STOCK AND STOCKHOLERS&#8217; EQUITY </font>
                <br >
                <font style="letter-spacing:-0.2pt;">(DEFICIT)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Current liabilities</font><font style="font-weight:normal;letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">4,084</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">4,599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,997</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">33,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">B</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,926</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,230</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">5,184</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">5,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Convertible promissory notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">33,175</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(33,175<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">C</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">157</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">381</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">538</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">53,834</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">34,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(36,046<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,483</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenues, noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">5,189</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(5,189<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">C</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease liabilities, noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,003</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,003</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease liabilities, noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other noncurrent liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">307</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">307</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">106,036</div>
            </td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">34,695</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(41,235<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">D</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">99,496</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(107,808<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Stockholders&#8217; equity (deficit):</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">633</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,141</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">493,629</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(230,957<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">263,813</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:209.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated other comprehensive income (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(235<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(141,484<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(328,567<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">325,734</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(144,317<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; equity (deficit) attributable </font>
                <br >
                <font style="letter-spacing:0.2pt;">to Carisma and Sesen Bio </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(140,503<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">165,029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">95,645</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">120,171</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Equity attributable to noncontrolling</font>
                <br >
                <font style="letter-spacing:0.2pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(14,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">F</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 0.5pt 0pt; width:209.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total stockholders&#8217; equity (deficit)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(126,108<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">165,029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">81,250</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">120,171</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:209.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">87,736</td>
            <td style="padding:0pt;padding-left:0.809999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">199,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(67,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.765000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">219,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:226pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Condensed Combined Statements of Operations</font>
          <br >
          <font style="letter-spacing:-0.2pt;">For the Nine Months Ended September&#160;30, 2022</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:339pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:169.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Combined </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Collaboration revenues </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,103</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">I</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,103</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,536</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">37,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">76,172</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,407</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">41,112</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:169.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">46,943</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">57,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">103,995</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(17,052<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(97,892<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-operating income (expense): </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:169.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,369</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">G</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,551</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">G</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(16,185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,920</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">96,752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,920</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">92,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:169.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40.16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.11<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:169.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average common shares outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,108</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">630,901</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">H</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">831,810</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:253pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Condensed Combined Statements of Operations</font>
          <br >
          <font style="letter-spacing:-0.2pt;">For the Year Ended December&#160;31, 2021</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:312pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:176.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Transaction</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Combined </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Collaboration revenues </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">26,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3pt; text-align:right; white-space:nowrap;">J</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating Expenses: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34,387</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">59,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,407</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">29,393</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:176.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,794</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">35,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">75,887</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,794<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,549<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(69,343<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-operating income (expense): </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(69,393<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(61,120<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37.62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.00<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.07<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:176.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average common shares outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,084</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">182,323</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">841,832</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">H</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">825,239</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1.&nbsp;&nbsp;&nbsp;Description of Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Merger Transaction</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, Sesen Bio and Carisma entered into the Original Merger Agreement, as amended by the First Amendment thereto on December&#160;29, 2022 and the Second Amendment thereto on February&#160;13, 2023, pursuant to which a wholly-owned subsidiary of Sesen Bio will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio. After completion of the merger, Sesen Bio is expected to be renamed &#8220;Carisma Therapeutics Inc.&#8221; and to trade under the symbol &#8220;CARM.&#8221; As of October&#160;14, 2022, the Sesen Bio common stock is listed on the Nasdaq Capital Market under the symbol &#8220;SESN.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, each outstanding share of Carisma capital stock (including shares of Carisma common stock issued in connection with the Carisma pre-closing financing) will be converted into the right to receive shares of Sesen Bio common stock equal to the exchange ratio. Based on estimates made as of at the time of the Second Merger Agreement Amendment, the exchange ratio was estimated to be 40.0154 shares of Sesen Bio common stock for each share of Carisma capital stock and is subject to adjustment prior to the closing. Among other things, the exchange ratio will be adjusted to the extent that Sesen Bio&#8217;s net cash at closing is less than or greater than $70.0&#160;million and based on the amount of the Carisma pre-closing financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio currently estimates, assuming the closing of the merger occurred on December&#160;31, 2022, that (i)&#160;it would have approximately $70.0&#160;million in net cash immediately prior to closing, (ii)&#160;the Carisma pre-closing financing amount will be $30.6&#160;million, (iii)&#160;the outstanding shares of Sesen Bio common stock, Sesen Bio RSUs, Sesen Bio options and Sesen Bio warrants as of the closing will be equal to 222,944,963 and (iv)&#160;the outstanding shares of Carisma capital stock as of the closing on a fully diluted and as-converted basis will be equal to 14,855,514. Accordingly, it is currently estimated that the exchange ratio at closing will be 40.0154 and, based solely on such exchange ratio, at closing: (a)&#160;the Sesen Bio stockholders as of immediately prior to the merger (excluding for this purpose certain out-of-the-money Sesen Bio options) are expected to own approximately 24.2% of the fully diluted closing Sesen Bio common stock, and (b)&#160;Carisma stockholders as of immediately prior to the merger are expected to own approximately 75.8% of the fully diluted closing Sesen Bio common stock, of which (i)&#160;the shares of Carisma common stock issued in the Carisma pre-closing financing to Carisma stockholders as of immediately prior to the merger are expected to represent approximately 8.5% of the fully diluted closing Sesen Bio common stock, (ii)&#160;the shares of Sesen Bio common stock issued upon the conversion of the Carisma convertible note are expected to represent approximately 11.4% of the fully diluted closing Sesen Bio common stock, and (iii)&#160;the shares of Carisma capital stock available for issuance under the Carisma Plan as of immediately prior to the merger are expected to represent approximately 11.3% of the fully diluted closing Sesen Bio common stock, in each case, subject to adjustment of the exchange ratio as set forth in the Merger Agreement and described herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because Sesen Bio&#8217;s final net cash will not be determined until the closing, Sesen Bio stockholders cannot be certain of the exact number of shares that will be issued to Carisma stockholders when Sesen Bio stockholders vote on the proposals at the Sesen Bio special meeting. The exchange ratio referenced above is an estimate only and the final exchange ratio will be determined pursuant to a formula described in more detail in the Merger Agreement and in the proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the effective time of the merger, each Carisma option that is outstanding and unexercised immediately prior to the effective time granted under the Carisma Plan, or otherwise, whether or not vested, will be, along with the Carisma Plan, assumed by Sesen Bio and will become an option to purchase solely that number of shares of Sesen Bio common stock equal to the product obtained by multiplying (i)&#160;the number of shares of Carisma common stock by (ii)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of Sesen Bio common stock. The per share exercise price for Sesen Bio common stock issuable upon exercise of each Carisma option assumed shall be determined by dividing (a)&#160;the per share exercise price of Carisma common stock by (b)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Any restriction on the exercise of any Carisma option </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">assumed will continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Carisma option shall otherwise remain unchanged. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-Closing Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a condition of the Merger Agreement, certain investors have entered into the subscription agreement with Carisma pursuant to which such investors have agreed, subject to the terms and conditions of the subscription agreement, to purchase shares of Carisma common stock prior to closing for an aggregate purchase price of $30.6&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-Closing Dividend</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will declare a pre-closing dividend to its stockholders consisting of the right to receive contingent payments as discussed in greater detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 192 of the proxy statement/prospectus and a special cash dividend that is expected to be $75.0&#160;million in the aggregate, subject to Sesen Bio&#8217;s estimated net cash as of the closing of the merger being greater than or equal to $70.0&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conversion of Carisma Convertible Note</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon completion of the merger, Carisma&#8217;s $35.0&#160;million convertible note and accrued interest will convert into shares of Sesen Bio common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contingent Value Rights Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will enter into the CVR Agreement with a rights agent pursuant to which Sesen Bio stockholders will receive one CVR for each share of Sesen Bio common stock held. Each CVR will represent the contractual right to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum. The CVR will be recognized when the achievement of the milestone payment becomes probable. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sesen Bio Sale of Legacy Technology to Roche</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio executed the Roche Asset Purchase Agreement pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by Sesen Bio. Sesen Bio received an upfront payment from Roche of $40.0&#160;million upon execution of the Roche Asset Purchase Agreement. In addition, Sesen Bio is eligible to receive an additional $30.0&#160;million payment from Roche upon Roche&#8217;s initiation of a Phase&#160;3 clinical trial with EBI-031 for a defined indication if initiated prior to December&#160;31, 2026 which would be paid to Sesen Bio stockholders through the CVR Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2.&nbsp;&nbsp;&nbsp;Basis of Presentation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements were prepared in accordance with the regulations of the SEC. The unaudited pro&#160;forma condensed combined balance sheet as of September&#160;30, 2022 is presented as if the merger had been completed on September&#160;30, 2022. The unaudited pro&#160;forma condensed combined statements of operations for the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021 assumes that the merger occurred on January&#160;1, 2021, and combines the historical results of Carisma and Sesen Bio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, the unaudited pro&#160;forma condensed combined balance sheet and statements of operations data reflect the other transactions that will have occurred at or prior to the completion of the merger. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For accounting purposes, Carisma is considered to be the acquiring company and the merger will be accounted for as a reverse recapitalization of Sesen Bio by Carisma because at the closing of the merger, the primary pre-combination assets of Sesen Bio will be cash, cash equivalents and marketable securities. The final exchange ratio will be determined based on a net cash calculation prior to the closing. Sesen Bio currently estimates that it will have approximately $70.0&#160;million in net cash immediately prior to the closing of the merger, assuming for this purpose that the closing of the merger occurred on December&#160;31, 2022. The exchange ratio will be adjusted dollar-for-dollar by the amount that the net cash amount is less than $70.0&#160;million. The pro&#160;forma financial statements reflect Sesen Bio management&#8217;s estimates of the fair value of Sesen Bio&#8217;s net assets that will be contributed to Carisma as part of the merger. However, the actual exchange ratio will vary based on the net cash calculation prior to the closing as described above and that difference could be material. A 10% decrease in Sesen Bio&#8217;s net cash would increase the exchange ratio by 9.0%. A 10% increase in Sesen Bio&#8217;s net cash could decrease the exchange ratio by 7.6%. As such, the estimated exchange ratio reflected in these unaudited pro&#160;forma condensed combined financial statements does not purport to represent what the actual exchange ratio will be when the merger is completed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Under reverse recapitalization accounting, the assets and liabilities of Sesen Bio will be recorded, as of the completion of the merger, at their fair values which are expected to approximate book values because of the short-term nature of the instruments. No goodwill or intangible assets are expected to be recognized. The historical financial statements of Sesen Bio and Carisma, which are provided elsewhere in the proxy statement/prospectus, have been adjusted to give pro&#160;forma effect to events that are (i)&#160;directly attributable to the merger, (ii)&#160;factually supportable, and (iii)&#160;with respect to the statements of operations, expected to have a continuing impact on the combined results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pro&#160;forma adjustments related to the Carisma pre-closing financing for aggregate cash proceeds of $30.6&#160;million and reflect the conversion of the Carisma convertible note into shares of Sesen Bio common stock effective as of immediately after the effective time of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements also give effect to the other transactions that are not directly attributable to the merger but are deemed relevant to the pro&#160;forma financial position and operations of the combined companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent there are significant changes to the business following completion of the merger, the assumptions and estimates set forth in the unaudited pro&#160;forma condensed combined financial statements could change significantly. Accordingly, the pro&#160;forma adjustments are subject to further adjustments as additional information becomes available and as additional analyses are conducted following the completion of the merger. There can be no assurances that these additional analyses will not result in material changes to the estimates of fair value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3.&nbsp;&nbsp;&nbsp;Pro Forma Adjustments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The pro&#160;forma adjustments were based on the preliminary information available at the time of the preparation of the unaudited pro&#160;forma condensed combined financial information. The unaudited pro&#160;forma condensed combined financial information, including the notes thereto, are qualified in their entirety by reference to, and should be read in conjunction with, the separate historical audited financial statements of Sesen Bio and Carisma for the year ended December&#160;31, 2021 and the unaudited condensed financial statements of Sesen Bio and Carisma for the nine&#160;months ended September&#160;30, 2022 included elsewhere in the proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Merger Transaction Adjustments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Reflects (i)&#160;approximately $30.6&#160;million in proceeds from the Carisma pre-closing financing, (ii)&#160;payment of a $75.0&#160;million special cash dividend (iii)&#160;payment of total estimated unpaid transaction costs and (iv)&#160;payment of severance costs upon consummation of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:114pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:265.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from Carisma pre-closing financing, net of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">30,640</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">30,640</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Special cash dividend payment to Sesen Bio stockholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(75,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(75,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,033<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of severance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma adjustment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">23,307</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(91,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(67,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.69pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">B</font>
          <br >
        </div>
        <div style=" margin-top:11.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Reflects payment of total estimated unpaid transaction costs as of September&#160;30, 2022 in connection with the merger and settlement of accrued interest upon conversion of the Carisma convertible note: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:72pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unpaid transaction costs as of September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(290<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,315<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued interest for Carisma convertible note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(846<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.69pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">C</font>
          <br >
        </div>
        <div style=" margin-top:11.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Settlement of the Carisma convertible note and related derivative liability through the issuance of Sesen Bio common stock upon completion of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">D</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Conversion of Carisma convertible preferred stock into common stock of the combined company upon completion of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">E</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To record the (i)&#160;exchange ratio adjustment to Carisma&#8217;s common stock outstanding, (ii)&#160;conversion of Carisma convertible preferred stock into common stock, (iii)&#160;the elimination of Carisma&#8217;s noncontrolling interest upon conversion of Carisma convertible preferred stock, (iv)&#160;sale of Carisma common stock, net of issuance costs, in connection with Carisma pre-closing financing, (v)&#160;automatic conversion of the Carisma convertible note, (vi)&#160;elimination of Sesen Bio&#8217;s historical equity carrying value, (vii)&#160;issuance of common stock upon the acceleration of unvested Sesen Bio RSUs and PSUs upon closing of the merger, (viii)&#160;special cash dividend payment to Sesen Bio stockholders, (ix)&#160;post-combination stock-based compensation expense for Sesen Bio options and Sesen Bio RSUs and (x)&#160;payment of transaction and severance costs: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:185.16pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:22.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:142.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">comprehensive</font>
                <br >
                <font style="letter-spacing:-0.16pt;">income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Noncontrolling</font>
                <br >
                <font style="letter-spacing:-0.16pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:142.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:1.99pt 0pt 1pt 0pt; width:142.85pt;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Adjustment to Carisma common </font>
                <br >
                <font style="letter-spacing:0.19pt;">stock outstanding in connection </font>
                <br >
                <font style="letter-spacing:0.19pt;">with the Exchange Ratio </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">44,986</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(46<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.25pt 0pt 0.99pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Issuance of common stock upon conversion of Carisma convertible preferred shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">362,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">363</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107,445</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.25pt 0pt 0.99pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Issuance of common stock upon conversion of Carisma noncontrolling interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">34,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">14,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.26pt 0pt 0.99pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Issuance of common stock upon completion of Pre-Closing Financing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,594</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">30,560</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.26pt 0pt 0.99pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">30,640</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:22.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:142.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">comprehensive</font>
                <br >
                <font style="letter-spacing:-0.16pt;">income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Noncontrolling</font>
                <br >
                <font style="letter-spacing:-0.16pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:142.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:1.99pt 0pt 1pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Issuance of common stock upon settlement of Carisma convertible promissory note, accrued interest and related derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,836</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">104</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">40,641</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,825<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.99pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,920</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.24pt 0pt 1.01pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Elimination of Sesen Bio&#8217;s historical carrying value </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(328,802<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">328,567</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.24pt 0pt 1pt 0pt; width:142.85pt;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Issuance of shares of common </font>
                <br >
                <font style="letter-spacing:0.19pt;">stock of the continuing company </font>
                <br >
                <font style="letter-spacing:0.19pt;">to Sesen Bio shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.24pt 0pt 1.01pt 0pt; width:142.85pt;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Special dividend payment to Sesen </font>
                <br >
                <font style="letter-spacing:0.19pt;">Bio shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(75,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(75,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:2.24pt 0pt 1.01pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:0.19pt;">Post-combination stock-based compensation costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,008</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,008<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.01pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.24pt 0pt 1.945pt 0pt; width:142.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt; line-height:11.39pt; margin-bottom:-0.499999999999996pt;">
                <font style="letter-spacing:0.19pt;">Payment of transaction costs and severance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(21,118<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.945pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(21,118<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
            <td style="padding:3.25pt 0pt 3.325pt 0pt; width:142.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.19pt;">Pro&#160;forma Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">629,710</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">633</td>
            <td style="padding:0pt;padding-left:2.915pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(230,957<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:14.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">325,734</td>
            <td style="padding:0pt;padding-left:3.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.575pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">81,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="44">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F</font>
          <br >
        </div>
        <div style=" margin-top:11.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Issuance of common stock upon conversion of Carisma noncontrolling interests. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">G</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Elimination of interest expense and change in fair value of derivative liability associated with the Carisma convertible note and related derivative, respectively, that were settled upon completion of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">H</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The pro&#160;forma combined basic and diluted earnings per share have been adjusted to reflect the pro&#160;forma net loss for the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. In addition, the number of shares used in calculating the pro&#160;forma combined basic and diluted net income per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company that would be outstanding as of the closing. The following table sets forth the calculation of the pro&#160;forma weighted average number of common shares outstanding&#8201;&#8212;&#8201;basic and diluted. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:150pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine&#160;months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Effect of applying estimated exchange ratio to Carisma common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">43,221</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">42,296</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Carisma preferred stock and noncontrolling interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">397,599</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">391,977</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock in connection with Carisma pre-closing financing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,594</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,594</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon settlement of Carisma convertible note, accrued interest and related derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,836</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,836</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares of common stock of the combined company to Sesen Bio stockholders </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,651</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">25,129</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:338.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">630,901</td>
            <td style="padding:0pt;padding-left:4.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">641,832</td>
            <td style="padding:0pt;padding-left:3.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Other Transaction Adjustments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">I</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Elimination of one time payments received in connection with the Roche Asset Purchase Agreement in July&#160;2022 of $40.0&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">J</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Elimination of development milestone revenue received from Roche during the year ended December&#160;31, 2021 related to the assets sold to Roche in July&#160;2022.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUTPS1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UPDATE TO PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The section entitled &#8220;Principal Stockholders of the Combined Company&#8221; beginning on page 400 of the proxy statement/prospectus is replaced in its entirety with the following:</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except where specifically noted, the following information and all of the information in this proxy statement/prospectus does not give effect to the proposed reverse stock split. The table below sets forth certain information with respect to the beneficial ownership of the common stock of the combined company upon consummation of the merger based on beneficial ownership of Sesen Bio common stock and Carisma common stock as of February&#160;13, 2023 (assuming the closing of the merger occurred on February&#160;13, 2023) by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each director of the combined company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each named executive officer of the combined company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all of the combined company&#8217;s directors and executive officers as a group; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each person or entity expected by Carisma and Sesen Bio to become the beneficial owner of more than 5% of the common stock of the combined company upon the consummation of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table assumes effectiveness of the Carisma pre-closing financing, an exchange ratio of 40.0154, that the closing of the merger occurred on February&#160;13, 2023 and that the conversion of the Carisma convertible note occurred immediately after the effective time of the merger. Assuming a closing date of February&#160;13, 2023, immediately prior to the merger and after the closing of the Carisma pre-closing financing and conversion of the Carisma convertible note, Carisma is expected to have 15,698,900 shares of common stock outstanding and Sesen Bio is expected to have 202,759,043 shares of common stock outstanding. Upon the closing of the merger on the assumed date of February&#160;13, 2023, the 15,698,900 shares of Carisma common stock would be converted into the right to receive an aggregate of 628,197,763 shares of Sesen Bio common stock such that there would be a total of 830,956,806 shares of common stock of the combined company outstanding upon the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include (a)&#160;shares of Sesen Bio common stock (i)&#160;subject to Sesen Bio options that are currently exercisable or exercisable within 60&#160;days after February&#160;13, 2023 and (ii)&#160;underlying Sesen Bio RSUs that are expected to vest and settle within 60&#160;days after February&#160;13, 2023 and (b)&#160;shares of Carisma common stock issuable pursuant to the exercise of Carisma options that are either immediately exercisable or exercisable within 60&#160;days of February&#160;13, 2023. Such shares of Sesen Bio common stock or Carisma common stock are, in each case, deemed to be outstanding and beneficially owned by the person holding such Sesen Bio option, Sesen Bio RSU or Carisma option, as applicable, for the purpose of calculating the&#160;percentage ownership of that person, but they are not treated as outstanding for the purpose of calculating the&#160;percentage ownership of any other person. Except as otherwise set forth below, Sesen Bio and Carisma believe that the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. Except as otherwise set forth below, the address of each person or entity listed in the table is c/o&#160;CARISMA Therapeutics Inc., 3675 Market Street, Suite 200, Philadelphia, Pennsylvania 19104. </font>
        </div>
        <table style="width:456pt;height:115pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:345.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:345.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors and Named Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael Torok</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,404,839</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.01</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Steven Kelly</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,356,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.16<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">14,398,595</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.72<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:250pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:345.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Morris</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">3,197,174</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">1,570,838</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">1,377,530</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All current executive officers and directors as a group (9 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">47,305,680</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.63<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Greater than 5% stockholders:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">57,932,295</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.97<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">71,592,232</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.62<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with IPG(10) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">60,995,714</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.34<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Moderna Biotech Ventures, LLC.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">105,282,478</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">12.67<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SymBiosis II, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">46,682,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.62<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">45,986,178</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.53<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">48,403,308</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.83<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.6pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:12.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:12.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents less than 1% of the issued and outstanding shares of common stock of the combined company as of February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;1,025,000 shares of common stock of the combined company held by Michael Torok, (ii)&#160;6,399,839 shares of common stock of the combined company held by JEC II Associates, LLC and (iii)&#160;1,000,000 shares of common stock of the combined company held by the K. Peter Heiland 2008 Irrevocable Trust. Michael Torok is the Manager of JEC II Associates, LLC and the Trustee of the K. Peter Heiland 2008 Irrevocable Trust and has sole voting and dispositive power over the shares. The address of the principal business office of each of JEC II Associates, LLC, the K. Peter Heiland 2008 Irrevocable Trust and Michael Torok is 68 Mazzeo Drive, Randolph, Massachusetts 02368. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 18,356,705 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;10,203,927 shares of common stock of the combined company and (ii)&#160;4,194,668 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 3,197,174 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;256,499 shares of common stock of the combined company and (ii)&#160;1,314,339 shares of common stock issuable upon the exercise of options of the combined company exercisable within 60&#160;days after February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 1,377,530 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;18,865,265 shares of common stock of the combined company and (ii)&#160;28,440,415 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after February&#160;13, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 57,932,295 shares of common stock of the combined company held by AbbVie Biotechnology Ltd. AbbVie Biotechnology Ltd. holds voting and investment control over the shares. The Board of Directors of AbbVie Biotechnology Ltd. consists of Lindsey Bristow, Jonathan C. Clipper, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Stephen Muldoon and Arthur Price. Each of Ms.&#160;Bristow and each of Messrs. Clipper, Muldoon and Price may be deemed to share voting and investment power with respect to the shares held by AbbVie Biotechnology Ltd. and disclaim beneficial ownership of all shares held by AbbVie Biotechnology Ltd., except to the extent of their pecuniary interest therein, if any. Margarita Chavez is employed as a Managing Director of AbbVie Ventures and is a member of the Carisma board of directors. Ms.&#160;Chavez disclaims beneficial ownership of all shares held by AbbVie Biotechnology Ltd. except to the extent of her pecuniary interest therein, if any. The business address of AbbVie Biotechnology Ltd. is Thistle House, 4 Burnaby Street, Hamilton HM 11, Bermuda. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 71,592,232 shares of common stock of the combined company held by HealthCap VII, L.P. HealthCap VII GP SA, a Swiss registered L.C.C., is the sole general partner of HealthCap VII, L.P. and has voting and investment control over the shares. HealthCap VII GP SA disclaims beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Fabrice Bernhard is the General Manager of HealthCap VII GP SA. Dag Richter, Daniel Schafer and Frans Wuite are each Directors of HealthCap VII GP SA. Each of Messrs. Bernhard, Richter, Schafer and Wuite may be deemed to share voting and investment power with respect to the shares held by HealthCap VII L.P. and disclaim beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Bj&#246;rn Odlander is a Managing Partner of HealthCap and is a member of the Carisma board of directors. Dr.&#160;Odlander disclaims beneficial ownership of all shares held by HealthCap VII L.P. except to the extent of his pecuniary interest therein, if any. The business address of HealthCap VII L.P. is c/o&#160;HealthCap VII GP SA, Avenue Villamont&#160;23, CH 1005 Lausanne Switzerland. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;47,400,722 shares of common stock of the combined company held by IPG Cayman LP, (ii)&#160;5,643,212 shares of common stock of the combined company held by IPG USA SCO LP and (iii)&#160;7,951,780 shares of common stock of the combined company held by CT SPV Investment LP, or collectively, the IPG entities. IP Group, Inc. has voting and investment control over the shares held by the IPG entities. The business address of the IPG entities is c/o&#160;IP Group, Inc., 1 Righter Parkway, Suite 260, Wilmington, Delaware 19803. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 105,282,478 shares of common stock of the combined company held by ModernaTX, Inc. ModernaTX, Inc. is wholly owned by Moderna, Inc., a publicly-traded company. The business address of ModernaTX, Inc. is 200 Technology Square, Cambridge, MA 02139. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 46,682,766 shares of common stock of the combined company held by SymBiosis II, LLC, which exercises voting and investment control of the shares. Chidozie Ugwumba is the Managing Partner of Symbiosis II, LLC and as such has sole voting and investment control over the shares. Mr.&#160;Ugwumba is also a member of the Carisma board of directors. The business address of&#160;Symbiosis II, LLC is 609 S.W. 8th Street, Suite 365, Bentonville, Arkansas 72712. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 45,986,178 shares of common stock of the combined company held by The Trustees of the University of Pennsylvania. The Board of Trustees of the University of Pennsylvania has voting and dispositive power over the shares. The Board of Trustees of the University of Pennsylvania is comprised of more than three individuals who have authority over the voting and disposition of the share. A business address of The Trustees of the University of Pennsylvania is 2929 Walnut Street, Suite 300, Philadelphia, Pennsylvania 19104. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 48,403,308 shares of common stock of the combined company held by Wellington Life Sciences V GmbH &amp; Co. KG, or the Wellington Fund. The Wellington Fund is represented by Wellington Life Sciences Venture Capital Consulting GmbH, or the Wellington General Partner. The Wellington General Partner holds voting and investment control over the shares. Dr.&#160;Regina Hodits and Dr.&#160;Rainer Strohmenger, in their functions as managing directors of the Wellington General Partner, have individual signatory power as well as voting and/or investment control over the shares. Dr.&#160;Regina Hodits is a member of the Carisma board of directors. Dr.&#160;Regina Hodits disclaims beneficial ownership of all shares held by the Wellington Fund except to the extent of her pecuniary interest therein, if any. The business address of the Wellington Fund and the Wellington General Partner is Tuerkenstrasse 5, 80333 Munich, Germany. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:109pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio files annual, quarterly and current reports, proxy statements and other information with the SEC. Sesen Bio&#8217;s SEC filings are available to the public electronically at the SEC&#8217;s website at www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also makes available free of charge on or through its website at www.ir.sesenbio.com, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Sesen Bio electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Sesen Bio are inactive textual references, and information on those websites are not part of this supplement or the proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this supplement, Sesen Bio has filed with the SEC a registration statement on Form S-4, of which this supplement and the proxy statement/prospectus form a part of, under the Securities Act to register the shares of Sesen Bio common stock that Sesen Bio will issue to Carisma stockholders in the merger. The proxy statement/prospectus, including this supplement, constitutes a proxy statement of Sesen Bio for its special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has supplied all information contained in the proxy statement/prospectus, including this supplement, relating to Sesen Bio, and Carisma has supplied all information contained in the proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, including this supplement, relating to Carisma. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you would like to request documents from Sesen Bio or Carisma, please send a request in writing or by telephone to either Sesen Bio or Carisma at the following addresses: </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">Sesen Bio, Inc.</font>
                <br >
                <font style="letter-spacing:0.2pt;">245 First Street, Suite 1800</font>
                <br >
                <font style="letter-spacing:0.2pt;">Cambridge, Massachusetts 02142</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (617) 444-8550</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: ir@sesenbio.com </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">CARISMA Therapeutics Inc</font><font style="letter-spacing:0.2pt;">.</font>
                <br >
                <font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200</font>
                <br >
                <font style="letter-spacing:0.2pt;">Philadelphia, PA 19104</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (267) 491-6422</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: info@carismatx.com</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder and would like additional copies, without charge, of the proxy statement/prospectus or this supplement, or if you have questions about the merger, including the procedures for voting your shares, you should contact Sesen Bio&#8217;s proxy solicitor: </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_mackenziepartners-bw.jpg" alt="[MISSING IMAGE: lg_mackenziepartners-bw.jpg]" height="57" width="192" >
        </div>
        <div style="margin-top:13pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MacKenzie Partners, Inc.</font>
          <br >
          <font style="letter-spacing:0.2pt;">1407 Broadway, 27th Floor</font>
          <br >
          <font style="letter-spacing:0.2pt;">New York, New York 10018</font>
          <br >
          <font style="letter-spacing:0.2pt;">(800) 322-2885</font>
          <br >
          <font style="letter-spacing:0.2pt;">proxy@mackenziepartners.com</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>

<P STYLE="text-align: right; margin: 0"><B>ANNEX S-A</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDMENT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS SECOND AMENDMENT
TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </B>(this &ldquo;<B><I>Second Amendment</I></B>&rdquo;) is made and entered into as
of February&nbsp;13, 2023, by and among <B>SESEN BIO,&nbsp;INC.</B>, a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), <B>SEAHAWK
MERGER SUB,&nbsp;INC.</B>, a Delaware corporation and wholly-owned subsidiary of Parent (&ldquo;<B><I>Merger Sub</I></B>&rdquo;), and
<B>CARISMA THERAPEUTICS INC.</B>, a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;).&nbsp;&nbsp;Parent, Merger Sub and
the Company are sometimes individually referred to herein as a &ldquo;<B><I>Party</I></B>&rdquo; or collectively referred to herein as
the &ldquo;<B><I>Parties</I></B>&rdquo;. Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the
Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
Parties previously entered into that certain Agreement and Plan of Merger and Reorganization dated as of September&nbsp;20, 2022, as
amended by the First Amendment to Agreement and Plan of Merger and Reorganization dated as of December&nbsp;29, 2022 (the &ldquo;<B><I>Merger
Agreement</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Section&nbsp;10.2
of the Merger Agreement provides that the Merger Agreement may be amended with the approval of the respective boards of directors of
the Company, Merger Sub and Parent at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
Parties desire to amend the Merger Agreement pursuant to the terms and conditions of this Second Amendment and the respective boards
of directors of the Company, Merger Sub and Parent have each approved this Second Amendment to be effective as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">D.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Following
the execution and delivery of this Second Amendment, each Company Signatory shall promptly (and in any event no later than ten Business
Days following the date hereof) execute and deliver an acknowledgement letter reaffirming its Company Stockholder Support Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties, intending to
be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT
TO SECTION&nbsp;5.21 &ldquo;Pre-Closing Dividend&rdquo;.&nbsp; </B>Section&nbsp;5.21 &ldquo;Pre-Closing Dividend&rdquo; of the Merger
Agreement is hereby amended by replacing the phrase &ldquo;equal to or greater than $70,000,000&rdquo; with &ldquo;equal to $75,000,000&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>AMENDMENT
TO EXHIBIT&nbsp;D &ldquo;Form&nbsp;of Contingent Value Right Agreement&rdquo;. </B>Exhibit&nbsp;D to the Merger Agreement shall be deleted
in its entirety and replaced with the form attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT
TO SECTION&nbsp;8.5 &ldquo;Minimum Parent Final Net Cash&rdquo;.&nbsp; </B>Section&nbsp;8.5 &ldquo;Minimum Parent Final Net Cash&rdquo;
of the Merger Agreement is hereby amended by replacing the phrase &ldquo;greater than or equal to $75,000,000&rdquo; with the phrase
 &ldquo;greater than or equal to &ldquo;$70,000,000&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>AMENDMENT
TO SCHEDULE 5.12. </B>Schedule 5.12 to the Merger Agreement is hereby deleted in its entirety and replaced with the schedule set forth
on Annex A attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>COMPANY
STOCKHOLDER MATTERS</B>. Promptly after the date hereof (and in any event no later than ten Business Days) the holders of Company Capital
Stock sufficient to adopt and approve the Merger Agreement as amended by this Second Amendment (the &ldquo;<B><I>Required Amendment Vote</I></B>&rdquo;)
as required under the DGCL and the Company&rsquo;s certificate of incorporation and bylaws will execute and deliver a Company stockholder
written consent to Parent evidencing the Required Amendment Vote (the &ldquo;<B><I>Amendment Consent</I></B>&rdquo;). This Section&nbsp;5
shall supersede and take precedence over Section&nbsp;5.3(a)&nbsp;of the Merger Agreement with respect to the required timing of delivery
of the Company Stockholder Written Consent. Section&nbsp;9.1(d)&nbsp;&ldquo;Termination&rdquo; of the Merger Agreement is hereby deleted
in its entirety and replaced with the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;by Parent if the Amendment
Consent evidencing the Required Amendment Vote shall not have been delivered within ten Business Days of February&nbsp;13, 2023;&nbsp;<I>provided</I>,&nbsp;<I>however</I>,<I>&nbsp;</I>that
once the Amendment Consent evidencing the Required Amendment Vote has been obtained, Parent may not terminate this Agreement pursuant
to this&nbsp;<U>Section&nbsp;9.1(d)</U>;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APPLICABLE
LAW. </B>This Second Amendment shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless
of the Laws that might otherwise govern under applicable principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HEADINGS.
</B> The bold-faced headings contained in this Second Amendment are for convenience of reference only, shall not be deemed to be a part
of this Second Amendment and shall not be referred to in connection with the construction or interpretation of this Second Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASSIGNABILITY.
</B> This Second Amendment shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their
respective successors and permitted assigns; <I>provided</I>, <I>however</I>, that neither this Second Amendment nor any of a Party&rsquo;s
rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and
any attempted assignment or delegation of this Second Amendment or any of such rights or obligations by such Party without the other
Party&rsquo;s prior written consent shall be void and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONSTRUCTION.
</B>&nbsp; The terms of this Second Amendment amend and modify the Merger Agreement as if fully set forth in the Merger Agreement. Upon
the effectiveness of this Second Amendment, all references in the Merger Agreement to &ldquo;the Agreement&rdquo; or &ldquo;this Agreement,&rdquo;
as applicable, shall refer to the Merger Agreement, as modified by this Second Amendment. If there is any conflict between the terms,
conditions and obligations of this Second Amendment and the Merger Agreement, this Second Amendment&rsquo;s terms, conditions and obligations
shall control.&nbsp;&nbsp;All other provisions of the Merger Agreement not specifically modified by this Second Amendment are expressly
preserved.&nbsp;&nbsp;This Second Amendment may be executed in several counterparts, each of which shall be deemed an original and all
of which shall constitute one and the same instrument. The exchange of a fully executed Second Amendment (in counterparts or otherwise)
by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Second
Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AUTHORITY.
</B>&nbsp;By their execution of this Second Amendment, the undersigned Parties hereby confirm that they are duly authorized to execute
this Second Amendment and any necessary requisite approval has been obtained with respect to this Second Amendment and all matters set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Remainder of page&nbsp;intentionally left
blank)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Parties have caused this Second Amendment to be executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SESEN BIO,&nbsp;INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Thomas Cannell</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive
    Officer</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEAHAWK
    MERGER SUB,&nbsp;INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Mark Sullivan</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Sullivan</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Secretary&nbsp;&amp;
    Treasurer</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARISMA
    THERAPEUTICS INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Steven Kelly</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Kelly</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;to Second Amendment to
Agreement and Plan of Merger and Reorganization</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<!-- Field: Page; Sequence: 4; Options: Last -->
        <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"></DIV>
		<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX S-B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of CVR Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONTINGENT
VALUE RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS CONTINGENT VALUE RIGHTS
AGREEMENT, dated as of [&bull;], 2023 (this &ldquo;<B><I>Agreement</I></B>&rdquo;), is entered into by and among Sesen Bio,&nbsp;Inc.,
a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), and Computershare Inc. (&ldquo;<B><I>Computershare</I></B>&rdquo;) and its
affiliate, Computershare Trust Company, N.A., together, as the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, Seahawk
Merger Sub,&nbsp;Inc., a Delaware corporation (&ldquo;<B><I>Merger Sub</I></B>&rdquo;), and CARISMA Therapeutics Inc., a Delaware corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of September&nbsp;20,
2022 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;),
pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a subsidiary of Parent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the
Merger Agreement, Parent has agreed to provide to the holders of record of Parent&rsquo;s common stock, par value $0.001 per share (&ldquo;<B><I>Parent
Common Stock</I></B>&rdquo;), immediately prior to the Effective Time, the right to receive certain contingent cash payments, on the
terms and subject to the conditions hereinafter described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the consummation of the transactions referred to above, Parent and the Rights Agent agree, for the proportionate
benefit of all Holders (as hereinafter defined), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">1.</FONT></TD><TD>DEFINITIONS;
                                            CERTAIN RULES OF CONSTRUCTION</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>1.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions.
Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the Merger Agreement, unless expressly
set forth otherwise herein. As used in this Agreement, the following terms will have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Acquiror</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Acquisition</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Acting Holders</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.3(d)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Affiliate</I></B>&rdquo;
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. The term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo; and &ldquo;under
common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Agreement</I></B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Asset Disposition
Proceeds</I></B>&rdquo; means, without duplication, any and all consideration of any kind that is paid to Parent, or is received by,
Parent or any of its Affiliates during the CVR Term in respect of an Asset Disposition, if any. The value of any securities (whether
debt or equity) or other non-cash property constituting Asset Disposition Proceeds shall be determined as follows: (A)&nbsp;the value
of securities for which there is an established public market shall be equal to the volume weighted average of their closing market prices
for the five (5)&nbsp;trading days ending the day prior to the date of payment to, or receipt by, Parent or its relevant Affiliate, and
(B)&nbsp;the value of securities that have no established public market and the value of consideration that consists of other non-cash
property, shall be the fair market value thereof as of the date of payment to, or receipt by, Parent or its relevant Affiliate. Asset
Disposition Proceeds shall be deemed to not include proceeds arising out of a Parent Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B><I>Assignee</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Board of Directors</I></B>&rdquo;
means the board of directors of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Board Resolution</I></B>&rdquo;
means a copy of the resolution(s)&nbsp;certified by the secretary or an assistant secretary (or other comparable officer) of Parent that
have been duly adopted by the Board of Directors and are in full force and effect on the date of such approval, and delivered to the
Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Business Day</I></B>&rdquo;
means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be
closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Company</I></B>&rdquo;
has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Computershare</I></B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Payment</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Payment
Amount</I></B>&rdquo; means, with respect to each Holder, an amount equal to (a)&nbsp;(i)&nbsp;the applicable Total Payment Amount, less
(ii)&nbsp;applicable accrued and documented Permitted Deductions, as calculated in accordance with GAAP, divided by (b)&nbsp;the total
number of CVRs and then multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register (rounded down to
the nearest whole cent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Register</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Sale Assets</I></B>&rdquo;
means any and all assets, tangible and intangible, including, without limitation, patents, patent applications, know-how, trade secrets
and other intellectual property rights, data, documentation, agreements and licenses, inventory related to Vicineum<SUP>TM</SUP>, also
known as VB4-845, which Parent or any of its subsidiaries owned or had rights to, as of immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Term</I></B>&rdquo;
means the period beginning on the date hereof and ending on the earlier of (a)&nbsp;the final CVR Payment with respect to any Roche Payment
Amount and Asset Disposition Proceeds, as applicable, being delivered to each Holder in accordance with <U>Section&nbsp;2.4</U> of this
Agreement or (b)&nbsp;March&nbsp;31, 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVRs</I></B>&rdquo;
means the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Disposition</I></B>&rdquo;
means the sale, license, transfer, disposition or other monetizing event of any CVR Sale Assets, in each case (i)&nbsp;during the CVR
Term and (ii)&nbsp;in a transaction identified by Parent&rsquo;s financial advisor who was engaged as of the Effective Time for the purpose
of identifying and proposing a potential Disposition transaction to Parent. For clarity, a Disposition constitutes an Asset Disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>DTC</I></B>&rdquo;
means The Depository Trust Company or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Funds</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Holder</I></B>&rdquo;
means a Person in whose name a CVR is registered in the CVR Register at the applicable time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Merger Agreement</I></B>&rdquo;
has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Merger Sub</I></B>&rdquo;
has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Officer&rsquo;s
Certificate</I></B>&rdquo; means a certificate signed by the chief executive officer, president, chief financial officer, any vice president,
the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the
Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Parent</I></B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Parent Change
of Control</I></B>&rdquo; means a merger, consolidation, business combination or other similar transaction involving Parent or its subsidiaries
or a sale of all or substantially all of the assets or a majority of the equity securities of Parent; provided that Parent Change of
Control shall not include such a transaction if at the time of such transaction the only remaining non-cash assets held by Parent are
the Potentially Transferable Assets. For clarity, the term Asset Disposition as used in this Agreement shall be deemed to not include
any Parent Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Parent Common
Stock</I></B>&rdquo; has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Permitted Deductions</I></B>&rdquo;
means the following costs or expenses, without duplication (as approved by the Board of Directors, including, if applicable, the Parent
Designee (as defined in the Merger Agreement)):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
applicable Tax (including any unreimbursed applicable value added or sales tax) imposed on the Total Payment Amount and payable by Parent
or any of its Affiliates to any tax authority and, without duplication, any income or other similar Taxes payable by Parent or any of
its Affiliates that would not have been incurred by Parent or any of its Affiliates but for the Total Payment Amount; provided that,
for purposes of calculating income Taxes incurred by Parent and its Affiliates in respect of the Total Payment Amount, any such income
Taxes shall be computed after reduction for any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent
or its subsidiaries (owned prior to the Merger) as of the Closing Date that are available to the maximum extent permitted by law to offset
such gain after taking into account any limits on the usability of such attributes, including under Section&nbsp;382 of the Code, in
each case, as reasonably determined by a nationally recognized tax advisor (and for the sake of clarity such income taxes shall be calculated
without taking into account any net operating losses or other Tax attributes generated by Parent or its subsidiaries after the Closing
Date or any Tax attributes of the Company, whether generated before or after the Closing Date), assuming for this purpose that (i)&nbsp;the
only item of gross income of Parent and its subsidiaries is the Total Payment Amount (for the avoidance of doubt, assuming that the Total
Payment Amount is taxable in the hands of Parent or its subsidiaries no later than the taxable year that includes the corresponding CVR
Payment), and (ii)&nbsp;the net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries
shall only include any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries
(owned prior to the Merger) existing as of immediately prior to the Merger for U.S. federal income tax purposes and applicable state
and local income tax purposes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
reasonable and documented out-of-pocket expenses incurred by Parent or any of its Affiliates in respect of its performance of this Agreement
following the Effective Time, losses incurred and paid by Parent or any of its Affiliates following the Effective Time arising out of
any Legal Proceeding relating to or in connection with (i)&nbsp;an Asset Disposition, (ii)&nbsp;Parent&rsquo;s, Roche&rsquo;s or any
of their respective Affiliates&rsquo; obligations under the Roche Agreement or (iii)&nbsp;otherwise with respect to the Total Payment
Amount; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Liabilities that were ascertainable prior to or at the Effective Time which Parent reasonably and in good faith determines should have
been, but were not, deducted from &ldquo;Net Cash&rdquo; (as defined in the Merger Agreement), in connection with the Closing of the
Merger, to the extent that deduction of such Liabilities would have resulted in a change in the Exchange Ratio under the Merger Agreement
were such amounts properly deducted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that no Permitted Deductions shall be
deducted to the extent they were otherwise deducted from the calculation of Net Cash (as defined in the Merger Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Permitted Transfer</I></B>&rdquo;
means a transfer of CVRs: (a)&nbsp;on death of a Holder by will or intestacy; (b)&nbsp;by instrument to an inter vivos or testamentary
trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c)&nbsp;pursuant to a court order; (d)&nbsp;made
by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or
termination of any corporation, limited liability company, partnership or other entity; (e)&nbsp;in the case of CVRs held in book-entry
or other similar nominee form, from a nominee to a beneficial owner (through an intermediary if applicable) or from a nominee to another
nominee for the same beneficial owner, to the extent allowable by DTC; (f)&nbsp;a transfer from a participant&rsquo;s account in a tax-qualified
employee benefit plan to the participant or to such participant&rsquo;s account in a different tax-qualified employee benefit plan or
to a tax-qualified individual retirement account for the benefit of such participant; (g)&nbsp;to Parent or its Affiliates for any or
no consideration; or (h)&nbsp;as provided in <U>Section&nbsp;2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Person</I></B>&rdquo;
means any natural person, corporation, limited liability company, trust, unincorporated association, partnership, joint venture or other
entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Record Time</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.3(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Rights Agent</I></B>&rdquo;
means the Rights Agent named in the Preamble, until a successor Rights Agent will have become such pursuant to the applicable provisions
of this Agreement, and thereafter &ldquo;Rights Agent&rdquo; will mean such successor Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Roche</I></B>&rdquo;
means the collective reference to F. Hoffman-La Roche Ltd and Hoffmann La Roche Inc. or its successors or any of its or their respective
Affiliates; provided, that neither Chugai Pharmaceutical Co., Ltd, a Japanese corporation (&ldquo;<B><I>Chugai</I></B>&rdquo;) nor its
subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to Parent of its desire to include
Chugai or its respective subsidiaries (as applicable) as Affiliate(s)&nbsp;of Roche.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Roche Agreement</I></B>&rdquo;
means that certain Asset Purchase Agreement, dated as of July&nbsp;15, 2022, by and among F. Hoffman-La Roche Ltd, Hoffmann La Roche
Inc. and Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Roche Payment
Amount</I></B>&rdquo; means the thirty million dollar ($30,000,000) milestone payment to be made by Roche to Parent upon the initiation
of a phase III clinical study in diabetic macular disorder with the compound known as &ldquo;EBI-031&rdquo; during the CVR Term, as set
forth in Section&nbsp;11.1 of the Roche Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Third Party</I></B>&rdquo;
means any Person other than Parent, Rights Agent or their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Total Payment
Amount</I></B>&rdquo; means, as of any applicable time of determination, any Asset Disposition Proceeds plus any Roche Payment Amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>1.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rules&nbsp;of
Construction. Except as otherwise explicitly specified to the contrary, (a)&nbsp;whenever the context requires, the singular number shall
include the plural, and vice versa; (b)&nbsp;the masculine gender shall include the feminine gender and neuter genders, the feminine
gender shall include the masculine and neuter genders, and the neuter genders shall include masculine and feminine genders; (c)&nbsp;the
word &ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends, and does
not simply mean &ldquo;if&rdquo;; (d)&nbsp;the word &ldquo;including&rdquo; (in its various forms) means &ldquo;including without limitation&rdquo;;
(e)&nbsp;references to a &ldquo;Section&rdquo; means a Section&nbsp;of this Agreement unless another agreement is specified; (f)&nbsp;references
to a particular statute or regulation include all rules&nbsp;and regulations thereunder and any predecessor or successor statute, rules&nbsp;or
regulation, in each case as amended or otherwise modified from time to time; (g)&nbsp;words in the singular or plural form include the
plural and singular form, respectively; (h)&nbsp;references to a particular Person include such Person&rsquo;s successors and assigns
to the extent not prohibited by this Agreement; (i)&nbsp;the word &ldquo;or&rdquo; shall not be exclusive (i.e., &ldquo;or&rdquo; shall
be deemed to mean &ldquo;and/or&rdquo;) unless the subject of the conjunction are mutually exclusive; and (j)&nbsp;all references to
dollars or &ldquo;$&rdquo; refer to United States dollars. For clarity, the parties agree that the phrase &ldquo;materially adverse&rdquo;
when used in this Agreement with respect to the Holders includes any amendment or other action, as applicable, that does or would be
reasonably expected to reduce, eliminate, or materially delay the Roche Payment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">2.</FONT></TD><TD STYLE="text-align: justify">CONTINGENT
                                            VALUE RIGHTS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>2.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVRs;
Appointment of Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Each
Holder is entitled to one CVR in the form of a dividend for each share of Parent Common Stock held by such Holder as of the Record Time.
The CVRs represent the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. The
initial Holders will be the holders of Parent Common Stock as of immediately prior to the Effective Time, and a list of the initial Holders
shall be furnished to the Rights Agent by or on behalf of Parent in accordance with <U>Section&nbsp;4.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
hereby appoints the Rights Agent to act as rights agent for Parent as contemplated hereby in accordance with the express terms and conditions
set forth in this Agreement (and no implied terms or conditions), and the Rights Agent hereby accepts such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
intends to treat the issuance of the CVRs as a distribution of property by Parent to the holders of Parent Common Stock for U.S. federal
income tax purposes. Consistent with such intended tax treatment, Parent will timely send Forms 1099-DIV to all Holders notifying them
of the portion of the CVR value that is a nondividend distribution (or a dividend to the extent of Parent&rsquo;s earnings and profits)
for U.S. federal income tax purposes, and take all necessary steps to file its tax returns and any information statements consistent
with such tax treatment. Parent will determine, in consultation with and with the consent of the Parent Designee, the fair market value
of the CVRs in connection with the issuance and Parent will utilize such fair market value for purposes of all tax reporting (including
on Forms 1099-DIV) with respect to the CVR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>2.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nontransferable.
The CVRs shall not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or
in part, other than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance, transfer or disposition,
in whole or in part, that is not a Permitted Transfer will be void <I>ab initio </I>and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>2.3</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Certificate; Registration; Registration of Transfer; Change of Address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
CVRs will not be evidenced by a certificate or other instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Rights Agent will create and keep a register (the &ldquo;<B><I>CVR Register</I></B>&rdquo;) for the purpose of identifying the Holders
and registering CVRs and transfers of CVRs as permitted herein. The CVR Register will be created, and CVRs will be distributed, pursuant
to written instructions to the Rights Agent from Parent. The CVR Register will initially show one position for Cede&nbsp;&amp; Co. representing
all the CVRs provided to the holders of shares of Parent Common Stock held as of immediately prior to the Effective Time. The Rights
Agent will have no responsibility whatsoever directly to the street name holders or DTC participants with respect to transfers of CVRs
unless and until such CVRs are transferred into the name of such street name holders or DTC participants in accordance with <U>Section&nbsp;2.2
</U>of this Agreement. With respect to any payments to be made under <U>Section&nbsp;2.4(a)</U>&nbsp;below, the Rights Agent will accomplish
the payment to any former street name holders of shares of Parent Common Stock by sending one lump-sum payment to DTC. The Rights Agent
will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subject
to the restrictions on transferability set forth in <U>Section&nbsp;2.2</U>, every request made to transfer a CVR must be in writing
and accompanied by a written instrument of transfer and other reasonably requested documentation in form reasonably satisfactory to the
Rights Agent, duly executed by the Holder thereof or the Holder&rsquo;s attorney duly authorized in writing, personal representative
or survivor and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the
Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form, notify Parent that it has
received such written notice. Upon receipt of such notice from the Rights Agent, Parent shall determine whether the transfer otherwise
complies with the other terms and conditions of this Agreement (including the provisions of <U>Section&nbsp;2.2</U>), and if it determines
that it does so comply, Parent shall instruct the Rights Agent in writing to register the transfer of the CVRs in the CVR Register and
notify Parent of the same. No service charge shall be made for any registration of transfer of a CVR; however Parent and the Rights Agent
may require payment of a sum sufficient to cover any stamp or other tax or governmental charge that is imposed in connection with any
such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement
that requires the payment by a Holder of applicable taxes or charges unless and until the Rights Agent is satisfied that all such taxes
or charges have been paid or will be paid. All duly transferred CVRs registered in the CVR Register will be the valid obligations of
Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer
by the transferor. No transfer of a CVR will be valid until registered in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>A
Holder may make a written request to the Rights Agent to change such Holder&rsquo;s address of record in the CVR Register. The written
request must be duly executed by the Holder. Upon receipt of such written request, the Rights Agent is hereby authorized to promptly
record the change of address in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Parent Common Stock as of immediately
prior to the Effective Time (the &ldquo;<B><I>Record Time</I></B>&rdquo;). Subject to the terms and conditions of this Agreement and
Parent&rsquo;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable
tax withholding, to each holder of Parent Common Stock as of the Record Time by the mailing of a statement of holding reflecting such
CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>2.4</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
Procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Within
thirty (30) days after the receipt of any portion of the Total Payment Amount, Parent shall (i)&nbsp;deliver to the Rights Agent a certificate
certifying to and specifying in reasonable detail (A)&nbsp;the amount of the applicable Total Payment Amount received by Parent or its
Affiliates, (B)&nbsp;a calculation of the CVR Payment Amount and CVR Payment, and (C)&nbsp;the Permitted Deductions reflected in such
CVR Payment Amount, (ii)&nbsp;deliver to the Rights Agent an amount equal to the aggregate CVR Payment Amount in immediately available
funds (each, a &ldquo;<B><I>CVR Payment</I></B>&rdquo;) and (iii)&nbsp;instruct the Rights Agent to deliver the CVR Payment to the Holders.
The Rights Agent will promptly, and in any event within ten (10)&nbsp;Business Days after receipt of each applicable CVR Payment, pay
to each Holder, by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the date
of the receipt of the CVR Payment statement, such Holder&rsquo;s CVR Payment Amount less any applicable tax withholding. Until such certificate,
CVR Payment and instructions are received by the Rights Agent, the Rights Agent may presume conclusively for all purposes that such portion
of the Total Payment Amount has not been received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All
payments by Parent to the Rights Agent under this Agreement shall be made in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
shall be entitled to deduct or withhold, or cause the Rights Agent to deduct or withhold from any CVR Payment Amount otherwise payable
or otherwise deliverable pursuant to this Agreement, in each case directly or through an authorized payroll agent, such amounts as are
reasonably determined to be required to be deducted or withheld therefrom under the Code or any other provision of any applicable federal,
state, local or non-U.S. Tax Law as may be determined by Parent. To the extent such amounts are so deducted or withheld and paid over
or deposited with the relevant Tax authority, such amounts shall be treated for all purposes under this Agreement as having been paid
to the Holder(s)&nbsp;to whom such amounts would otherwise have been paid or delivered. Prior to making any such Tax withholdings or
causing any such Tax withholdings to be made with respect to any Holder, Parent shall instruct the Rights Agent, to the extent practicable,
to provide notice to the Holder of such potential withholding and a reasonable opportunity for the Holder to provide any necessary Tax
forms (including an IRS Form&nbsp;W-9 or an applicable IRS Form&nbsp;W-8) in order to avoid or reduce such withholding amounts; provided,
that the time period for payment of a CVR Payment Amount by the Rights Agent set forth in <U>Section&nbsp;2.4(a)</U>&nbsp;shall be extended
by a period equal to any delay caused by the Holder providing such forms; provided, further, that in no event shall such period be extended
for more than ten (10)&nbsp;Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed
to by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
portion of any CVR Payment that remains undistributed to any Holder six (6)&nbsp;months after such CVR Payment is received by the Rights
Agent from Parent, provided, that the Rights Agent has fully complied with <U>Section&nbsp;2.4(a)</U>, will be delivered by the Rights
Agent to Parent, upon demand, and such Holder will thereafter look only to Parent for payment of its share of such returned CVR Payment,
without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Neither
Parent nor the Rights Agent will be liable to any person in respect of any CVR Payment Amount delivered to a public official pursuant
to any applicable abandoned property, escheat or similar Law. If, despite Parent&rsquo;s and/or the Rights Agent&rsquo;s commercially
reasonable efforts to deliver a CVR Payment Amount to the applicable Holder, such CVR Payment Amount has not been paid immediately prior
to the date on which such CVR Payment Amount would otherwise escheat to or become the property of any Governmental Body, any such CVR
Payment Amount will, to the extent permitted by applicable Law, become the property of Parent, free and clear of all claims or interest
of any person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees
to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or
be subject to in connection with transferring such property to Parent and such indemnification obligation shall survive the termination
of this Agreement, the resignation, replacement or removal of the Rights Agent, and the payment, termination and the expiration of the
CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>2.5</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Voting, Dividends or Interest; No Equity or Ownership Interest in Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
CVRs will not represent any equity or ownership interest in Parent or in any constituent company to the Merger. The sole right of the
Holders to receive property hereunder is the right to receive the CVR Payment in accordance with the terms hereof. It is hereby acknowledged
and agreed that a CVR shall not constitute a security of Parent or any constituent company to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Each
Holder acknowledges and agrees that such Holder will not challenge or contest any action, inaction, determination or decision of Parent
or the Rights Agent, except via written action of the Acting Holders, and will not threaten, bring, commence, institute, maintain, prosecute
or voluntarily aid any action, which challenges the validity of or seeks to enjoin the operation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>2.6</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ability
to Abandon CVR. A Holder may at any time, at such Holder&rsquo;s option, abandon all of such Holder&rsquo;s remaining rights in a CVR
by transferring such CVR to Parent without consideration therefor, and such rights will be cancelled, with the Rights Agent being promptly
notified in writing by Parent of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Parent from offering
to acquire CVRs, in a private transaction or otherwise, for consideration in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">3.</FONT></TD><TD STYLE="text-align: justify">THE
                                            RIGHTS AGENT</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>3.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
Duties and Responsibilities. The Rights Agent will be authorized and protected and will not have any liability for or in respect of any
actions taken, suffered or omitted to be taken by it in connection with its acceptance and administration of this Agreement and the exercise
and performance of its duties hereunder, except to the extent of its own willful misconduct, bad faith or gross negligence (each as determined
by a final non-appealable judgment of a court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>3.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
Rights of the Rights Agent. The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in
this Agreement, and no implied duties, covenants or obligations will be read into this Agreement against the Rights Agent. The Rights
Agent shall not assume any obligations or relationship of agency or trust with any Holder. In addition:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad
faith to be genuine and to have been signed or presented by the proper party or parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>whenever
the Rights Agent will deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder,
the Rights Agent may request and rely upon an Officer&rsquo;s Certificate with respect to such matter, which certificate shall be full
authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of gross negligence, bad faith or willful
or intentional misconduct (each as determined by a final non appealable judgment of a court of competent jurisdiction) on its part, incur
no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it in the absence
of bad faith under the provisions of this Agreement in reliance upon such certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in
the event the Rights Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or
other communication, paper or document received by the Rights Agent hereunder, the Rights Agent, may, in its sole discretion, refrain
from taking any action, and shall be fully protected and shall not be liable in any way to Parent, any Holder or any other person or
entity for refraining from taking such action, unless the Rights Agent receives written instructions from the Parent which eliminates
such ambiguity or uncertainty to the satisfaction of the Rights Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent may engage and consult with counsel of its selection (who may be legal counsel for the Rights Agent or the Parent or an
employee of the Rights Agent) and the written advice of such counsel or any opinion of counsel will be full and complete authorization
and protection to the Rights Agent and the Rights Agent shall be held harmless by Parent and shall incur no liability for or in respect
of any action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the
premises;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to any of the statements of fact
or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed
to have been made by the Parent only and the Rights Agent will have no liability and shall be held harmless by Parent in respect of the
validity of this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent), nor
shall the Rights Agent be responsible for any breach by Parent of any covenant or condition contained in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment, fine, penalty,
settlement, claim, demands, suits, cost or expense (including without limitation, the reasonable and documented fees and expenses of
legal counsel) for any action taken, suffered or omitted to be taken by the Rights Agent or arising out of or in connection with the
Rights Agent&rsquo;s duties under this Agreement, including the reasonable and documented out-of-pocket costs and expenses of defending
the Rights Agent against any claims, charges, demands, suits or loss arising therefrom, directly or indirectly, or enforcement of its
rights hereunder, unless such loss has been determined by a final non-appealable judgment of a court of competent jurisdiction to be
a result of the Rights Agent&rsquo;s gross negligence, bad faith or willful or intentional misconduct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>anything
to the contrary notwithstanding, (i)&nbsp;any liability of the Rights Agent under this Agreement will be limited to the aggregate amount
of the annual fees (but not reimbursed expenses) paid by Parent to the Rights Agent under this Agreement during the twelve months immediately
preceding the event for which recovery is sought, and (ii)&nbsp;in no event shall the Rights Agent be liable for any special, punitive,
indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits) arising out of
any action taken, suffered or omitted to be taken by it, even if the Rights Agent has been advised of the likelihood of such loss or
damage and regardless of the form of action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
agrees (i)&nbsp;to pay the fees and expenses of the Rights Agent in connection with the Rights Agent&rsquo;s duties under this Agreement
as agreed upon in writing by the Rights Agent and Parent on or prior to the date hereof, and (ii)&nbsp;to reimburse the Rights Agent
for all taxes and governmental charges, reasonable and documented out-of-pocket expenses and other charges of any kind and nature incurred
by the Rights Agent in the preparation, delivery, amendment and execution of this Agreement and the exercise and performance of its duties
hereunder (other than taxes imposed on or measured by the Rights Agent&rsquo;s net income and franchise or similar taxes imposed on it
(in lieu of net income taxes)). The Rights Agent will also be entitled to reimbursement from Parent for all reasonable and documented
out-of-pocket expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder, and the
Rights Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith, unless and until
it has received such notice in writing from the Parent and all notices or other instruments required by this Agreement to be delivered
to the Rights Agent must, in order to be effective, be received by the Rights Agent as specified herein, and in the absence of such notice
so delivered the Rights Agent may conclusively assume no such event or condition exists;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities
of the Parent or become peculiarly interested in any transaction in which the Parent may be interested, or contract with or lend money
to the Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein shall
preclude the Rights Agent from acting in any other capacity for the Parent or for any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or
by or through its attorneys or agents, and the Rights Agent shall not be liable, answerable or accountable for any act, omission, default,
neglect or misconduct of any such attorneys or agents or for any loss to the Parent, any Holder or any other person or entity resulting
from any such act, omission, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined
by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>no
provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing
that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect
to any action or default by the Parent or its Affiliates, including, without limiting the generality of the foregoing, any duty or responsibility
to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Rights Agent shall neither be responsible for, nor chargeable with, knowledge of, nor have any requirements to comply with, the terms
and conditions of any other agreement, instrument or document, including, without limitation, the Merger Agreement, nor shall the Rights
Agent be required to determine if any person or entity has complied with any such agreements, instruments or documents, nor shall any
additional obligations of the Rights Agent be inferred from the terms of such agreements, instruments or documents even though reference
thereto may be made in this Agreement. In the event of any conflict between the terms and provisions of this Agreement and those of any
other agreement, instrument or document, including but not limited to the Merger Agreement, the terms and conditions of this Agreement
shall control as they relate to the Rights Agent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
provisions of <U>Section&nbsp;3.1</U> and this <U>Section&nbsp;3.2</U> shall survive the termination of this Agreement, the resignation,
replacement or removal of the Rights Agent, and the payment, termination and the expiration of the CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>3.3</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resignation
and Removal; Appointment of Successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such resignation will take effect,
which notice will be sent at least thirty (30) days prior to the date so specified, and such resignation will become effective on the
earlier of (i)&nbsp;the date so specified and (ii)&nbsp;the appointment of a successor Rights Agent. Parent has the right to remove the
Rights Agent at any time by a Board Resolution specifying a date when such removal will take effect (or, if earlier, the appointment
of the successor Rights Agent). Notice of such removal will be given by Parent to the Rights Agent, which notice will be sent at least
thirty (30) days prior to the date so specified. Notwithstanding anything to the contrary contained herein, such replacement or removal
of the Rights Agent shall not affect any of the provisions of this Agreement that expressly survive the termination of this Agreement,
or the resignation, replacement or removal of the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent, by a Board Resolution, will
as soon as is reasonably possible appoint a qualified successor Rights Agent, who shall be a stock transfer agent or national reputation
or the corporate trust department of a commercial bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of
such appointment in accordance with <U>Section&nbsp;3.4</U>, become the successor Rights Agent. Notwithstanding the foregoing, if Parent
shall fail to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified
in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply
to any court of competent jurisdiction for the appointment of a new Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
will give notice to each Holder of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent
by delivering a written notice of such event to the Holders as their names and addresses appear in the CVR Register in accordance with
<U>Section&nbsp;7.1</U>. Each notice will include the name and address of the successor Rights Agent. If Parent fails to send such notice
within ten (10)&nbsp;Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause
the notice to be mailed at the expense of Parent. Failure to give any notice provided for in this <U>Section&nbsp;3.3</U>, however, and
any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of
the successor Rights Agent, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
anything to the contrary in this <U>Section&nbsp;3.3</U>, unless consented to in writing by, at the applicable time of determination,
Holders of at least 33% of the then outstanding CVRs, as set forth in the CVR Register (the &ldquo;<B><I>Acting Holders</I></B>&rdquo;),
Parent will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate
trust department of a commercial bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and
responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register,
to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any
additional liability in connection with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>3.4</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acceptance
of Appointment by Successor. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge
and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement,
and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers,
trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent will execute
and deliver an instrument transferring to the successor Rights Agent all the rights (except such rights of the predecessor Rights Agent
which survive pursuant to <U>Section&nbsp;3.3</U> of this Agreement), powers and trusts of the retiring Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">4.</FONT></TD><TD STYLE="text-align: justify">COVENANTS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>4.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;List
of Holders. Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from Parent&rsquo;s transfer
agent (or other agent performing similar services for Parent), the names and addresses of the Holders within ten (10)&nbsp;Business Days
of the Effective Time. Until such initial list of Holders is furnished to the Rights Agent, the Rights Agent shall have no duties, responsibilities
or obligations with respect to such Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>4.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
of CVR Payment Amounts. If a CVR Payment is due under <U>Section&nbsp;2.4(a)</U>, Parent will deposit the CVR Payment with the Rights
Agent for payment to the Holders in accordance with <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>4.3</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roche
Agreements. Without the prior written consent of the Acting Holders, neither Parent nor any of its Affiliates shall (a)&nbsp;amend, restate,
supplement, terminate or otherwise modify the Roche Agreement in a manner materially adversely affecting the Holders&rsquo; rights under
this Agreement, (b)&nbsp;in the event that Roche fails to make a payment of a Roche Payment at the time rightfully due and payable, take
action with respect to, or unreasonably waive or fail to enforce, the right to receive the applicable payments which are rightfully due
and payable under the Roche Agreement, in a manner materially adversely affecting the Holders&rsquo; rights under this Agreement or (c)&nbsp;agree
to any of the foregoing. Without limiting the foregoing, Parent and its Affiliates shall pursue their rights under the Roche Agreement
in good faith, and not take any action (or fail to take any action) with the intention of avoiding, reducing or materially delaying any
payment to the Holders hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>4.4</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Records.
Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Holders
and their consultants or professional advisors to confirm (a)&nbsp;whether the Roche Payment Amount or the Asset Disposition Proceeds
have been received by Parent or its successors or Affiliates and (b)&nbsp;the applicable CVR Payment Amount payable to each Holder hereunder
in accordance with the terms specified in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">5.</FONT></TD><TD><FONT STYLE="text-transform: uppercase">Disposition</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>5.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the period beginning on the date hereof and ending on December&nbsp;31, 2023, Parent will, and will cause its subsidiaries to, use commercially
reasonable efforts to effectuate a Disposition, including the negotiation and execution of a Sale Agreement and completion of the transactions
contemplated thereby. Further, Parent will not take any actions for the primary purpose of frustrating the payment of CVR Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>5.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holders acknowledge and agree that, except as expressly set forth in the foregoing Section&nbsp;5.1, (a)&nbsp;Parent has a fiduciary
obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay any potential CVR Payments
will not create any express or implied obligation to operate its business in any particular manner in order to maximize any such CVR
Payments, (b)&nbsp;the Holders are not relying on any representation of Parent or any other Person with regard to any Asset Disposition
or other action involving Potentially Transferable Assets, including CVR Sale Assets, following the Closing, and neither Parent nor any
other Person has provided, or can provide, any assurance to the Holders that any potential CVR Payments will in fact be earned and paid,
and (c)&nbsp;none of Parent or any of its Subsidiaries, officers or directors shall have any obligation or liability whatsoever to any
Person relating to or in connection with any action, or failure to act, with respect to the sale of Potentially Transferrable Assets,
including CVR Sale Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">6.</FONT></TD><TD STYLE="text-align: justify">AMENDMENTS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>6.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments
without Consent of Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Without
the consent of any Holders, Parent, when authorized by a Board Resolution, at any time and from time to time, and the Rights Agent may
enter into one or more amendments hereto, solely to evidence any successor to or permitted Assignee of Parent and the assumption by any
such successor or permitted Assignee of the covenants of Parent herein as provided in <U>Section&nbsp;7.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Without
the consent of any Holders, Parent, when authorized by a Board Resolution, may, with the consent of the Rights Agent, which consent shall
not be unreasonably withheld, conditioned or delayed, at any time and from time to time, enter into one or more amendments hereto, solely
for any of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>to
evidence the succession of another Person as a successor Rights Agent in accordance with <U>Section&nbsp;3</U> and the assumption by
any successor of the covenants and obligations of the Rights Agent herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>to
add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent shall consider to be for the
protection of the Holders; provided, that, in each case, such provisions do not adversely affect the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>to
cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein,
or to make any other provisions with respect to matters or questions arising under this Agreement; provided, that, in each case, such
provisions do not adversely affect the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>as
may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act
or any applicable state securities or &ldquo;blue sky&rdquo; laws; provided, that, in each case, such provisions do not adversely affect
the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>to
cancel any CVRs (A)&nbsp;in the event that any Holder has abandoned its rights in accordance with <U>Section&nbsp;2.6</U>, or (B)&nbsp;following
a transfer of such CVRs to Parent or its Affiliates in accordance with <U>Section&nbsp;2.2</U> or <U>Section&nbsp;2.3</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination
or change is adverse to the interests of the Holders; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>as
may be necessary or appropriate to ensure that Parent complies with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Promptly
after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;6.1</U>, Parent
will transmit a notice thereof in accordance with <U>Section&nbsp;7.1</U> to the Holders at their addresses as they appear on the CVR
Register, setting forth in general terms the substance of such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>6.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments
with Consent of Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subject
to <U>Section&nbsp;6.1</U> (which amendments pursuant to <U>Section&nbsp;6.1</U> may be made without the consent of the Holders), with
the consent of the Acting Holders, whether evidenced in writing or taken at a meeting of such Holders, Parent, when authorized by a Board
Resolution, and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any
provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Promptly
after the execution by Parent, and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;6.2</U>, Parent
will transmit (or cause the Rights Agent to transmit) a notice thereof in accordance with <U>Section&nbsp;7.1</U> to the Holders at their
addresses as they appear on the CVR Register, setting forth in general terms the substance of such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>6.3</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execution
of Amendments. In executing any amendment permitted by this <U>Section&nbsp;6</U>, the Rights Agent will be entitled to receive, and
will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized
or permitted by this Agreement. Notwithstanding anything contained herein, the Rights Agent may, but is not obligated to, enter into
any such amendment that affects the Rights Agent&rsquo;s own rights, privileges, covenants or duties under this Agreement or otherwise.
No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>6.4</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Amendments. Upon the execution of any amendment under this <U>Section&nbsp;6</U>, this Agreement will be modified in accordance therewith,
such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase; color: #010000">7.</FONT></TD><TD STYLE="text-align: justify">OTHER
                                            PROVISIONS OF GENERAL APPLICATION</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.1</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices
to Rights Agent and Parent. Any notice or other communication required or permitted hereunder shall be in writing and shall be deemed
given when delivered and received hereunder (a)&nbsp;one Business Day after being sent for next Business Day delivery, fee prepared,
via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand, or (c)&nbsp;on the date
delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m.&nbsp;New
York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If to the Rights Agent, to it at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Computershare Inc. and Computershare
Trust Company, N.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">150 Royall Street, 2nd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Canton, MA 02021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Attention: Relationship Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If to Parent, to it at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Sesen Bio,&nbsp;Inc.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">Telephone:</TD><TD STYLE="text-align: justify">[&bull;]</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">Email:</TD><TD STYLE="text-align: justify">[&bull;]</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">Attention:</TD><TD STYLE="text-align: justify">[&bull;]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">[&bull;]</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">Telephone:</TD><TD STYLE="text-align: justify">[&bull;]</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">Email:</TD><TD STYLE="text-align: justify">[&bull;]</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">Attention:</TD><TD STYLE="text-align: justify">[&bull;]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Rights Agent or Parent may specify
a different address, email address by giving notice to each other in accordance with this <U>Section&nbsp;7.1</U> and to the Holders
in accordance with <U>Section&nbsp;7.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.2</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
to Holders. Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein expressly
provided) if in writing and mailed, first-class postage prepaid or, if applicable, transmitted through the facilities of DTC in accordance
with DTC&rsquo;s procedures, to each Holder affected by such event, at the Holder&rsquo;s address as it appears in the CVR Register,
not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case
where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular
Holder will affect the sufficiency of such notice with respect to other Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.3</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
Successors and Assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Parent
may not assign this Agreement without the prior written consent of the Acting Holders. Notwithstanding the foregoing (i)&nbsp;Parent
may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder
to one or more direct or indirect wholly-owned subsidiaries of Parent for so long as they remain wholly-owned subsidiaries of Parent
(each, an &ldquo;<B><I>Assignee</I></B>&rdquo;) and the Assignee agrees to assume and be bound by all of the terms of this Agreement;
provided, however, that in connection with any assignment to an Assignee, Parent shall, and shall agree to, remain liable for the performance
by such Assignee of all obligations of Parent hereunder, with such Assignee substituted for Parent under this Agreement, and (ii)&nbsp;Parent
may assign this Agreement in its entirety without the consent of any other party to its successor in interest in connection with the
sale of all or substantially all of its assets or of its stock, or in connection with a merger, acquisition or similar transaction (such
successor in interest, the &ldquo;<B><I>Acquiror</I></B>&rdquo;, and such transaction, the &ldquo;<B><I>Acquisition</I></B>&rdquo;).
This Agreement will be binding upon, inure to the benefit of and be enforceable by Parent&rsquo;s successors, acquirers and each Assignee.
Each reference to &ldquo;<B><I>Parent</I></B>&rdquo; in this Agreement shall be deemed to include Parent&rsquo;s successors, acquirers
and all Assignees. Each of Parent&rsquo;s successors, acquirers and assigns shall expressly assume by an instrument supplemental hereto,
executed and delivered to the Rights Agent, the due and punctual payment of the CVR Payments and the due and punctual performance and
observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent. Notwithstanding anything
to the contrary contained herein, no assignment pursuant to this <U>Section&nbsp;7.3</U> shall relieve Parent of its obligations and
liabilities to the Rights Agent hereunder, unless specifically agreed to in writing by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any Person resulting
from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to
the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to
the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties
hereto; provided, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of this Agreement.
The purchase of all or substantially all of the Rights Agent&rsquo;s assets employed in the performance of transfer agent activities
shall be deemed a merger or consolidation for purposes of this <U>Section&nbsp;7.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.4</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benefits
of Agreement; Action by Acting Holders. The holders shall be intended third-party beneficiaries hereof and shall be entitled to, solely
by action by the written consent of the Acting Holders, specifically enforce the terms hereof; <U>provided</U> that under no circumstances
shall the rights of Holders as third-party beneficiaries pursuant to this <U>Section&nbsp;7.4</U> be enforceable by such Holders or any
other Person acting for or on their behalf other than through the action of the Acting Holders, which Acting Holders shall have the sole
power and authority to act on behalf of the Holders in enforcing any of their rights hereunder. Nothing in this Agreement, express or
implied, will give to any Person (other than the Rights Agent, Parent, Parent&rsquo;s successors and permitted assignees, and the Holders
and their respective successors and permitted assignees) any benefit or any legal or equitable right, remedy or claim under this Agreement
or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Rights Agent,
Parent, Parent&rsquo;s successors and permitted Assignees, and the Holders and their respective successors and permitted assignees. The
rights of Holders are limited to those expressly provided in this Agreement and the Merger Agreement. Except for the rights of the Rights
Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of
this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or
other group of Holders will be entitled to exercise such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.5</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law. This Agreement, the CVRs and all claims and causes of action based upon, arising out of or in connection herewith shall be governed
by, and construed in accordance with, the Laws of the State of Delaware, without regard to Laws that may be applicable under conflicts
of laws principles (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction
other than the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In any Legal Proceeding between
any of the parties arising out of our relating to this Agreement, each of the parties hereby (i)&nbsp;irrevocably and unconditionally
consent and submits, for itself and its property, to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware,
New Castle County, or, if such court does not have jurisdiction, the United States District Court for the District of Delaware or, to
the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware, (ii)&nbsp;agrees that
any claim in respect of any such Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)&nbsp;of this
Section&nbsp;7.5, (iii)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter
have to the laying of venue of any such Legal Proceeding in any such court, (iv)&nbsp;waives, to the fullest extent permitted by Law,
any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)&nbsp;agrees that service
of process upon such party in any such Legal Proceeding shall be effective if notice is given in accordance with Section&nbsp;7.1 of
this Agreement. Nothing in this Section&nbsp;7.5, however, shall affect the right of any Person to serve legal process in any manner
permitted by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.6</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or
provision in any other situation or in any other jurisdiction. If any term or other provision of this Agreement is determined by a final
judgement of a court of competent jurisdiction to be invalid or unenforceable, the parties agree that the court making such determination
shall have the power to limit such term or provisions, to delete specific words or phrases or to replace such term or provision with
a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable
term or provision, and this Agreement shall be valid and enforceable as so modified. Notwithstanding anything to the contrary herein,
if any such excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights
Agent shall be entitled to resign immediately upon written notice to Parent. In the event such court does not exercise the power granted
to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business or other purposes of such invalid or unenforceable
term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.7</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts
and Signature. This Agreement may be signed in any number of counterparts, including by electronic transmission, each of which shall
be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.8</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination.
This Agreement will expire and be of no force or effect, the parties hereto will have no liability hereunder (other than with respect
to monies due and owing by Parent to the Rights Agent or any other rights of the Rights Agent which expressly survive the termination
of this Agreement), and no additional payments will be required to be made, upon the later of (i)&nbsp;the conclusion of the CVR Term,
and (ii)&nbsp;the payment of the full amount of all CVR Payments made to Parent on or prior to the end of the applicable CVR Term to
the Rights Agent and the payment of the full amount of all CVR Payment Amounts to the Holders by the mailing by the Rights Agent of each
applicable CVR Payment Amount to each Holder at the address reflected in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.9</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Funds.
All funds received by the Rights Agent under this Agreement that are to be distributed or applied by Computershare in the performance
of services hereunder (the &ldquo;<B><I>Funds</I></B>&rdquo;) shall be held by Computershare as agent for Parent and deposited in one
or more bank accounts to be maintained by Computershare in its name as agent for Parent. Until paid pursuant to the terms of this Agreement,
Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1 billion
or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&rsquo;s (Long Term Rating) and Fitch
Ratings,&nbsp;Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility
or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this paragraph,
including any losses resulting from a default by any bank, financial institution or other Third Party. The Rights Agent may from time
to time receive interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay
such interest, dividends or earnings to Parent, any Holder or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.10</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement. As between Parent and the Holders, this Agreement and the Merger Agreement (including the schedules, annexes and exhibits
thereto, the documents and instruments referred to therein and the documents delivered pursuant thereto) constitute the entire agreement
of Parent and the Holders and supersede all prior agreements and undertakings, both written and oral, among Parent and the Holders, or
any of them, with respect to the subject matter hereof and, except as otherwise expressly provided herein or therein, are not intended
to confer upon any other Person any rights or remedies hereunder or thereunder. As between Parent and the Rights Agent, this Agreement
(including the documents and instruments referred to herein (other than the Merger Agreement) and the documents delivered pursuant thereto)
contains the entire understanding of the parties with reference to the transactions and matters contemplated hereby and thereby and supersedes
all prior agreements, written or oral, among the parties with respect thereto. If and to the extent that any provision of this Agreement
is inconsistent or conflicts with the Merger Agreement, this Agreement will govern and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>7.11</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver
of Jury Trial. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION,
OR CAUSE OF ACTION (i)&nbsp;ARISING UNDER THIS AGREEMENT OR (ii)&nbsp;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS
OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY,&nbsp;IN EACH CASE WHETHER NOW EXISTING
OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM,
DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY&nbsp;FILE
AN ORIGINAL COUNTERPART&nbsp;OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE
WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of page&nbsp;intentionally left
blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, each of the parties has caused
this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">SESEN BIO,&nbsp;INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp; &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">COMPUTERSHARE INC. and<BR>
    COMPUTERSHARE TRUST COMPANY, N.A., jointly as RIGHTS AGENT</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule 5.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Post-Closing Directors and Officers of Parent
and the Surviving Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>ANNEX S-C</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><B>VOTING AND SUPPORT
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This VOTING AND SUPPORT AGREEMENT
(this &ldquo;<B><I>Support Agreement</I></B>&rdquo;) is entered into as of February 13, 2023, among CARISMA Therapeutics Inc., a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), Sesen Bio, Inc., a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), and
the undersigned stockholders (collectively, the &ldquo;<B><I>Stockholders,</I></B>&rdquo; and each, a &ldquo;<B><I>Stockholder</I></B>&rdquo;)
of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, as of the date hereof,
each Stockholder beneficially owns directly, and has the sole power to vote (or to direct the voting of), the number of shares of common
stock, par value $0.001 per share, of Parent (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), set forth opposite such Stockholder&rsquo;s
name on <U>Schedule I</U> hereto (the &ldquo;<B><I>Shares</I></B>&rdquo;, together with any other shares of Parent that are hereafter
issued to or otherwise acquired or owned by, including upon exercise of options or securities convertible into or exercisable or exchangeable
for Common Stock, the voting power of which is acquired by such Stockholder during the Initial Voting Period (as defined below), are collectively
referred to herein as the &ldquo;<B><I>Subject Shares</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the Company, Parent,
and Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&ldquo;<B><I>Merger Sub</I></B>&rdquo;),
have entered into an Agreement and Plan of Merger and Reorganization, dated September 20, 2022, which was subsequently amended on December
29, 2022 (as further amended from time to time, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), pursuant to which Merger Sub shall
be merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of Parent
(the &ldquo;<B><I>Merger</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, (i) concurrently
with the execution and delivery of this Support Agreement, the Company and Parent intend to further amend the Merger Agreement in the
form attached as <U>Exhibit A</U> hereto (the &ldquo;<B><I>Second Merger Agreement Amendment</I></B>&rdquo;), pursuant to which, among
other things, (a) the cash portion of the pre-closing dividend payable to Parent&rsquo;s stockholders will be further increased to $75
million, on the terms and conditions set forth therein, and (b) Parent shall cause, effective as of the Effective Time, Michael Torok
to be appointed as a Class I director of the Parent Board (the &ldquo;<B><I>Stockholder Designee</I></B>&rdquo;), and (ii)&nbsp;at or
prior to 9:30 a.m. Eastern Time on February 14, 2023 (the &ldquo;<B><I>Release Date</I></B>&rdquo;), the Company and Parent intend to
issue the joint press release in the form attached as <U>Exhibit B</U> hereto (the &ldquo;<B><I>Joint Press Release</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the adoption of
the Merger Agreement and the transactions contemplated thereby requires the written consent or affirmative vote of (i) the holders of
a majority of the outstanding shares of Common Stock entitled to vote on the record date for the Parent Stockholders&rsquo; Meeting (the
 &ldquo;<B><I>Record Date</I></B>&rdquo;) and (ii) the holders of a majority in voting power of the votes cast by the holders of all shares
of Common Stock present or represented by proxy at the Parent Stockholders&rsquo; Meeting and entitled to vote thereon; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, as a condition and
inducement to the Company&rsquo;s and Parent&rsquo;s willingness to enter into the Second Merger Agreement Amendment, Parent and the Company
have required each of the Stockholders to, as an inducement and in consideration therefor, and each of the Stockholders (in such Stockholder&rsquo;s
capacity as holder of the Subject Shares) has agreed to, enter into this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NOW, THEREFORE, in consideration
of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
I<BR>
DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Capitalized
Terms</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of this Support Agreement, capitalized terms used and not defined herein shall have the respective meanings ascribed
to them in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B><I>Expiration Time</I></B>&rdquo; shall mean the earliest to occur of (i) the Effective Time, (ii)&nbsp;any amendment
to the Merger Agreement entered into after the date hereof that reduces the amount, or changes the form of any consideration payable to
any Stockholder in the transaction or otherwise materially and adversely affects any Stockholder, (iii)&nbsp;the date and time of the
valid termination of the Merger Agreement in accordance with its terms, (iv) one (1) year from the date hereof or (v) such date that is
ten (10) Business Days after Parent&rsquo;s or the Company&rsquo;s receipt of notice from any Stockholder specifying a material breach
of this Support Agreement by Parent or the Company; <I>provided</I> that such material breach is not cured within such ten (10) Business
Day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B><I>Initial Voting Period</I></B>&rdquo; shall mean such period of time beginning on the date hereof and ending on the
date of the Expiration Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B><I>Standstill Period</I></B>&rdquo; shall mean such period from the date of this Support Agreement until the later of
(A) the earlier of (i) fifteen (15) days prior to the deadline under Parent&rsquo;s Amended and Restated By-laws (the &ldquo;<B><I>Parent
Bylaws</I></B>&rdquo;) for director nominations and stockholder proposals for Parent&rsquo;s 2024 annual meeting of stockholders, and
(ii) one hundred (100) days prior to the first anniversary of Parent&rsquo;s 2023 annual meeting of stockholders (the &ldquo;<B><I>Parent
2023 AGM</I></B>&rdquo;), and (iii) such date that is ten (10) Business Days after Parent&rsquo;s or the Company&rsquo;s receipt of notice
from any Stockholder specifying a material breach of this Support Agreement by Parent or the Company; provided that such material breach
is not cured within such ten (10) Business Day period, and (B) the date when the Stockholder Designee is not on the Parent Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
II<BR>
VOTING AGREEMENT AND IRREVOCABLE PROXY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Agreement
to Vote.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder hereby agrees that, during the Initial Voting Period, and at any duly called meeting of the stockholders of Parent
(or any adjournment or postponement thereof), or in any other circumstances (including action by written consent of stockholders in lieu
of a meeting) upon which a vote, adoption or other approval or consent with respect to the adoption of the Merger Agreement or the approval
of the Merger and any of the transactions contemplated thereby is sought, such Stockholder, if a meeting is held, shall appear at the
meeting, in person or by proxy, and shall provide a written consent or vote (or cause to be voted), in person or by proxy, all of the
Subject Shares, in each case (i)&nbsp;in favor of (A)&nbsp;any proposal to adopt and approve or reapprove the Merger Agreement and the
transactions contemplated thereby, including (1)&nbsp;adoption and approval of the Merger Agreement and the Contemplated Transactions,
(2)&nbsp;the issuance of shares of Common Stock to the Company&rsquo;s stockholders in connection with the Contemplated Transactions pursuant
to the terms of the Merger Agreement, (3)&nbsp;the change of control of Parent resulting from the Merger pursuant to Nasdaq rules, (4)&nbsp;an
amendment to the restated certificate of incorporation of Sesen Bio, as amended, to effect a reverse stock split of the issued and outstanding
shares of Common Stock, at a ratio of 1-for-20, and reduce the number of authorized shares of Common Stock to 100,000,000, (5) the approval
of the Equity Plan Amendments, and (B)&nbsp;waiving any notice that may have been or may be required relating to the Merger or any of
the other Contemplated Transactions (the &ldquo;<B><I>Stockholder Approval Matters</I></B>&rdquo;), and (ii)&nbsp;against any Acquisition
Proposal and any action in furtherance of any such Acquisition Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder further agrees that, following the Effective Time and until the expiration of the Standstill Period, such Stockholder
shall, and shall cause its controlled Affiliates to, (i)&nbsp;cause, in the case of all Common Stock owned of record, and (ii) instruct
the record owner, in the case of all Common Stock beneficially owned but not owned of record, directly or indirectly, by such Stockholder,
as of the record date for all meetings of stockholders (whether annual or special and whether by vote or written consent) at which directors
are elected, in each case that are entitled to vote at such meetings or at any adjournments or postponements thereof, to be present for
quorum purposes and to vote at any such meeting or any adjournments or postponements thereof: (A) for all directors nominated and recommended
by the Parent Board for election at any such meeting, (B) in accordance with the recommendation of the Parent Board for the ratification
of the appointment of its independent registered public accounting firm at any such meeting and (C) in accordance with the Parent Board&rsquo;s
recommendation with respect to any other Parent or Company proposal or stockholder proposal or nomination subject to a vote of the stockholders
at any such meeting; <I>provided, however</I>, that if Institutional Shareholder Services Inc. (&ldquo;<B><I>ISS</I></B>&rdquo;) or Glass
Lewis &amp; Co. LLC (&ldquo;<B><I>GL</I></B>&rdquo;) recommend otherwise with respect to any Parent or stockholder proposals (other than
as related to the election, removal or replacement of directors), each Stockholder shall be permitted to vote in accordance with ISS&rsquo;s
or GL&rsquo;s recommendation; <I>provided, further</I> that each Stockholder shall be permitted to vote in its sole discretion with respect
to any extraordinary transaction requiring a vote of Parent&rsquo;s stockholders. For the avoidance of doubt, it is understood and agreed
by the parties hereto that nothing in this <U>Section 2.1(b)</U> limits or in any way modifies the Stockholders&rsquo; obligations as
set forth in <U>Section 2.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Grant
of Irrevocable Proxy.</U> In the event and to the extent that a Stockholder fails to vote the Subject Shares in accordance with <U>Section
2.1(a)</U> at least five (5) Business Days prior to (or takes or attempts to take any actions inconsistent with <U>Section 2.1(a)</U>
prior to or at) any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders
of Parent, such Stockholder hereby appoints Parent and any designee of Parent, and each of them individually, as such Stockholder&rsquo;s
proxy, with full power of substitution and re-substitution, to vote, including by executing written consents, during the Initial Voting
Period with respect to any and all of the Subject Shares on the matters and in the manner specified in <U>Section 2.1(a)</U>. Each Stockholder
shall take all further action or execute such other instruments as may be necessary to effectuate the intent of any such proxy. Each Stockholder
affirms that the irrevocable proxy given by it hereby with respect to the Merger Agreement and the Contemplated Transactions is given
to Parent by such Stockholder to secure the performance of the obligations of such Stockholder under this Support Agreement. It is agreed
that Parent (and its designees) will use the irrevocable proxy that is granted by such Stockholder hereby only in accordance with applicable
Laws and that, to the extent Parent (and its designees) uses such irrevocable proxy, it will only vote (or sign written consents in respect
of) the Subject Shares subject to such irrevocable proxy with respect to the matters specified in, and in accordance with the provisions
of, <U>Section 2.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Nature
of Irrevocable Proxy.</U> The proxy granted pursuant to <U>Section 2.2</U> to Parent by each Stockholder shall be irrevocable during the
term of this Support Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall
revoke any and all prior proxies or powers of attorney granted by such Stockholder and no subsequent proxy or power of attorney shall
be given or written consent executed (and if given or executed, shall not be effective) by such Stockholder with respect thereto. The
proxy that may be granted hereunder shall terminate at the Expiration Time, but shall survive the death or incapacity of the granting
Stockholder and any obligation of such Stockholder under this Support Agreement shall be binding upon the heirs, personal representatives
and successors of such Stockholder until the Expiration Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
III<BR>
COVENANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Subject
Shares.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder agrees during the Initial Voting Period it shall not, and shall not commit or agree to, without the prior written
consent of Parent and the Company, (i) directly or indirectly, whether by merger, consolidation or otherwise, offer for sale, sell (including
short sales), transfer, tender, pledge, encumber, assign or otherwise dispose of (including by gift or by operation of law) (collectively,
a &ldquo;<B><I>Transfer</I></B>&rdquo;), or enter into any contract, option, derivative, hedging or other agreement or arrangement or
understanding (including any profit-sharing arrangement) with respect to, or consent to or permit, a Transfer of any or all of the Subject
Shares or any interest therein; (ii) grant any proxies or powers of attorney with respect to any or all of the Subject Shares or agree
to vote (or sign written consents in respect of) the Subject Shares on any matter or divest itself of any voting rights in the Subject
Shares that would conflict with the terms of this Support Agreement, or (iii)&nbsp;take any action that would have the effect of preventing
or disabling such Stockholder from performing its obligations under this Support Agreement. Notwithstanding the foregoing, each Stockholder
may, at any time, Transfer its Subject Shares (1)&nbsp;by will or other testamentary document or by intestacy, (2)&nbsp;to any investment
fund or other entity controlled or managed by such Stockholder or the investment adviser or general partner of such Stockholder, (3)&nbsp;to
any member of such Stockholder&rsquo;s immediate family, (4)&nbsp;to any trust for the direct or indirect benefit of such Stockholder
or the immediate family of such Stockholder or otherwise for estate planning purposes or (5) to the extent required by applicable Law;
<I>provided</I>, that in the case of clauses (1)-(4), such transferee shall have executed and delivered to Parent and the Company a support
agreement substantially identical to this Support Agreement (each such transferee, a &ldquo;<B><I>Permitted Transferee</I></B>&rdquo;).
Each Stockholder agrees that any Transfer of Subject Shares not permitted hereby shall be null and void and that any such prohibited Transfer
shall be enjoined. If any voluntary or involuntary Transfer of any Subject Shares covered hereby shall occur (including a sale by a Stockholder&rsquo;s
trustee in bankruptcy, or a sale to a purchaser at any creditor&rsquo;s or court sale), the Permitted Transferee (which term, as used
herein, shall include any and all transferees and subsequent transferees of the initial Permitted Transferee) shall take and hold such
Subject Shares subject to all of the restrictions, liabilities and rights under this Support Agreement, which shall continue in full force
and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event of a stock dividend or distribution, or any change in the Subject Shares by reason of any stock dividend or distribution,
split-up, recapitalization, combination, conversion, exchange of shares or the like, the term &ldquo;<B><I>Subject Shares</I></B>&rdquo;
shall be deemed to refer to and include the Subject Shares as well as all such stock dividends and distributions and any securities into
which or for which any or all of the Subject Shares may be changed or exchanged or which are received in such transaction. Each Stockholder
further agrees that, in the event such Stockholder purchases or otherwise acquires beneficial or record ownership of or an interest in,
or acquires the right to vote or share in the voting of, any additional shares of Common Stock, in each case after the execution of this
Support Agreement and prior to the Expiration Time, such Stockholder shall deliver promptly to the Company and Parent written notice of
such event, which notice shall state the number of additional shares so acquired. Each Stockholder agrees that any such additional shares
of Common Stock shall constitute Subject Shares for all purposes of this Support Agreement and shall be subject to the terms of this Support
Agreement, including all covenants, agreements, obligations, representations and warranties set forth herein as if those additional shares
were owned by such Stockholder on the date of this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Stockholder&rsquo;s
Capacity.</U> All agreements and understandings made herein shall be made solely in each Stockholder&rsquo;s capacity as a holder of the
Subject Shares and not in any other capacity, including not in such Stockholder&rsquo;s capacity as a director or officer of Parent. Notwithstanding
anything herein to the contrary, nothing in this Support Agreement (including, for the avoidance of doubt, <U>Section 3.7</U> below),
shall in any way restrict a director of Parent (including any director who is an Affiliate of a Stockholder) in the taking of any actions
(or failure to act) solely in his or her capacity as a director of Parent, or in the exercise of his or her fiduciary duties as a director
of Parent, or prevent or be construed to create any obligation on the part of any director of Parent from taking any action in his or
her capacity as such director, and no action taken solely in any such capacity as a director of Parent shall be deemed to constitute a
breach of this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Other
Offers.</U> Except to the extent Parent is permitted to take such action pursuant to the Merger Agreement, each Stockholder (in such Stockholder&rsquo;s
capacity as such) shall not, and shall instruct and cause its Representatives not to, take any of the following actions: (a)&nbsp;solicit,
initiate, knowingly encourage or knowingly facilitate an Acquisition Proposal; (b)&nbsp;furnish any non-public information regarding Parent
to any Person in connection with or in response to an Acquisition Proposal (except as required by applicable Law or pursuant to a request
by a Governmental Body); (c)&nbsp;engage in, enter into, continue or otherwise participate in any discussions or negotiations with any
Person with respect to, or otherwise knowingly cooperate in any way with any Person (or any representative thereof) with respect to, any
Acquisition Proposal; (d) approve, endorse or recommend or publicly propose to approve, endorse or recommend, any Acquisition Proposal;
or (e) enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or publicly
proposing to approve, endorse or recommend, any Acquisition Transaction; <I>provided</I>, <I>however</I>, that none of the foregoing restrictions
shall apply to a Stockholder&rsquo;s and its Representatives&rsquo; interactions with Parent, Merger Sub, the Company and their respective
subsidiaries and Representatives; <I>provided</I>, <I>further</I>, that nothing in this <U>Section 3.3</U> shall prevent a Stockholder
from referring a Person to this <U>Section 3.3</U> or to the Merger Agreement. Without limiting the foregoing, it is understood that any
violation of the foregoing restrictions by any Representatives of the Stockholders shall be deemed to be a breach of this <U>Section 3.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Communications.
</U><FONT STYLE="text-transform: uppercase">Section 3.5</FONT> During the Initial Voting Period, each Stockholder shall not, and shall
use its reasonable best efforts to cause its Representatives and Affiliates, if any, not to, directly or indirectly, make any press release,
public announcement or other public communication that (a) criticizes or disparages this Support Agreement or the Merger Agreement or
any of the transactions contemplated hereby and thereby or (b) is in opposition to the Stockholder Approval Matters, without the prior
written consent of Parent and the Company, except as may be required by applicable Law in which circumstance such announcing party shall
reasonably consult with the Company and Parent to the extent legally permissible prior to any such disclosure; <I>provided</I>, that
the foregoing shall not limit or affect any actions taken by the Stockholders (or any affiliated officer or director of the Stockholders)
that would be permitted to be taken by the Stockholders pursuant to the Merger Agreement. Each Stockholder hereby: (i)&nbsp;consents
to and authorizes the publication and disclosure in all documents and schedules filed with the SEC, and any press release or other disclosure
document that Parent or the Company reasonably determines to be necessary in connection with the Merger or any Contemplated Transaction
of (A)&nbsp;such Stockholder&rsquo;s identity, (B)&nbsp;such Stockholder&rsquo;s ownership of the Subject Shares, (C)&nbsp;this Support
Agreement and (D)&nbsp;the nature of the such Stockholder&rsquo;s commitments, arrangements and understandings under this Support Agreement;
and (ii)&nbsp;agrees as promptly as practicable to notify Parent, Merger Sub and the Company of any required corrections with respect
to any written information supplied by such Stockholder specifically for use in any such disclosure document. Further, the Stockholder
Designee shall, during the term of his service as a director of the Parent Board, comply with the Code of Conduct and all other policies
and guidelines applicable to independent directors serving on the Parent Board that (i) have been as of the date hereof or are prior
to the Effective Time validly adopted by the Company Board to be effective as of the Effective Time or (iii) are validly adopted by the
Parent Board after the Effective Time.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Voting Trusts.</U>
Except for this Support Agreement or otherwise disclosed to Parent prior to the date hereof, each Stockholder agrees that it will not,
nor will it permit any entity under its control to, deposit any of its Subject Shares in a voting trust or subject any of its Subject
Shares to any arrangement with respect to the voting of such Subject Shares that would restrict such Stockholder from performing its obligations
under this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver
of Appraisal Rights.</U> Each Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect
(or attempt to exercise, assert or perfect) any rights of appraisal or rights to dissent from the Merger or quasi-appraisal rights that
it may at any time have under applicable Laws, including Section&nbsp;262 of the DGCL. Each Stockholder agrees not to commence, join in,
facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to,
any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective successors, directors or officers,
(a)&nbsp;challenging the validity, binding nature or enforceability of, or seeking to enjoin the operation of, this Support Agreement
or the Merger Agreement, or (b)&nbsp;alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation,
entry into or consummation of the Merger Agreement; <I>provided, however</I>, that (i) each Stockholder may defend against, contest or
settle any action, claim, suit or cause of action brought against such Stockholder that relates solely to such Stockholder&rsquo;s capacity
as a director, officer or securityholder of Parent and (ii) the foregoing shall not limit or restrict in any manner each Stockholder from
enforcing such Stockholder&rsquo;s rights under this Support Agreement and the other agreements entered into by such Stockholder in connection
herewith, or otherwise in connection with the Merger, including such Stockholder&rsquo;s right to receive the Merger Consideration pursuant
to the terms of the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Additional
Agreements.</U> Each Stockholder agrees that during the Standstill Period, each Stockholder shall not, and shall cause each of its controlled
Affiliates and Associates (as used in this <U>Section 3.7</U>, the terms &ldquo;<B><I>Affiliate</I></B>&rdquo; and &ldquo;<B><I>Associate</I></B>&rdquo;
shall have the respective meanings set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act and shall include all persons
or entities that at any time during the term of this Support Agreement become Affiliates or Associates of any person or entity referred
to in this Support Agreement) not to, in each case directly or indirectly, in any manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage in any solicitation of proxies or become a &ldquo;participant&rdquo; in a &ldquo;solicitation&rdquo; (as such terms are
defined in Regulation 14A under the Exchange Act) of proxies (including, without limitation, any solicitation of consents that seeks to
call a special meeting of stockholders), in each case, with respect to securities of Parent or the Company, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>form, join, or knowingly participate in any &ldquo;group&rdquo; (within the meaning of Section 13(d)(3) of the Exchange Act) with
respect to shares of Common Stock (other than a &ldquo;group&rdquo; that includes all or some of the members of each Stockholder, but
does not include any other entities or persons that are not members of each Stockholder as of the date hereof); <I>provided, however</I>,
that nothing herein shall limit the ability of an Affiliate or Associate of any Stockholder to join the &ldquo;group&rdquo; following
the execution of this Support Agreement so long as any such Affiliate or Associate agrees to be bound by the terms and conditions of this
Support Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>deposit any shares of Common Stock in any voting trust or subject any shares of Common Stock to any arrangement or agreement with
respect to the voting of any shares of Common Stock, other than (i) any such voting trust, arrangement or agreement solely among the members
of each Stockholder, (ii)&nbsp;otherwise in accordance with this Support Agreement or (iii) customary brokerage accounts, margin accounts,
prime brokerage accounts and the like;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>seek or submit, or knowingly encourage any person or entity to seek or submit, nomination(s) in furtherance of a &ldquo;contested
solicitation&rdquo; for the appointment, election or removal of directors with respect to Parent or the Company, publicly seek, or knowingly
encourage or take any other action with respect to the appointment, election or removal of any directors, in each case in opposition to
the recommendation of the Parent Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) make any proposal for consideration by stockholders at any annual or special meeting of stockholders of Parent or the Company
or through any referendum of stockholders, (ii) make any offer or proposal (with or without conditions) with respect to any merger, tender
(or exchange) offer, acquisition, recapitalization, restructuring, disposition or other business combination involving each Stockholder
and Parent or the Company, (iii) affirmatively solicit a third party to make an offer or proposal (with or without conditions) with respect
to any merger, tender (or exchange) offer, acquisition, recapitalization, restructuring, disposition or other business combination involving
Parent or the Company, or publicly encourage, initiate or support any third party in making such an offer or proposal, (iv) publicly comment
on any third party proposal regarding any merger, tender (or exchange) offer, acquisition, recapitalization, restructuring, disposition,
or other business combination with respect to Parent or the Company by such third party prior to such proposal becoming public, or (v)
call or seek to call a special meeting of stockholders of Parent or the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make any request under Section 220 of the DGCL;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>seek, alone or in concert with others, representation on the Parent Board, except as specifically set forth pursuant to the Second
Merger Agreement Amendment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) nominate or recommend for nomination any person for election at any annual or special meeting of stockholders of Parent or
the Company, (ii) submit any proposal for consideration at, or bring any other business before, any annual or special meeting of the stockholders
of Parent or the Company, or (iii) initiate, knowingly encourage or participate in any &ldquo;vote no,&rdquo; &ldquo;withhold&rdquo; or
similar campaign with respect to any annual or special meeting of stockholders of Parent or the Company, or publicly or privately encourage
or support any other stockholder, person or entity to take any of the actions described in this <U>Section 3.7(h</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>advise, knowingly encourage, knowingly support or knowingly influence any person or entity with respect to the voting or disposition
of any securities of Parent or the Company at any annual or special meeting of stockholders (other than as expressly set forth in <U>Section
2.1</U>); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make any request or submit any proposal to amend the terms of this Support Agreement other than through non-public communications
with Parent, the Parent Board, the Company or the Company Board that would not be reasonably determined to trigger public disclosure obligations
for any party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary contained in <U>Section 3.7 </U>or elsewhere in this Support Agreement, a Stockholder shall not be prohibited or restricted
from: (A) communicating privately with Parent, the Parent Board, the Company, the Company Board or any officer or director of Parent or
the Company regarding any matter, so long as (1) such communications are not intended to, and would not reasonably be expected to, require
any public disclosure of such communications by any party to this Support Agreement, and (2), unless otherwise agreed between Parent and
the Company, at least one representative of each of Parent and the Company is present for any such communications; (B) taking any action
necessary to comply with any law, rule or regulation or any action required by any governmental or regulatory authority or stock exchange
that has, or may have, jurisdiction over such Stockholder, <I>provided</I> that a breach by such Stockholder of this Support Agreement
is not the cause of the applicable requirement; or (C) communicating with stockholders of Parent and the Company and others in a manner
that does not otherwise violate and is not inconsistent with this Support Agreement, <I>provided</I> such communications are not reasonably
expected to be publicly disclosed and are understood by all parties to be private communications and not undertaken with the intent to
circumvent this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Parent Agreements</U>.
Solely in the event that either Parent has not yet obtained the Required Parent Stockholder Vote or the Company has not yet obtained the
Required Company Stockholder Vote by April 1, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Parent acknowledges and agrees to provide each Stockholder with written notice of the date of the Parent 2023 AGM at least seventy
(70) days prior to such meeting (such notice, the &ldquo;<B><I>Parent AGM Notice</I></B>&rdquo;). Notwithstanding anything to the contrary
contained in this Support Agreement or the Parent Bylaws with respect to the requirement that the notice comply with the time deadlines
set forth in the Parent Bylaws with respect to the proposal of business and/or nomination of director candidates, a Stockholder&rsquo;s
notice of director nominations or stockholder proposals for consideration at the Parent 2023 AGM shall be deemed timely received by Parent
in accordance with the Parent Bylaws if such notice (i) is received in writing by the secretary of Parent at the principal executive offices
of Parent during the ten (10) day period following such Stockholder&rsquo;s receipt of the Parent AGM Notice, and (ii) otherwise complies
with the requirements set forth in the certificate of incorporation of Parent, the Parent Bylaws and applicable Law; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Parent acknowledges and agrees that it shall not hold the Parent 2023 AGM prior to seventy (70) days after the delivery of the
Parent AGM Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
IV<BR>
REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each Stockholder hereby represents
and warrants to Parent and the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Due
Authorization, etc.</U></FONT> Such Stockholder is a natural person, corporation, trust, limited partnership or limited liability company.
If such Stockholder is a corporation, trust, limited partnership or limited liability company, such Stockholder is an entity duly organized,
validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted. Such Stockholder
has all necessary power and authority to execute and deliver this Support Agreement, perform such Stockholder&rsquo;s obligations hereunder
and to consummate the transactions contemplated hereby. The execution and delivery by such Stockholder of this Support Agreement, the
performance by such Stockholder of its obligations hereunder and the consummation by such Stockholder of the transactions contemplated
hereby have been duly authorized by all necessary action on the part of such Stockholder and no other proceedings on the part of such
Stockholder are necessary to authorize this Support Agreement, or to consummate the transactions contemplated hereby. This Support Agreement
has been duly executed and delivered by such Stockholder and (assuming the due authorization, execution and delivery by Parent and the
Company) constitutes a valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms,
except to the extent enforcement is limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws
of general applicability relating to or affecting creditors&rsquo; rights and by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Ownership
of Shares. Schedule&nbsp;I</U> hereto sets forth opposite such Stockholder&rsquo;s name the Shares which such Stockholder beneficially
owns directly as of the date hereof. As of the date hereof, each Stockholder is the beneficial owner of the Shares denoted as being owned
by such Stockholder on <U>Schedule&nbsp;I</U> hereto, has the power to vote or cause to be voted such Shares and has the power to dispose
of, or cause to be disposed, such Shares (other than, if such Stockholder is a partnership or a limited liability company, the rights
and interest of Persons that own partnership interests or units in such Stockholder under the partnership agreement or operating agreement
governing such Stockholder and applicable partnership or limited liability company law, or if such Stockholder is a married individual
and resides in a state with community property laws, the community property interest of his or her spouse to the extent applicable under
such community property laws, which spouse hereby consents to this Support Agreement by executing the spousal consent attached hereto
as <U>Exhibit C</U>). Each Stockholder has, and will at all times up until the Expiration Time have, good and valid title to the Shares
denoted as being owned by such Stockholder on <U>Schedule&nbsp;I</U> hereto, free and clear of any and all pledges, mortgages, liens,
charges, proxies, voting agreements encumbrances, adverse claims, options, security interests and demands of any nature or kind whatsoever,
other than (a)&nbsp;those created by this Support Agreement, (b) those existing under applicable securities laws and (c) those that would
not adversely affect such Stockholder&rsquo;s ability to perform its obligations under this Support Agreement. Without limiting the generality
of the foregoing, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Shares, and no
Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Shares except as provided
hereunder. <U>Schedule&nbsp;II</U> hereto sets forth opposite such Stockholder&rsquo;s name the Shares which such Stockholder beneficially
owned directly as of the Record Date. As of the Record Date, each Stockholder was the beneficial owner of the Shares denoted as being
owned by such Stockholder on <U>Schedule&nbsp;II</U> hereto, had the power to vote or cause to be voted such Shares and had the power
to dispose of, or cause to be disposed, such Shares, except as otherwise indicated to Parent prior to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>No
Conflicts.</U> (a)&nbsp;No filing with any Governmental Body, and no authorization, consent or approval of any other Person, is necessary
for the execution of this Support Agreement by such Stockholder and (b)&nbsp;none of the execution and delivery of this Support Agreement
by such Stockholder, the performance of such Stockholder&rsquo;s obligations hereunder, the consummation by such Stockholder of the transactions
contemplated hereby or compliance by such Stockholder with any of the provisions hereof shall (i)&nbsp;conflict with or result in any
breach of the organizational documents of such Stockholder, (ii)&nbsp;result in, or give rise to, a violation or breach of or a default
under any of the terms of any material Contract, understanding, agreement or other instrument or obligation to which such Stockholder
is a party or by which such Stockholder or any of the Subject Shares or its assets may be bound or (iii)&nbsp;violate any applicable order,
writ, injunction, decree, judgment, statute, rule or regulation, except for any of the foregoing as would not reasonably be expected to
impair such Stockholder&rsquo;s ability to perform its obligations under this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Finder&rsquo;s
Fees.</U> No investment banker, broker, finder or other intermediary is entitled, whether directly or indirectly, to a fee, commission
or other benefit from Parent, Merger Sub or the Company in respect of this Support Agreement based upon any Contract made by or on behalf
of such Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Reliance.</U>
Such Stockholder has had the opportunity to review the Merger Agreement, the Second Merger Agreement Amendment and this Support Agreement
with counsel of such Stockholder&rsquo;s own choosing. Such Stockholder has had an opportunity to review with its own tax advisors the
tax consequences of the Merger and the Contemplated Transactions. Such Stockholder understands that it must rely solely on its advisors
and not on any statements or representations made by Parent, the Company or any of their respective Representatives with respect to the
tax consequences of the Merger and the Contemplated Transactions. Such Stockholder understands that such Stockholder (and not Parent,
the Company or the Surviving Corporation) shall be responsible for such Stockholder&rsquo;s tax liability that may arise as a result of
the Merger or the Contemplated Transactions. Such Stockholder understands and acknowledges that Parent and the Company are entering into
the Merger Agreement in reliance upon such Stockholder&rsquo;s execution, delivery and performance of this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>No
Litigation.</U> As of the date of this Support Agreement, there is no Legal Proceeding pending or, to the knowledge of such Stockholder,
threatened against such Stockholder that would reasonably be expected to impair the ability of such Stockholder to perform its obligations
hereunder or consummate the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
V<BR>
REPRESENTATIONS AND WARRANTIES OF PARENT AND THE COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of Parent and the Company,
solely on their own behalf, hereby represents and warrants to each Stockholder as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Due
Authorization, etc.</U></FONT> Each of Parent and the Company is a corporation, and is duly organized, validly existing and in good standing
under the laws of the State of Delaware. Each of Parent and the Company has all necessary power and authority to execute and deliver this
Support Agreement, perform such party&rsquo;s obligations hereunder and to consummate the transactions contemplated hereby. The execution
and delivery by Parent and the Company of this Support Agreement, the performance by Parent and the Company of its obligations hereunder
and the consummation by Parent and the Company of the transactions contemplated hereby have been duly authorized by all necessary action
on the part of Parent and the Company and no other proceedings on the part of Parent and the Company are necessary to authorize this Support
Agreement, or to consummate the transactions contemplated hereby. This Support Agreement has been duly executed and delivered by each
of Parent and the Company and (assuming the due authorization, execution and delivery by each Stockholder) constitutes a valid and binding
obligation of Parent and the Company, enforceable against Parent and the Company in accordance with its terms, except to the extent enforcement
is limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating
to or affecting creditors&rsquo; rights and by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>No
Conflicts.</U> (a)&nbsp;No filing with any Governmental Body, and no authorization, consent or approval of any other Person, is necessary
for the execution of this Support Agreement by each of Parent and the Company and (b)&nbsp;none of the execution and delivery of this
Support Agreement by Parent and the Company, the performance of Parent and the Company&rsquo;s obligations hereunder, the consummation
by Parent and the Company of the transactions contemplated hereby or compliance by Parent and the Company with any of the provisions hereof
shall (i)&nbsp;conflict with or result in any breach of the organizational documents of Parent and the Company, as applicable, (ii)&nbsp;result
in, or give rise to, a violation or breach of or a default under any of the terms of any material Contract, understanding, agreement or
other instrument or obligation to which Parent or the Company is a party or by which Parent or the Company, as applicable, or their respective
assets may be bound or (iii)&nbsp;violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except
for any of the foregoing as would not reasonably be expected to impair Parent or the Company&rsquo;s ability to perform its obligations
under this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
VI<BR>
TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Termination.</U>
This Support Agreement shall automatically terminate, and none of Parent, the Company or the Stockholders shall have any rights or obligations
hereunder and this Support Agreement shall become null and void and have no effect upon the earliest to occur of: (a) the failure of Parent
and the Company to issue the Joint Press Release by 9:30 a.m. Eastern Time on the Release Date; (b) the valid termination of the Merger
Agreement in accordance with its terms; (c) any amendment to the Merger Agreement that reduces the amount, or changes the form of any
consideration payable to the Stockholders in the Contemplated Transactions or otherwise materially and adversely affects the Stockholders;
(d) the expiration of the Standstill Period, (e) solely in the event that either Parent has not yet obtained the Required Parent Stockholder
Vote or the Company has not yet obtained the Required Company Stockholder Vote by such date, April 1, 2023, and (f) the time this Support
Agreement is terminated upon the written agreement of each of the Stockholders, the Company and Parent. The parties acknowledge that upon
termination of this Support Agreement as permitted under and in accordance with the terms of this Support Agreement, no party to this
Support Agreement shall have the right to recover any claim with respect to any losses suffered by such party in connection with such
termination, and no party shall have any further obligations or liabilities under this Support Agreement, subject to the following sentence.
Notwithstanding anything to the contrary herein, (i)&nbsp;nothing set forth in this <U>Section 6.1</U> shall relieve any party from liability
for any willful breach of this Support Agreement prior to termination hereof, and (ii)&nbsp;the provisions of <U>Section 3.8</U>, this
<U>Section 6.1</U> and <U>Section 7.4</U> through <U>Section 7.14</U> shall survive the termination of this Support Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
VII<BR>
MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Press
Release, SEC Filings.</U> No later than 9:30 a.m. Eastern Time on the Release Date, the Company and Parent shall issue the Joint Press
Release. Prior to the Release Date, none of the Stockholders (individually or jointly) nor any of their Representatives or Affiliates
shall issue a press release, public announcement or other public communication with respect to Parent, the Company, the entry into this
Support Agreement or the actions contemplated hereby without the prior written consent of Parent and the Company. Promptly following the
execution and delivery of this Support Agreement, Parent will file a Current Report on Form 8-K (the &ldquo;<B><I>Form 8-K</I></B>&rdquo;),
which will report the entry into this Support Agreement and file the Support Agreement as an exhibit thereto. The Stockholders shall be
given a reasonable opportunity to review and comment on the Form 8-K or any other filing with the SEC made by Parent with respect to this
Support Agreement, and Parent shall give reasonable consideration to any comments of the Stockholders. Parent acknowledges that the Stockholders
may file this Support Agreement as an exhibit to the Stockholders&rsquo; Schedule 13D. In such event, Parent shall be given a reasonable
opportunity to review and comment on such Schedule 13D filing made by the Stockholders with respect to this Support Agreement, and the
Stockholders shall give reasonable consideration to any comments of Parent. Following the Release Date, each Stockholder shall, and shall
cause its Representatives and Affiliates to, cause any public or private filings, announcements, statements or communications that reference
the entry into this Support Agreement or the actions contemplated to be taken in connection with the entry into this Support Agreement
or are otherwise made in connection herewith, to be consistent with the Joint Press Release and the terms of this Support Agreement. Parent
and Company shall be given a reasonable opportunity to review and comment on any such filings, announcements, statements or communications
by the Stockholders, and the Stockholders shall give reasonable consideration to any comments of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Non-Disparagement.</U>
Each of the parties hereby agrees that, during the Initial Voting Period, neither it nor any of its Representatives or Affiliates or any
of its or its Representatives&rsquo; and Affiliates&rsquo; respective agents, subsidiaries, officers, directors, managers, principals
or managing members shall in any way publicly (or in any way reasonably expected to be made public) attack, disparage, call into disrepute,
criticize, impugn, defame, slander or otherwise make any public statements or statements reasonably expected to be made public that would
reasonably be expected to damage the business or reputation of any other party or such other party&rsquo;s subsidiaries, Affiliates, officers
(including any current officer of a party or a party&rsquo;s subsidiaries who no longer serves in such capacity following the execution
of this Support Agreement), directors (including any current director of a party or a party&rsquo;s subsidiaries who no longer serves
in such capacity following the execution of this Support Agreement) or employees, or any of their businesses, products or services, including,
for the avoidance of doubt, the making of statements that would reasonably be expected to have any of the foregoing adverse consequences.
Each party shall use its commercially reasonable efforts to cause its and its Representatives&rsquo; and Affiliates&rsquo; employees to
comply with this <U>Section 7.2</U>. For the avoidance of doubt, the foregoing shall not restrict the ability of any person to comply
with compelled testimony or production of information by legal process, subpoena or as part of a response to a request for information
from any Governmental Body with purported jurisdiction over the party from whom information is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Further
Actions.</U> Subject to the terms and conditions set forth in this Support Agreement, each party hereto agrees to take any all actions
and to do all things reasonably necessary to effectuate this Support Agreement. If a Stockholder is a married individual, his or her spouse
shall deliver the spousal consent attached hereto as <U>Exhibit C</U> unless such Stockholder can demonstrate to Parent&rsquo;s and the
Company&rsquo;s reasonable satisfaction that his or her spouse does not have any community property interests in the Subject Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Fees
and Expenses.</U> Parent agrees to reimburse the Stockholders for the reasonable and documented out-of-pocket expenses incurred by the
Stockholders prior to the date hereof directly in connection with their investment in Parent, including but not limited to the negotiation
and execution of this Support Agreement, in an aggregate amount not to exceed $180,000. The reimbursement provided in this <U>Section
7.4</U> shall be paid by Parent to the Stockholders no later than five (5) Business Days following Parent&rsquo;s receipt of reasonable
documentation supporting such reimbursable expenses hereunder. Except as otherwise specifically provided in this <U>Section 7.4</U>, each
party shall bear its own fees and expenses in connection with this Support Agreement and the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Amendments,
Waivers, etc.</U> This Support Agreement may not be amended except by an instrument in writing signed by all the parties hereto and specifically
referencing this Support Agreement. No failure on the part of any party to exercise any power, right, privilege or remedy under this Support
Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Support Agreement, shall
operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed
to have waived any claim arising out of this Support Agreement, or any power, right, privilege or remedy under this Support Agreement,
unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered
on behalf of such party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is
given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>
<U>Notices.</U> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and
received hereunder (a) one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight
courier service, (b) upon delivery in the case of delivery by hand, or (c) on the date delivered in the place of delivery if sent by email
(with a written or electronic confirmation of delivery) prior to 5:00&nbsp;p.m. New York time, otherwise on the next succeeding Business
Day, in each case to the intended recipient as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Company, to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">CARISMA Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">3675 Market Street, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Philadelphia, Pennsylvania 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Attn: President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Email: steven.kelly@carismatx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Wilmer Cutler Pickering Hale and Dorr LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">7 World Trade Center<BR>
250 Greenwich Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">New York, NY 10007<BR>
Attention: Brian A. Johnson; Christopher Barnstable-Brown<BR>
Email: Brian.Johnson@wilmerhale.com;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Chris.Barnstable-Brown@wilmerhale.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to Parent, to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Sesen Bio, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">245 First Street, Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Cambridge, MA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Email: tom.cannell@sesenbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Hogan Lovells US LLP<BR>
1735 Market St<BR>
Philadelphia, PA 19103<BR>
Attention: Steve Abrams; Jessica Bisignano<BR>
Email: steve.abrams@hoganlovells.com; jessica.bisignano@hoganlovells.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If to a Stockholder, to the
address or electronic mail address set forth on the signature pages hereto or to such other Person or address as any party shall specify
by written notice so given, and with a copy to its counsel (which shall not constitute notice) as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Olshan Frome Wolosky LLP<BR>
1325 Avenue of the Americas<BR>
New York, NY 10019<BR>
Attention: Ryan Nebel; Rebecca Van Derlaske<BR>
Email: rnebel@olahanlaw.com; rvanderlaske@olshanlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Interpretation;
Construction.</U> Headings of the Articles and Sections of this Support Agreement are for convenience of the parties only, and shall be
given no substantive or interpretive effect whatsoever. Except as otherwise indicated, all references in this Support Agreement to &ldquo;Exhibits&rdquo;,
 &ldquo;Sections&rdquo; or &ldquo;Schedules&rdquo; are intended to refer to Sections of this Support Agreement and the Exhibits or Schedules
to this Support Agreement. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall
not be applied in the construction or interpretation of this Support Agreement. As used in this Support Agreement, the words &ldquo;include&rdquo;
and &ldquo;including,&rdquo; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed
by the words &ldquo;without limitation.&rdquo; For purposes of this Support Agreement, whenever the context requires: the singular number
shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall
include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Severability.</U>
Any term or provision of this Support Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect
the validity or enforceability of the remaining terms and provisions of this Support Agreement or the validity or enforceability of the
offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction
declares that any term or provision of this Support Agreement is invalid or unenforceable, the parties agree that the court making such
determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision
with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable
term or provision, and this Support Agreement shall be valid and enforceable as so modified. In the event such court does not exercise
the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid
and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid
or unenforceable term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Entire
Agreement; Assignment.</U> This Support Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings,
both written and oral, between the parties, or any of them, with respect to the subject matter hereof; <I>provided</I>, <I>however</I>,
that, as between the Company and Parent, to the extent of any conflict between the Merger Agreement and this Support Agreement, the terms
of the Merger Agreement shall control and supersede any such conflicting terms. This Support Agreement will be binding upon, inure to
the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns, and, in the case of each
Stockholder, such Persons to which record or beneficial ownership of such Stockholder&rsquo;s Subject Shares shall pass; <I>provided,
however</I>, that neither this Support Agreement nor any of the rights, interests or obligations hereunder shall be assigned or delegated
by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties, except
that, without consent, each of Parent and the Company may assign all or any of its rights and obligations hereunder to any of its Affiliates
that assume the rights and obligations of such party under the Merger Agreement, and any attempted assignment or delegation of this Support
Agreement or any of the rights, interests or obligations by any of the parties without the other parties prior written consent shall be
void and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Governing
Law.</U> THIS SUPPORT AGREEMENT AND ALL QUESTIONS RELATING TO THE INTERPRETATION OR ENFORCEMENT OF THIS SUPPORT AGREEMENT SHALL BE DEEMED
TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE
WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Specific
Performance.</U> The parties hereto acknowledge that any breach of this Support Agreement would give rise to irreparable harm for which
monetary damages, even if applicable, would not be an adequate remedy, and would occur in the event that any party does not perform the
provisions of this Support Agreement (including failing to take such actions as are required of it hereunder to consummate the transactions
contemplated hereby) in accordance with its specified terms or otherwise breaches such provisions. Accordingly, the parties shall be entitled
to seek a decree of specific performance, an injunction or other equitable relief to prevent breaches or threatened breaches of any of
the provisions of this Support Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy
to which they are entitled at law or in equity. Each of the parties agrees that it will not oppose the granting of specific performance,
an injunction or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific
performance or other equitable relief is not an appropriate remedy for any reason at law or in equity. Any party seeking an injunction
or injunctions to prevent breaches of this Support Agreement shall not be required to provide any bond or other security in connection
with any such order or injunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Submission
to Jurisdiction.</U> The parties hereby (a) irrevocably and unconditionally submit to the exclusive personal jurisdiction and venue of
the Court of Chancery of the State of Delaware, New Castle County, or, if the Chancery Court declines jurisdiction, the United States
District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court
of the State of Delaware, (b) agree that all claims in respect of such action or proceeding shall be heard and determined exclusively
in accordance with clause (a) of this <U>Section 7.12</U>, (c) waive any objection to laying venue in any such action or proceeding in
such courts, (d) waive any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (e) agree
that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section
7.6</U> of this Support Agreement. Nothing in this <U>Section 7.12</U>, however, shall affect the right of any person to serve legal process
in any other manner permitted by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Waiver
of Jury Trial.</U> EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND,
ACTION, OR CAUSE OF ACTION (i) ARISING UNDER THIS SUPPORT AGREEMENT OR (ii) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE
DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS SUPPORT AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER
NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY
SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS SUPPORT AGREEMENT
MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS SUPPORT AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES
HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section
7.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Counterparts</U>.
This Support Agreement may be executed in two or more counterparts (including by facsimile transmission or other means of electronic transmission,
such as by electronic mail in &ldquo;pdf&rdquo; form), each of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties
and delivered (by facsimile or otherwise) to the other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IN WITNESS WHEREOF, the Company,
Parent and each of the Stockholders have caused this Support Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><B>CARISMA THERAPEUTICS INC.</B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: justify">/s/ Steven Kelly</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify; width: 42%">Steven Kelly</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><B>SESEN BIO, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">By: </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: justify">/s/ Thomas R. Cannell</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify">Name:</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify">Thomas R. Cannell</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">President &amp; CEO&nbsp;&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page to Stockholder
Support Agreement</I>]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><B>THE RADOFF FAMILY FOUNDATION</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">By: </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: justify">/s/ Bradley L. Radoff</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify; width: 42%">Bradley L. Radoff</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Director</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: justify"><B>BRADLEY L. RADOFF</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">By:</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: justify">/s/ Bradley L. Radoff</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">[<I>Signature Page to Stockholder
Support Agreement</I>]</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left"><B>JEC II ASSOCIATES, LLC </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: justify">/s/ Michael Torok</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify; width: 42%">Michael Torok</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Manager</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left"><B>THE K. PETER HEILAND 2008 IRREVOCABLE TRUST </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: justify">/s/ Michael Torok</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify">Name:</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify">Michael Torok</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Trustee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: justify"><B>MICHAEL TOROK</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: justify">/s/ Michael Torok</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">[<I>Signature Page to Stockholder
Support Agreement</I>]</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Second Merger Agreement Amendment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Joint Press Release</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Spousal Consent</U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><SUP>1</SUP></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I acknowledge that I have read the Voting and
Support Agreement (to which this consent is attached) and that I know and understand, and have been fully advised by my attorney with
respect to, its contents. As the spouse of the Stockholder, I hereby agree: (i) that all shares of capital stock, all options, all warrants
and all additional securities of Parent held by the Stockholder, and all other rights with respect to the capital stock of Parent held
by the Stockholder, and my interest in such shares, options, warrants, additional securities and other rights, if any, are subject to
the provisions of the Voting and Support Agreement and the Merger Agreement (as defined in the Voting and Support Agreement), which I
consent to; and (ii) that I will take no action at any time to hinder the operation of the Voting and Support Agreement or the Merger
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">Signature
    of Spouse:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Printed Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP> NTD: Only individual stockholders
who reside in Alaska, Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and Wisconsin are required to provide
a spousal consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule&nbsp;I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><B>Ownership of Shares
as of February 13, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; width: 48%; text-align: center"><B>Name and Address of Stockholder</B></TD>
    <TD STYLE="padding-bottom: 1pt; width: 4%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%; text-align: center"><B>Number of Shares of Common<BR>
    Stock</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Radoff Family Foundation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2727 Kirby Drive, Unit 29L</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Houston, Texas 77098</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,879,344</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bradley L. Radoff</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2727 Kirby Drive, Unit 29L</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Houston, Texas 77098</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7,420,756</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JEC II Associates, LLC</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">68 Mazzeo Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Randolph, Massachusetts 02368</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6,399,839</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The K. Peter Heiland 2008 Irrevocable Trust</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">68 Mazzeo Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Randolph, Massachusetts 02368</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,000,000</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Michael Torok</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">68 Mazzeo Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Randolph, Massachusetts 02368</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,025,000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule&nbsp;II</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><B>Ownership of Shares
as of January 17, 2023 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%; text-align: center"><B>Name and Address of Stockholder</B></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%; text-align: center"><B>Number of Shares of Common Stock</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Radoff Family Foundation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2727 Kirby Drive, Unit 29L</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Houston, Texas 77098</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,879,344</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bradley L. Radoff</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2727 Kirby Drive, Unit 29L</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Houston, Texas 77098</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7,025,058</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JEC II Associates, LLC</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">68 Mazzeo Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Randolph, Massachusetts 02368</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6,379,839</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The K. Peter Heiland 2008 Irrevocable Trust</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">68 Mazzeo Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Randolph, Massachusetts 02368</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,000,000</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Michael Torok</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">68 Mazzeo Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Randolph, Massachusetts 02368</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,025,000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_sesenbio-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_sesenbio-4c.jpg
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M%!04%!04%!3_P  1" %M F@# 1$  A$! Q$!_\0 R0 !  (# 0$! 0
M      <(!08)! ,! @$!  (# 0$               $"! 4& P<0  $# P(#
M P8(" H' P8/  $  @,$!081!R$Q$D$3"%%A<2(R%(&10E)B(U88<K/3U!5U
MI3>AP8*2,R2T%G8)L=&B0U-SD^%C-O'"5"55E;+2@S1$9'2$E#5%A;47.!$!
M  (" 0(#!0@" @(" P    $"$0,$(3%1$@5!87$B,I&AL5(3,Q05@4+1(_#!
MX6+Q<I+_V@ , P$  A$#$0 _ +_(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @\=TNMNLM#+<KM4QT=# .J
M6>5W2T>0><GD .)[%>E)M.(C,IB,H#S'Q$U<DDE%A5,V& :M_2=6WJD=QYQQ
M'U6CR=>OX(6[T>FQWO/^&175XHBN^8Y5?9'27:\5=5U'4QNE<(AV\(VD,'P!
M;6FFE.T0]HK$,&O9+/6?-<ML#VOM%YJZ8-.HB$KGPGTQ/ZF'X6KPOHUW^J(5
MFL2FG!_$)'42QV[-X60%Q#676F:1'K_WL?$C\)G\T<UJ-_IN.NO['C;5X)VA
MFAJ88ZBGD;-3RM#XI8W!['L<-0YKAJ"".1"TLQ,=)8[Z* 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$!!X[E=*&T4KJNX3-AA;P!/$N/D:!Q)]"]*:[7G$/#?OIIKYKSB$;WG<R
MOJ'.BLT0I(>0FD ?*?@.K1_"MMJX-8^KJY+D^N;+=-4>6/&>_P#Q^+5*F_WN
ML<75-PJ'Z_)[QP;\#00 LVNFE>T0TM^7NO\ 5>?M?!MSN3'=3*R=KAR(E>#_
M *5;].OA#SC?LCM:?MEEJ+-LFH2.FN?,P<V5 $NOPN];^%>%N+KM[&;J]4Y.
MO_;/QZMOM.Z%-*6Q7FF,#CP-1!J]GI+#ZP'H+E@[.!,?3+>\?UVL]-M<>^/^
M/_RWFCKJ.X0"IH9V5$#N3XR'#7R'R'S%:VU)K.)C#H]6VFROFI,3#T*KU8K(
M\BM>*V>HO=XE[JCIQR'%\CS[+&#AJYQY#^)>NK5;9;RU[IB,SA4'/=P;UGMR
M-37/,-MA<?<;<P_5Q-/#4\NIY'M./P:#@NJX_&KIKB._BS*UBK45E+B @(""
M6=G=TYL5KH[!?)G/QNK>&QR/.ONDKN3AK_NR?;'9[0[==7S>)^I'FK]4?>\M
ME,]86G!! (.H/$$+FF(_4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!XKM=*6S4$UPJW:11#@T>T
MYQY-;YR5Z:]<WMB&/R-]=%)O;M"#[[?:Z_UKJRL=HT<(80?4C9Y!_&>U=%JU
M5UUQ#YUR^7?D7\UO\1X,8O9B" @("#V6ZZ7"TU J;?.Z"4<^D^JX#L<T\"/2
MO.^NMXQ:'OIW[--O-2<2D['=PZ"O:*>\N90U;1_3./3 _0<3U.]CX3IYUI]W
M#M7K7K#L>#ZO3=BNSY;?=/\ PKKNQN'-G-]='2/<W'K>YT=OBX@2'71T[AY7
M?)\C?/KKN^'QHU5Z_5/?_AUE*>6$?+.>@@(" @(""TVP^<.R''WX]<).NZV5
MK6Q.<=7249X,/G+#ZA\W2N:]0T>2_FCM;\6+MKB<I;6K>(@(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @B3<>]NKKJ+5$[^JT/M@<G3.&I/\D>K\:WG"U>6OF]LN']:Y7ZFW]..U/Q
M:4M@Y\0$! 0$!!'6[62FUVAEEI7]-9<@>^(/%M,W@[^>?5]&JV/"U>:WFGM#
M8<+5YK>:>T(GM-^DINFGK"7T_)K^;F?ZPMANX\6ZU[NRXGJ$T^6_6/P;4Q[)
M&!\;@YCAJUP.H(6LF,.EK:)C,=G]*$B @(" @VO;C)SB68VV[/?T4?>>[UWD
M---ZKR?P>#_2%B\G5^IKF/:K>,PNMSXCDN08(@(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#YU$S*:G
MEJ)/8A8Z1WH:-3_H4Q&9PI>T5K-I]BN]1/)55$M3*=99GND>?*YYU/\ "5U5
M8Q&'RR]YO:;3WF<OFI5$! 0$! ) !).@',H*R9C?#D.15MQ#M:<O[JE'DAC]
M5OQ^T?.5TVC7Y*1#I-&OR4B&"7N]F4M-WDM[Q'(2^D<?6;VM\[5C;M,7C,=V
MRX?,G3.)ZU_!N,<D<T;98G!T;AJUPY$+4S$Q.)=56T6C,=G]*%A 0$! 072V
MOOKLBP2S7"1W74M@]VJ">9DIB8B3YW=(=\*Y#EZ_)MM#"O&);>L500$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$&(RJ0Q8Y='#MIY&?SQT_QKWX\9V5^+!Y]L<>__P"LH&72OFH@(" @
M("#6-P+L;/B=PGC=TSSL%-"1SZIO5)'G#>H_ LGC4\^R(9/&IYMD*W+I'0B
M@REGNS[?)W<I+J1Y]9O/I/E'\:QMVGSQF.[9</F3IG$_3/W-R8]LC0]A#F.&
MK7#B""M3,8=7$Q,9A^J$B @\U3<*2DX32#K^8WB[XO\ 6KUI-NREME:]V)GR
M)YU%-$&CL=(=3\0_UKWC1XL>W(\(;5B.XF96^V3VFW7BHHZ-LIG$5.1%ZT@
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M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @@;** VW(*^ETT9WIDC'9T2^NW3T Z+I=%_-KB7S7GZOTM]J^_\
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M_%B[;9G"7EJGB(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MHS*1QE<2/P6\!_&L+=.;,_1&*Y91>#W$']Q12SRL@A8Z2:1P9'&P%SG.<=
M!S)*B9P+?[38 S!L?'O30;]<0V6XO''HT!+(0?(S7CY7:]FBY7F<C]6_3M'9
MAWMYI;^L%YB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @PN1XW0Y'2=S4?5U,>IIZEH]9A/8?*T]H61I
MWVU3F.S7\WA4Y-<3TF.TH9O%EK['5NI*^/I=Q,<@XLD:/E-/:%O]>VNR,PX#
MD\;9HOY;Q_\ +'KU8P@((,W<QQUNO#;Y3LTH[EPE('!M0P<?YP'5Z=5O.%M\
MU?+/>&ZX6WS5\L]X1TMBV @^51'WL3FCVN8](1>EL2Q*LSG],8Z1X8P:N<=
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M6'VNWA[6DYG-Q\E._MEX;-GLA8E:%C" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#5[Y@EEO!
M=-&WW*L=Q,T('2X_29R/P:'SK,U<N].G>&GY7I.G=UCY;>,?\-!NFWV0V\N=
M!$*Z <0^G.KM/.PZ.U]&JV>OF:[=^CF-_H_(U]H\T>[_ (:S-3STSS%41/AD
M'-DC2QP^ Z+,B8GLU%J6K.+1B6JYEAE#EM%T/T@N<(/NM6!J1V]#O*T_P<QY
M\K1OG5/N>^C?.N?<K_>K%=,?K#0W6G=#-S8[FR1OSF.Y$+H->RMXS$M[KV5O
M&:OXI+/7UA!9$61G_>2>JW^'B?@5;[J5]K8Z>%MV=HQ'C+9K=9J:@'6?K:@C
M0R.'('L [%K=N^U_@Z+C<*FGKWGQ>6X6,.)FHM >9A/ ?R?)Z%--WLEZ[-/M
MA@I(WQ.+)&ECQS:1H5E1.6),8&,=(X,8TN<> :!J2DS@B,L];;+W9$]8 7#B
MR+F!^$L79MSTAEZ]..LLVL9E,A9K%>,AK66ZR44M;6/Y1Q-UT&NFKCR:WZ3B
M O.^RM(S:<0B9B.ZQ^V^QU!CKXKUE/=W"],T?!2#UJ:G<.1.O](\>4CI!Y G
M1RT'*Y\W^6G2&-?9GLF):EXB @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#^)88IV]$T;9
M&?-> X?$5,3,=E;5BT8F,O"ZP6)YZGVND<[RFGB)_P#@KT_6O^:?M8\\31/>
ME?\ ^8?"X8IC5UHGVZOM-+-1OYQ&%@ (X M+0"TCL+3JIKOV5G,6G+VUZJ:_
MIB(^$(JR#PX6.K>^;';G-;7$DBFJ&^\PCS-=JUX'X1<MEK]3M'U1EEQMGVM,
MJ?#CFD1<::OML\8/JZR31O(\X,) _G++CU/7[8E?]6'WIO#;ECWZ5EUMT,?S
MH3/,?B=%'_I43ZGK]D2?K0V>W>&7&/5=D5RGN73Q[N!C:5GHU)D=I^"X+'MZ
MKL_UC'WO*U_-[']UWADQ'5SK!<*FV%WR)&LJFCT:]V_3TO*B/5=G^T1/W(I?
MR^QBV^&67O2'9,WN=.#A1'J)]'?Z#XUZ?VG_ -?O_P#AZ?K>YL=F\.V'T+VR
MW:KJ[HX?[HN%/"?2(]7_ .VL>_J6R>T1"L[92A:+'9[!2BBLM##0THYQP,#-
M2.UQ'%Q\YXK6WV6O.;3EY3,RR"H@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M07U<T'J\]*FEFA//L]?BL7EQG58AU9EEB@B?-,]L<,;2^21Y#6M:T:DDG@
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MP1P(XC@MY6T6C,=E7EI:6JKJF&BHH)*FLJ'MBIZ>%CI)9)'GI:UC6@ESB3H
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MTG>U-BK@9*8O/!SXR"'Q/([6'0_*#M%B[N-3;W[^)E<[;[QK[596V&DRGO\
M$;N\ .%8#44)>1Q#:F)NH'GEC8%J-G V5[=86RL)9[[9,BHVW&P7*ENMO?IT
M55#/'4Q'4:C1\;G!8%JS6<3&$L@J@@(" @("#C]O)E#LRW4R[).KKBK+G4"E
M=KK_ %:!_<P?%&QBZS13RZXCW*-'7L"#I_X.\5AQO8RS58:!69!-4W:K/E+Y
M#!%Q\G=0QGTDKF^;?S;9]RT)Z6"D0$! 0$! 04/_ ,P.RQPY'A61-:.]KJ*L
MM\CP./30RQRL!/\ ]Z=I\*W?IMNEH5E39;= @M]X <@=39IEF+EVD=RMD-P:
M#\^WSB+0><BJ/Q>9:KU&ORQ/O3"_:T2RF/CYP:>KM6,[AT<9>RWODM%T<!KT
MQ5![VG<?(T/;(TGRO;\.W].V8F:_Y5E11;M @]=KNERLEQIKO9ZN6ANE%(V:
MDK*=YCEBD8=0YKFD$$*)B)C$BW6V?CNOMM9#;-T;2+Q3-Z6&]6P,@K0T#0ND
M@=TQ2./T'1>@K5;?3XGK2<)RM9@V_FTFX;8F8YD](;A*!I;*UWN5;U::EHBG
MZ"\CM,?4/.M7LX^RG>$Y20L=(@(" @(""KGCLR=]IVIM^.0R=,N0W2)DS-=.
MJEHFNG=P[=)>Y*V?I],[,^$(ESI6_5$$P^%O%HLLWSQ2DJ6A]';YWW:<$:C_
M -7QNGBX=H,K8P5B<N_EU20ZL+F%Q 0$! 0$!!B\ELT61XY>,>J #!=J&IH)
M0[V>BJB=$=>?#1RM2WEM$^ XMN:YCG,>TM>TD.:1H01S!"[!1^(/UKG,<U['
M%KVD%K@="".1!0=F<%OW]Z<*QS)B077BV4=>_3L=4P,D</@+M%R.ROEM,>$K
ML^O,1UOY^Y7/?U'7?B7+(X_[M?BB7(M=4J("#KAL!BL>';-X=9FQ=U.ZVPUU
M8W31WO->/>I0[RD.D+?@7*\F_FV6GWK0DE8Z1 0$! 00]XIK6R[;"9I YH+H
M*:&L8=-2TTE5#/J.!TX,(]"R^).-M42Y3KIU1 0=N5QJZH_C%\/U7E]-_P#V
MAAE&ZHR*@A$=^H(1K)54<(]69C1Q=)$!TD#BYFFGL@':\'D^7Y+=O8B8<_EO
M51 0$'NM-ZO-AJQ7V.XU-LKF^S4T4TE/*/0^-S3_  J)K$]X$MXSXL-]L8<Q
MK,G?=J5FFM-=XHJT.T\LKFB;XI0L2_#U6]F/@93QA?C]@>Z.GW!Q0Q Z=Y<+
M'+UC7_[-4N! _P#ESZ%A;/3ORS]J<K+8%OAM;N5T18GD=-47!X__ "N<FEKM
M1S @F#'.T[2P.'G6MV<?9K^J$Y2$O!(@(,3E-T=9,8O5Z:>EUNH*JL!TUT-/
M"Z373C\U7I&;1 XN$DDDG4GF5UZ@@()=L'B?WSQ>R4&.V+*O=;/:X&4E#3?H
M^VR]W#$.EK>N2E<]V@'-SB5BVXFJTYF.O^3+(_>\\1'VR_9EJ_-%7^%I_+]\
MF3[WGB(^V7[,M7YHG\+3^7[Y,GWO/$1]LOV9:OS1/X6G\OWR9/O>>(C[9?LR
MU?FB?PM/Y?ODR?>\\1'VR_9EJ_-$_A:?R_?)D^]YXB/ME^S+5^:)_"T_E^^3
M)][SQ$?;+]F6K\T3^%I_+]\F3[WGB(^V7[,M7YHG\+3^7[Y,M+W!WDW(W4AH
M*?/+U^EH;8Z22A;[K24O=NG#0\ZTT,1.H8WVM5[:]%-?TQ@:*O8$%@?!?7NH
M]^K13AX:*^BN%,X$D=0;3.GT [>,6OP+!YT9U2F'3A<VLPF88I9LYQBZ8ED$
M/?VB[0.IZE@T#AKQ:]A(.CV. >P]C@"KTO-+1:.\#D]NYM/DNS^6U&-7^(OI
MG%\EIN;6D05M*':-D8>(#@-!(S75KO-H3U&G=7;7,*-"7N" @(-UQG=_=##6
MLCQK+;I04T>G12-J9)*8:<OJ)"Z/_97C?32W>($TXAXY]V+(619/26_)Z0:=
M;Y8O<*LZ>22F C&OG@*P[^GZY[9A.5B,%\;.TF4.CI<C%5B=P?P)K6>\41<3
MP J( 2/3)&P>=8&S@;*]NJ<K#6F\VB_4$5TL=?3W.V3C6&LHY65$#Q]%\9<T
M_&L"U9B<2E[54$!!0W_,"NAER7"K+U>K24-96=/'G5S1QZ\O_J_E6\]-CY;2
MK*G"VR!!LN#;@9=MK>SD6%7']&7ET#Z4U/<05/U,I:7-Z*B.1O$M''IU7GLU
MUV1BT=!)/WO/$1]LOV9:OS18_P#"T_E^^3)][SQ$?;+]F6K\T3^%I_+]\F3[
MWGB(^V7[,M7YHG\+3^7[Y,GWO/$1]LOV9:OS1/X6G\OWR9/O>>(C[9?LRU?F
MB?PM/Y?ODR?>\\1'VR_9EJ_-$_A:?R_?)D^]YXB/ME^S+5^:)_"T_E^^3)][
MSQ$?;+]F6K\T3^%I_+]\F3[WGB(^V7[,M7YHG\+3^7[Y,H4FFDJ)I*B9W5-*
MYTDCM -7..I.@X<UF#^$!!U=\,%P=<MA<(J'/ZRRCDIM=2>%)4RTX''R"/1<
MORXQMLM"7%BI1UOY^Y7/?U'7?B7+(X_[M?BB7(M=4J("#MG2TT5'2P4< TAI
MXV11CR-8T-'+S!<=,Y7?90" @(" @C_?2G?4[,Y]'&0'-L%RE/5RZ8J9\AY:
M\=&\%[\>?^ROQA$N0RZM40$';E<:N(*L[[>#FQ9Y4565;>20V#*YBZ:KM\C2
MVW5DAXEWJ F"1W,N:TM<>;027+9\?G33I;K")A17-MM\YVZKS;LTL=5:9NHL
MBEF9K3S$<S#.SJCD'X#BMWKVUO&:SE5JR] 0$! 0?TQ[XWMDC<62,(<Q[3HX
M.'$$$<B$%C]H/&+N!@4U/:\QDDRS%&Z,<VI?K<H&<M8JAW%^@^1,3KR#FK7[
M^%2_6O24Y= <"W!Q/<O'H<FP^X,KK;*>B1OLS03  NBFC/%CQKR/,<1J""M#
MLUVUSBRS9UYC2MXWOCVBS^2-Q9(S&[PYCVG1P<*&8@@CD0O;1^Y7XQ^(X]KK
M%! 0$! 0$! 0$! 0$! 03=X0_P#_ $1AO_[G_P#Q56L/F_LV_P ?B0ZEKF5Q
M!J6XNVN(;IX])C>8T(JZ,DOIIV'HJ::;302P2:$M<-?.#R<"."]=6VVN<U'/
MO=OP@[C[>RU%SQN!^68HS5[:FB9K70Q\3I-3-U<=!S?%U-[3T\EOM/-I?I/2
M5<*\O8^-[HY&EDC"6O8X:.#AP((/(A9Z'\H" @("#9\(W$S7;FZ"[X7>:BTU
M>H,S(7:P3!O)LT+M8Y&^9[2O/9JK>,6C(OCL3XPL?W FI<6SZ.+'\OF(BIJQ
MA+;;6R'@&M+R3#([D&/):X\G:D-6CY'"FG6O6%HE:%:U(@YW>/>60[MV* N^
MJ9CE.]K?(Y]=6AQ^$-"W_IW[<_'_ (5E5=;- @(" @(" @(" @(" @(.HG@[
MJ._\/F+Q=/3[M+<HM==>K6XU$FOF]O1<US8_[I_Q^"T)U6$E'6_G[E<]_4==
M^)<LCC_NU^*)<BUU2H@(.W*XU<0$! 0$!!I&\W[G]P?\-7G^P3+VT?N5^,?B
M./JZQ00$';E<:N("#S7"W6^[4<MONE)#74$XZ9Z6IC;-"]OD<QX+2/2%,3,=
M8$&YIX/-D\N,M126J;&KA)Q]XLLO<Q]79_5Y!)"!Y0QC?2LW7S=M?;GXHP@?
M)_ #DM.7R8=EM%7LYLI[K!+1/ \G>0^\!Q\_0WX%G4]1K_M",(1S#PU;U82'
MS7/%*JLH6 N-;:NFXQ=(YN(IR][!^&QJS*<K5?M*,(H<US'.8]I:]I(<TC0@
MCF"%E#\0$!!(FS>\&2;-Y9#?[+(Z:V3.9'>K0YVD-92AW%I[&R-!)CDYM/E:
M7-/AOT5VUQ(ZO8MDUGS/';9E-@G%39[M RJI)>1Z7CBUPU/2]IU:]OR7 A<O
M>DUF8GO"[&;FT7Z2VVS&W:=7OECN=/TZ].O>TDK-->SFK:IQ>)]\#C@NM4$!
M!9O%/!-GN78O9<JH,CLT5%>Z&FN,$4IJ3(QE7$V4,?TPD=3>KI=H>:UU^?2M
MIB8GHG#,?<$W(^TUC^.K_(*G]C3PDP?<$W(^TUC^.K_()_8T\),'W!-R/M-8
M_CJ_R"?V-/"3!]P3<C[36/XZO\@G]C3PDP?<$W(^TUC^.K_()_8T\),'W!-R
M/M-8_CJ_R"?V-/"3!]P3<C[36/XZO\@G]C3PDP?<$W(^TUC^.K_()_8T\),'
MW!-R/M-8_CJ_R"?V-/"3!]P3<C[36/XZO\@G]C3PDP?<$W(^TUC^.K_()_8T
M\),)$V,\(>8[7;GV7.KW?+964-J;5ZTU&:CO7.J:26F'])$T:#O=3Q6/R.;7
M92:Q$]4Q"X2U*1 0$&CYML]MEN*"[,,9H[A5$:>_!A@K -.0J("R73S=6B]M
M>^]/ID5YR[P#8?7.DGPK):VSR.U<VDN$;*^ 'L:US# ]H\[B\K84]1M'U1E&
M$*95X)-Z+"U\UF9;\EIV@N H*D0S](YZQU8A&OF8]WQ\%F4Y^N>_1&$&9-A>
M7895"CRRQUUEJ'$B-M=3R0!^G,L<]H#QYVDA9M-E;?3.4,$K@@("#H#X._$%
M59?3#:[,ZPSY'00F2PU\SM9:NDA&KX7N/%TL31U \W,UU]DDZ+F\;R_/7M[5
MHE;A:I+GYX_*$Q[B8O<ND 5%E-/U\=3[O53/T\G#OOX5OO3I^28]ZLJDK:($
M$@[.[27C>?**G%+'<*2W5M/0R7'O:\R"-[(98HBQO=M>2[ZWJY<@5X;]T:JY
MD3E]P3<C[36/XZO\@L+^QIX2G!]P3<C[36/XZO\ ()_8T\),'W!-R/M-8_CJ
M_P @G]C3PDP?<$W(^TUC^.K_ ""?V-/"3!]P3<C[36/XZO\ ()_8T\),'W!-
MR/M-8_CJ_P @G]C3PDP?<$W(^TUC^.K_ ""?V-/"3!]P3<C[36/XZO\ ()_8
MT\),'W!-R/M-8_CJ_P @G]C3PDP?<$W(^TUC^.K_ ""?V-/"3!]P3<C[36/X
MZO\ ()_8T\),'W!-R/M-8_CJ_P @G]C3PDPM_L5MQ7[4;96G";K50UMRHGU4
MM344I<8'.J*F25O1UM8[0,<T'4<]>Q:GD;8V7FT)A(ZQTHZW\_<KGOZCKOQ+
MED<?]VOQ1+D6NJ5$!!VY7&KB @(" @(-(WF_<_N#_AJ\_P!@F7MH_<K\8_$<
M?5UB@@(.W*XU<0$! 0$!!HV<[.[9[CQ/&7XW25U4\:"X-9W%<WAH-*B'HDT'
M/I+NGS+VU[[T^F14?=3P*W.UT]3>-K+H^ZP1!TAL%RZ65A:T:],,[ UDCO(U
M[6?A$K:Z?4(GI>,>]7"G=13STD\M+51/@JH'NBG@E:62,D8>ES7-=H001H05
MMXG*'S0$%[O 1GL];9\BVXK92\6M[+M:6DZEL%0[NZA@\C6R=#QYWN6D]1UX
MF+)A<B:*.>*2"5O5%*TL>WRM<-".'F6H6<7<ELTV.9'=\>J=?>+36U-!+U<'
M==+*Z)VOGU:NPI;S1$^*C%JP(.I7A(R>+)MBL<:).NJLIGL]6-=>AU+(3$W_
M *+XC\*YKFT\NV??U6A-ZPDB @(" @(" @(" @(" @(" @(/+<;;;KO1RVZ[
M4<%?;YQTSTE5&R>%[3V.8\%I'I"F)F)S KUN-X+]J<P9-5XS')A]Z>"6OH!W
MM"Y_TZ5YT \T+XUGZN=LKW^:$84AW@V+SC9>Y14V20LJ;/6.<VVWNDU=2SEH
MU+#J Z.0#FQX\O3U#BMUHY%=L=.ZN$9K(!!F,4R6YX;DMJRJS2=W<[1515E,
M3[)=$X.Z7>5KAZKAV@JMZ1:LQ/M'9&PWBCR*QVS(+<[JM]UI(*^D=Y8:J-LK
M#_-<%R-JS69B?8NJ1_F 8\^HQK#LI8WU:"MJK;,X#_TZ)LS-?,/=G:>E;7TV
MWS6A65#5NT"";?"7E$>+[ZXVZH?T4MW,UGE.NFKJR,MA'GUF$86'S*>;5/NZ
MD.IBYE<0$! 0$! 0$! 0$! 01UOY^Y7/?U'7?B7+(X_[M?BB7(M=4J("#MRN
M-7$! 0$! 0:1O-^Y_<'_  U>?[!,O;1^Y7XQ^(X^KK%! 0=N5QJX@(" @("
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M)+7W&IBI*&G:7SU-0]L44;!S<Y[R !YR5,1,](%8=W_&IA6)PU%HVYZ,HR,
ML%>-1:H'_.[P:&<CL$7J'Y_8MEIX-K=;=(^]&5!\NS')<\OM3DF67&6YWBJ/
MKSS'@U@)+8XVC1K&-U]5C0 %O*4K2,5CHJP:N/?9+Y=\;NM+?+#6S6Z[T3Q+
M2UE,\QRQO'D([#R(Y$<#P46K%HQ/8=+O"_OM>]Y\?KHLBM#X+Q8^ZBJ[S P-
MH*MT@.G2-1T3:#J>QH+1P/#4-7.<OCQJGI/25HE/BP4B".M_/W*Y[^HZ[\2Y
M9''_ ':_%$N1:ZI40$';E<:N(" @(" @TC>;]S^X/^&KS_8)E[:/W*_&/Q''
MU=8H(""?_$YL!?MK,DJ<FHW3W3"+U4OEI[I,YT\]/43$O=!5/=J2[77HD<?7
M';U:K!XG)C97':83,( 6<@0$&RX?N'G& 59K,-OU99I7D.E92RD0REO+O8CK
M')_+:5YWU5O]49$]8]XZ]W+7&R&]T-IOK&CUIY8)*6H<?PJ>1L8_Z2P;>GZY
M[9A.6TN_S \C]W#6X30BJX:R&ME,?G]3N@?]M>7];7\QEJ.1>.;>*[1206:G
MM-@8X$,GIJ9]14-U^E4R21DC_E+VKZ?KCOF3* ,IS'*LVN1N^6WBJO%Q((;-
M62NDZ&GCTL:?58WZ+  LZE*TC%8PAA%<$&;Q'$[YG.26[%,;IC57BZ3-@IXQ
MKTC7BY[R >EC&@O>[L:"52]XI69GL.N6V>!6O;+![/A-I/>4]LAZ9JDCI=/4
M2$R32N'9UO<X@:\!H.Q<KMV3LM-I7;8O($&H[E[<X[NIB-;B&2Q$TE2.NGJ8
M].^IJE@/=S1$\G-)]!&K3P)7KJVSKMYH'*W=7:G*MHLHFQO)8#W9+GVRY,:1
M3UM,':"6,ZGCRZF$]3#P/9KT^G=7;7,*-&7L" @V+%,^S7!IW5&(7^NLKWGJ
ME;1SOBCD/#^DC!Z'\A[32O.^NM_JC(F.S^-/?:UPB*JN-!=R!H)*ZAB#_-QI
MNXU(\_PK$MP=4^S"<LW-X\=Y)8PR.UX] X$'O(Z2L+CIV>O6.'\"I_7Z_&?_
M #_!EI&1^*_??)(GT\N526VF>-#':H8:)P[-1-&P3#X)%[5X>JOL1E#U;75M
MRJI*ZXU,M96S'JFJ:A[I97GRN>\DD^DK+B(CL/.I! 07K\)OACFM,E'NGN)1
M]%QT$^-V2=IZX->+:N=IY2:?T3"/5]H^MITZ7F<O/R5_RF(7.6G61'XB-FAO
M1@QLM)6/HK];9#76=SGN%-)4!A;W<[ ="UX/2'Z=3#Q'#J:[*XV_]*V?8B7+
M*^V*\8S=ZNPW^BEMUXH)##5T=0WHD8]OE\H/,$<".(X+IJVBT9CLJQZL" "0
M00=".102_A'B>WIP2*.DM^1R7*V1CI907AHKXP!R#7R?6M [ V0!8FSB:[]X
M^PRE^V^/_-8F 7C$;75O^4ZDFJ*0'@.0D-1IQ\ZQ9].K[)E.7[<?\P#-)6.%
MIQ"UTLA'J.JIZBJ .G:&&#7CYPD>G5]LR91%G?BAWGS^"6@N-_-LM,P+9+?9
MV"BC<UW-KI&DS.:1P+72D+*U\373M'VHRAU98(""WO@EV8J+S?SNW?8"VRV=
MTD&/L>"/>*\@L?, >;(6DM!_XAX<6%:KG[\1Y([SW3"_BT2P@(*>>*_PQ2Y*
MZKW/V[I.J_-:9<@LD#?6K WB:F!HYS ?TC!_2#B/7UZ]MP^7Y?DMV]BLPH20
M02"-".86\0("#]:YS7!S20X'4$<""$$FXMXB-Z<.CCI[+F5?[I$ V.FK2RX1
M-8/DM;5ME#1^#IIV+&OQM5N]3*0:3QO[X4T?1-)::QV@'>3T):[@.)^IDC''
MMX+PG@:O>G+'7;QF;]7-CHZ>]4MK:\G4T5#3]0![ Z=LI&G8==?.K1P=4>PR
MB+*,]S7-IA/EV07"]/:>J-M;4R31QG_NXW.Z&#S- 65376GTQA#7EZ @()#V
M?V=RO>3)H['8(C#;H2U]WO,C"::C@)YN/#J>[_=Q@ZN/D:'.'AOWUU5S(ZHX
M#@>.;;8M0XCB]-[O;*)O%SN,LTSN,DTKOE/>>)/P#1H ',;-D[+>:5VRKS!!
M'6_G[E<]_4==^)<LCC_NU^*)<BUU2H@(.W*XU<0$! 0$!!I&\W[G]P?\-7G^
MP3+VT?N5^,?B./JZQ00$':R\6>U9!;*JRWNCBN%IK8S#5T=0P2121NYAS3P7
M'UM-9S"Z@^^?@QO^,SU.2;4Q2WO&R72RV+4R7&D!XZ1:\:B,=FGUH[0_BY;S
MC\Z+=+])\59A4Z:&6GED@GC=%/$XLEB>"U[7M.A:X'B"#S"VB'\(" @(" @(
M,_AV$Y3G]\@QS$;9-=+M.>$4(]5C-=#)*\Z-C8->+WD!4OLK2,VD=*O#QX=K
M/LK:7UU;)'<\ZN4;6W*Y-;]7 SF:>FZ@'"/7VG'0R$ D   <[R>3.V?<M$)P
M6$D0$!!J>X>V^([HX[-C684(JZ*35T$[=&5---IPE@DT)8\?$>3@6ZA>NK;;
M7.:CG/O7X6\[VFEGNU%&_(<):2YMXI8R9*=G8*N)NICT_P"(-6'R@GI70:.7
M39T[2I,(*6:" @(" @("#,8QB>29I=X;#BELJ+M=Y_Z.EI6%[@T<W./)C1VN
M<0T=I5;WK2,S.(%_/#_X0K1@$E+EVX9AO&8Q%LU';V>O0T$@.K7<1];,TC7J
M(Z6GV02 ]:+D\V;_ "UZ0M$+2K6)$!!$.^'A[Q#>JV]Y6@6S+J6/HMM_A8'2
M-:-2(IVZCO8M2?5U!;\DCCKE\?DVU3[O!$PYQ[G[,Y_M'<C19=;',HGO+*.\
M4X,M!4]OU<N@T=IQZ'AKQY%T&K?39'RRJT!>X(" @(" @(+%>'[PKY)NE4TV
M1Y5%-9=OFD2=^\=W57  Z]%,UW$,/;,1I\WJ.O3@<GF5U](ZV3$.D5GL]LQ^
MU4=DLM+'16FWQ,IZ.DA'3''%&-&M ]"YZUIM.96>U5! 0$%9=_O"18MRI:K+
M,)?%8\WDUEJH7#IH+A(>)=*&@F.4_P#$:-''VAJ>H;+C<V=?RVZPB8<_\PPC
M+, O$EAS"TU%HN;.(BJ&Z-D9KIUQ2-U9(S7Y3'$>=;VFRMXS6<JL K@@(" @
M(" @L-LEX3,VW.EIKUDD<N-80[ID]\G9TUM7'STIH7C4 CE+(.GCJT/Y+ W\
MRNOI'64X=$<(P;%]N\>IL8Q&WQV^U4_$M8-9)92 '2RO/K/D=IQ<[T<@ M!L
MV6O.;+-B7F" @CK?S]RN>_J.N_$N61Q_W:_%$N1:ZI40$';E<:N(" @(" @T
MC>;]S^X/^&KS_8)E[:/W*_&/Q''U=8H("#MRN-7$$;;C["[7;IA\V56./]+N
M;TMO-$?=:\:#0:RL'UFG8)6O:/(LC5R+Z^T]$855S?P#Y%2225.WV1TURI>+
MF4%W:ZEJ0/FB:)LD;SYRV,+::_48GZH^Q&$$Y'X<][L7>]MRPJY31QZDS6Z,
M7*/I''JZJ,RZ#3CZVFG:LVO*U6[6A&$>W"S7BTNZ+K;ZFA>#TEM5#)"=3KPT
M>T<>!61%HGL/"I&4MF-9'>B!9[/6W N]D4E-+/KSY=VUWD*K-ZQWD2/CGABW
MTR9[128;6T,1/K377HMH:#VEM4Z-Y_DL)6/;EZJ_[&$_;?\ @'G[R*MW,R)@
MB!#GVFQ@N+AST?53M;T^1P;"?,[M6#L]1_)'VIPMWA.WV&;=6H67"[/3VFAX
M&7N6DRS. T#II7ETDCO.]Q6IV;+7G-IRLV5>8(" @(" 0"""-0>8001N;X2M
MI]Q7S7&FHW8QD$NKG5]H#8XI'GMEIB.[=KS)8&./:Y9VKF;*=.\>]&%6<T\#
MF[%@=)-BU11951-U+&PR"@K"!Y8JAPC'#YLSELM?J&NW?HC"$[_M1N9B[GB_
MXC=Z"-FNL\M%/W!TYZ2M:6'X'+-KNI;M,(:@YKF.<Q[2U[20YI&A!',$+U'X
M@]UMLMXO,H@L]OJ;A.2&B.DADG>7'D-(VDZJ)M$=Q*&*^&#?'+2QU)B55;J5
MY'54W?IMS6@]I94%LI'X$96-?EZJ^W[#"P^ > >DA=%6[F9$:EPT+[39 61\
M.QU5,WJ(/:&PM/D<M?L]1_)'VIPM?A>W^&;=VO\ 0^%V:GM%"2'2B!I,LKAP
M#I97ETDCO.]Q6KV;+7G-IRLV5>8(" @(/)<[7;;U0SVN\4<%PMM2WHJ*.JC9
M-#(T]CF/!:1Z0IB9B<P*U[A>"#;3*'RUV'5,^(W)Y+NYA!K+>7'C_0R.:]O\
MB4-'S5L=7/O7ZOF1A6W+?!9O7CKI)+524>2T;=2)+;4M9+T^>*J[EVOF9U+8
MTYVJW?HC"(KUMAN/CCG-ON)7BWAFNLE105#(R!VAY9TD<.8*RJ[:6[3"&K21
MR1/=%*PLD8=',<"UP(["#R7J/V&&:HD;#3QNEF=KTQQM+G'0:G0#CR0;;9=I
M]SLB>UMDPZ\UK7D 2QT%1W(UY=4A8&-'I<O*VZE>\P)=Q+P4;T9#)&^]046,
MT3B"^2OJ&S3]&O$MBI>]U=]%[F>D+$OS]=>W5.%I=KO!WMA@$D-SOK'9?D$1
M#FU%QC:VBC>.V.D!<WG_ ,5TFG9HM9NYM[](^6$X6&:UK6AK0 T#0 <  %@)
M?J @(" @(,'E6'8MF]K?9<MM-->+8_4]Q51A_2XC3JC=[3'>1S"#YU>E[4G-
M9P*M9YX"\7N+YJS;V_SV25Q+F6RXM-;2C7DUDH+96-'E?WA6SU^HVCZHRKA7
MG*/")OKC!>]E@9?*1FO]9L]1'4@Z>2)_=S'_ *2SZ<W5;VX^*,(NNV!9S87N
MCO>,W6W/:="*NAJ(./\ +8%E1LK/:8&O$$$@C0CF%<>JBMMQN3^[MU'/5R:@
M=%/&^4ZGD-& J)F([C>;!L/O)D[VMM&$79S'^Q/4TSZ* Z\.$M5W3/\ :7C;
MD:Z][0833AO@0W'N[HY\QNU!C=([0O@B)N-8/*"V,LB^$3'T+#OZA2/IC*<+
M0[:^%;:/;::"XP6UU]O\!#X[I>"VH='(#J'10AK8F$'V7=!>/G+6;>9LV=,X
MCW)PFQ8:1 0$!!JVY.,5>:X!DF)4$T=/6WJWU%#!//U=TQ\\98'/Z03H->.@
M7KJOY+Q:?9(I%]P3<C[36/XZO\@MS_8T\)5P?<$W(^TUC^.K_()_8T\),'W!
M-R/M-8_CJ_R"?V-/"3#H,M"L(" @(" @U[/;!4Y9@V38M1RL@K+Y::^V4\TV
MO=,EK*:2%KG]()Z07ZG0+TUV\MHGPD4:^X)N1]IK'\=7^06Z_L:>$JX/N";D
M?::Q_'5_D$_L:>$F#[@FY'VFL?QU?Y!/[&GA)AT&6A6$! 0$! 0$! 0$! 0$
M! 0$! 0$!!YZB@H:MP?54L4[VC1KI8VO('D!<"IB9@>2'',>IR]U/::*)TIZ
MI"RFB:7'RG1O$\5/FGQ&18QD;&QQM#(V -8QHT:&C@  .0"J/Z0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 01]4;Z;.4D\M+4YS98JF![HIHGUL(<Q[#TN:07<""-
M%[QQ]D_ZRC+>+?7T5UH*6Z6VH95VZNACJ:.JA<'Q2P3-#V/8X<"US2""O&8F
M)Q*7I4 @(" @(" @((DR?Q,[*XADDV*7S)F1W>ED$-8V"GJ:F&"7M9)+#&]@
M<WDX GI/!VA653B[;5S$=$92K25=+7TL%=0S,J:*JC9/35$+A)%)%(T.8]CF
MZ@M<""".:QIC"7V4 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#C#F?_C#(/UE6?CWKKZ?
M3'P4=9]F?W/[??X:LW]@A7+;_P!RWQG\5V[KQ! 0$! 0$! 0<K<]\.>\]KSJ
MY6N+%KE>F559-)27>A@DJ:2>.:0N;(^=H+(R0=7"5S2#S73Z^5KFL3F(4PZ+
M[,8C=\$VMQ?$K]*);Q;*)L=86N[QK)'N=)W0=J=1'U=V".'J\."Y_?>+WFT=
MEV]KP! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'&',_\ QAD'ZRK/Q[UU]/ICX*-[NGB-
MW=KK%9<9MN15-AL=AH*2V4=-9I'T+W,HH60M?)-$1*YS@S5PZ^GR +QCBZXF
M9F,S/B9?3$/$QO7A]PCKH,MKKO UP=-07N:2Y02M'-I[]SGM!\L;VGSJ+\75
M:.V/@9=%]D]X;)O1AT>26R/W.XT[_=;Q:G.ZWTU2 ':!V@ZHW@]3'Z<1P]H$
M#G]^B=5L2M"2%CI$! 0$! 0<Q\\\2^^5ISC)K7;\PJ(*"ANU?34L @I"&0PU
M,C&-!="2=&@#B5TFOBZIK$S'L5RZ&[7W6X7W;3#+W=IS4W6Y6*V5M=4N#6ND
MJ*BCBDD>0T  N<XG@-%H-L1%[1'C*S:UY @(" @(/A75M);:*IN-PG934%'$
M^HJJF5P9'%#$TO>]SCP#6M!)*F(S.('/K>/QJ9CD-QJ;1M?(<?QF)YCCNO0U
MUQJVM.G7K("(6'FUK1U^5W'I&^T<"M8S?K*N4)4^^F\]-5BMCSZ_NF!ZNF6Y
M5,L6O_*D>Z/3S=*S)X^O\L?8C*U_AR\7]PR>]4>![IOA_25>YE/9\AB8(1-4
M//2V&I8W1@=(3HQ[&M&N@+>/4M7RN%%8\U/L3$KE+4+" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @XPYG_X
MPR#]95GX]ZZ^GTQ\%'27PN;28GAFV&/9%#0P5.3Y%0P76NNTC&R3AM9&)8X8
MW.&K&,8YK2UO-VI*Y[E[K6O,>R%H0CXZ-L<5L5)8<_L5##;;I<*Q]NNL=+&V
M*.I+HG31RN:T =;>AS2[35VHUY+,]/VVG-91+7_ )=*R'<K);(QY%!66-U9/
M'QT,U'5P1Q'X&U,GQKT]1B/)$^\AT'6A6$! 0$! 0<;]S/WD9C^O+G_:Y5UV
MKZ(^$*.K.S/[G]OO\-6;^P0KE]_[EOC/XKMW7B" @(" @KIXV<DK;!LE+1T3
MS'_>"YTEIJ'MX'N"R6K<-?([W8-/E!(Y+8<"L6V_"$2IMX8=K+1NWNC#8LA+
MG6&V4<MWN-,QQ8ZHC@DBB;#UMT+0Y\S.HCCTZ@$'B-OR]TZZ9COV5AT(R/P^
M[/9+CK\;J,0MM%3=T8J:KM]+#25E.[30/CGC8'=0/K'J)#C[0<M#7D[*SG,K
M8<K,GLM5AN77G'75'578_<JFWFJB)9K+0SNBZVD'4<6:A=-2WFK$^,*NO>WM
M[J<EP'%<CK>-9=[/;[A4'E];54L<KN'I<N4VU\MYCPE=LB\P0$! 0$! 0$!
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M@6KIZ=.?FGHG*F]BLV0;@Y;26:WM?<,CO]9T-<[5SGSU#RY\CR = -7/>[L
M)*V]K12N9[0AV)QNR4^-8[:,<HSU4EGHJ:WP.TZ=8Z2)L33IQTX-7)6MYIF?
M%=DU4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$'+S*(O##_>6\^_U6>"N]^JO>1!36<Q=[WSNOH+IP>G7737
MCHNEI^OY8^G[U'YGE/X5)Z:U,Q*X930W$6ZD]]GIZ&DKJ<S]PSJ[^*HJZ4BH
MU_INYD,75KT)KG?U\V.__GL'GVWIO"]3W^A&<73*+E2F5O49[=26ZW#UO_I
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@%OEJ4B @(" @(" @(" @(" @(" @(" @(" @(" @_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lg_carismatherapeutics-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_carismatherapeutics-4c.jpg
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M -(  0 " @,! 0             '" $& @0% PD! 0 " P$! 0
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MV UIFMW'@\X- '$TT!(WU4ZRJM&B:U- 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'%^ZJ"
MBW.7$W>)YDYYETPM%Y<NO+=Q^FAG/$TCQ&H54KZ\FB+#*>.Z]C+F;4^7R[6D
M6=M9BW<_H,LTC7!OCHPE2KS0O*URL5" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M2FNK7M,/=<-XW^=Q]QPLN6D#;YM3Q#PM)"G$ZH3&C<@0=RRBR@(" @("#B9
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MXEI\VTFG&O&'9['O%,OLY/9G]B8(Y&. <TAS2 01MJ"%X'0N9>!O0>+J/5N
MTM9F[S=XRW:X'LHJUED(Z&,WE64QVO.E7FS[G'@KK>=/W^IIFA>;ECK+/76'
M=;&R'#VF.[1U7RM9Z8=MIQ4VT'0K\VVG'&K7[/NE-QDFD</+TI-8X$+QMRY+
M((" @(" @(" @(" @(,.<&BIW(*J<]^;TF7NKG1FFIV_H:)P;D+V)QK<2-WQ
M-<#_ #8._K(ZE"96UJ@78H+$R\JN1=_K 1YO4HEQ^G3YT,31V=S<T(-6\33P
MQGZKIZ.M2B%=K:+4Z?TSA-,6C+'"6$-E;-:&D1- <ZG2YV]Q\)4XA7,ZO866
M! 0$'5O["TR5NZTO8([FV>"'PS-#V&O6UP(*&J >97=RM[MDV9T&T6]YM?+B
M'N A>-I/8D^B[ZTGA\2A-5D65HO+*[QUU+8W\$EM>0.+)K>9I9(QPZ'-=0A1
M6)S[LVILK'J*ZTJZ1TN(N+9]TR,DD0S1.8*CJ#@:'PT6:H76L5BH0$%<N]1^
MF?9\%V9?^@.*43\->#VG9P<=/K>+AJH66T5TQ&&RN>OH\;AK.6^OI?0@@87N
MH-Y--P'22HK)E9SEYW<L7BA!E-9.;DLFWSQCXW?D;#U.JT&0C[GQJ40IFR=;
M2TMK&WCM;2&.WMXQPLBB:&,:!T #8%-!]T! 0$'6O[&TR5I+97T#+FUF:620
MRM#V.:=A!!05$YV\H1H>Y;G\"QSM,W;N&2,GB-K,XDAM:>@[Z4GQ*N875MJA
MWRT\(44URN[_ *X=JK2 Q]_+VF7PI;:REQJ]\%*Q//7L\TGP*R)46C1+F]21
M$! 0<7;O\NI!^=NH/U_E?CEQZURI>A,G=<<&ZJS3G&@%DRI_[0J4(7Y/'YX<
MTI=8YA^!P\X_9C'OH#&32YG;L+W$':T'8WW4F6:UX->Y;\J\_P Q+T&V:;3!
MQ. N\G*T\ &\MCV>>_P;ATI$,S.BV.B^5>D=$6[68NR$U[3S\A=!LMPX_9<(
MX?$T!3B%4RWA91$! 0$! 0$%?^]7\V]/_*+_ .SN4;+*<U63N*JGDFO_ ,N?
MF'ISY/M_5A70IELZRP(" @(.,GHH*<\_]=2ZEU9)@K64_HC!N=;\+2>&2Y!I
M(X[:'A/FA5S*ZL:(LQN.O<O?VV+QT+KB_NY&PV\+ 2YSWF@W**2Z'+'E'A=!
M8^.:2-E[J&0!UU?O:"6/(%615'FL'NGI5D0IF=4EC<%)$0$! *"/-=<GM)ZY
MA<^YMA996A+,C:!L<O%]>*4>/'M\*C,)1:54M?\ *W5'+Z[<W)0>T8IQ_)\I
M USK=U=P<:>8[ZUWDJH3"V)U=3EF<FW7VG?T1Q^V&^@![,$_@N,=KQ ?2\%>
M+P)!9?B/<=M=NQ6J'- 0$'YXZL^=6<^4+OUSU4]$<GN<NM<RZ!N,SEK1@?DK
MFP=9V =M:V:21CN-PV;&AI/CHD2Q,:M<A@S.J,QV4#)LCFLC*7<+09)9)7DE
MQ_A/4%C1GDL]RV[O.)PL4&7U>UF2S- \6-0ZSA=6HJ-[W#IKYO@*LBJN;)R@
MMXK:-D4$;8H6"C8V -: .@ *2M]4! 0"-A01IS)Y08+7EE)<-B;9:BC:[V6_
MC ;QNZ&S4!XF^^%&82BRFF;PN1T]E;K#9:$P7]G(Z*5A!IYI])IZ6G>#TA5K
MM7J:$U=>:(U-99^T\YD+N"ZAJ>&2!XX7M-#U&H\*0Q*Y.L.8.(TOHO\ :SM&
MS,N86NQ<7$/P\TK>*-HH=HZ74Z%;JJB%*<WFLSJ_.397(O?=Y6^D%&,!=M-
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MHW%I^@JUZ5.[CG#BN80L'N(@RUK);</096%LC#3K\TCRK,(VY+CMW!6*64!
M0<7;O\NI!^=NH/U_E?CEQZURI>AZNE-77.E<?GX[ N9D<M:QV<$[=G9L,G%*
M[Q\/FCQK),/2Y5\NKOF'J-ECYT6&M>&7)W0H"V*NQC*_3OW#RE(C5B9TA=[$
M8;'8+'6^*Q<#;>PM6".&%@H !]$]95JAWT! 0$! 0$! 00!WJ_FUI_Y1?_9W
M*%EE.:K!W%5SR6+_ /+GYAZ<^3[?U85T*);.LL" @("#SL_?#&83(Y,[K*VG
MN33?^!C<_P#@6)9A^>%U<R7EU-=S.XI;B1\TCCO+I'%Q/NE5+TW=V+3\&1U1
MDLW<,#_T7;M;;DBO#-.XBOCX6E2JC;DMBUO"**Q2R@(" @("#JY#&V.5M9;'
M(V\=S9S-X98)6A['#J(*#Q,!R^T;I:X?=X#$06-U(*/GC!+Z';0.<20/ %C1
MG66R <(HLL,H" @_/'5GSJSGRA=^N<JI>B.3RH89;B:."!ADFE<&1QM%7.<X
MT  ZR5@7-Y-<JK30V*9?Y*-DNI[V-K[B:E3 UP![%A\'TQ&\JR(4VMJE4 -%
M!N4D64! 0$!!@BNQ! 7>3T)#?X>+66/B'Z0QQ;%?<(H7VKJT<?L'$>0J%H3K
M*JZ@M>UE=49?,XG$82]F+['"QOCLX_QCRZI\(%&CP!)-%C>0G*:'%6<&LM0V
MX=EKMO%CK>0?U:([GD?5O&T=0\*G6%=K)]:P,K3I-5-6Y(" @("##AQ"B"*N
M>VA8-4Z/N;^VAXLWB&&ZM9&@<3HVD&6,^ MJ[QA1F$JRI>JURQ_==U0YKLMI
M"9U6NID+1IW T#) /<:5.LJ[PLN-P4U8@("#I93$X[-6<N/REM'=V,XX9H)6
MAS' &NT%8T9U>5I[0NDM*OEDT]BH+"2?9+)&"7D5K3B<2:>#<FA,MA:T-% L
ML,H" @(" @\S/8>RS^+O,/D&"6SO87P2L.W8\4!'A!VCPK$LQ+\_<[B;G YK
M(86\%+FPN);:2FXF)Q;4> TJ%6OA(W=[SS\/S$MK,D]CEHI+1[>MU.T9[[4B
M>*-HX+D^;]3[RMU4Z/L@XN-#2J 7"F]8 .J-Z#! <T^;M(Z5D0US.Y06^69+
MG=,PMARWIW%DVC8YA0U+12@?[Q6PV^ZFOLVY.<[CVJN6)OCC2RNSFNC<6/!:
M]IHYIV$$=:W.NKB.,<Q[WR.+I'%[C],XDG8*#:? FD1' FUK<9G5*'+;E%>Z
MI[/,YL/M=/UK&T>;-<;_ $:@T;4;2?(O!N-W%.%>;H>W=IG-I?)PKY>:R>,Q
MMEBK2&PQ\#(+.$<,<3!0  ?1\*TTS,SK+MJ4K2-*QI#O4"PF(" @("!0=2!0
M(,4'4@R@(" @("#%!U(([YB<J\7K.)]Y:!MEGXV'LKEH 9*16C90 :CZX;0O
M5@W,XY\X:C?=MIN8UY6CE/\ %6'-83*:=R,V*S%N;>]A])AV@@[0YIW$'K"W
ME+UO&M7!9]O;!::7C270J305W;!XE.(4S:9X-ZY;<N+O7-\Z68NML%:N'M5R
M-CG..T,CJ"">OJ7DW&X^%'#FV_;>W6W,]4\*QS6FPN&QV"L8\=C+9EM9Q"C(
MV#WSUD])6CM:;3K+O\>.N..FL:0]$@4K3=TJ*QQXJTVT*P,\6TCJ61GI6!E9
M! 0$! 0$! 0$'&1S61N>XT:T$DGH VU04/YK:K?K#6^2R39..QA>;6PWT$$)
M+0=I^F-7*J7HK'!X&FL#>:GSV/T_8"MU?S-A:>AK2:N<? UM248F=%^]-X*T
MTUA;'!V+ VUL8&0,^NX!0N/A<=I5D*9EZRRP(" @(" @(" @(" @(" @(" @
M(" @4'4@I3W@,0,7S.R<K&TBR$<-X/"Y[ UWOM5<KZ<FIZ OW8W6^ O&NX>S
MOH0X_6O=P'WBL0Q/)^@+=RM4LH" @P[<@_.S4'Z_ROQRX]:Y4O0Z,$$UU-';
M6[#+<3/;'%&T5+GN- !XR@O;RQT/%H+2MIAFT=>/_*,A,*>?</'G4/4WT6JV
M(4VG5NJRB(" @(" @(" @@#O5_-K3_RB_P#L[E"RRG-5@[BJUB__ "Y^8>G/
MD^W]6%="B6SK+ @(" @US7\;I=#ZCC8*O=C;R@Z_P#UB68YOS[;Z(\2J7K&]
MU.[B;=ZCL7._#O9;S-'UK2YI]\J=4+K- @[E-4(" @(" @(" @(" @_/'5GS
MJSGRA=^N>JGICDD#NZ8VSR7,F%UW&)?8;.>\MP=S9HWQ,:[R!Y680OR7.H.I
M6*1 0$! 0$!!YF>Q;,SB+_%RM#HKVWD@<#_M&%O3U;UAF'YYWUK+87MQ8S"D
MUM(^%X^NC<056O\ !LG+3'VN4U]IVQO8^UM9;Z$21'<X!W%0^ T2&)Y+]-:U
MH'" !3916J&4! 0$! 0$'![./80""*&O5U(/S\USA?V=UAF\,UI;':7<K(6G
M_5%Q<S^*0JI>B);+R.ROZ+YF89Y-&73I+1_A[9A 'W5%F&+<EX!2@IN5BAE
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MC5=RV9$R"-L%! &@1A@HT-Z*4Z%S3ZE$1IP?0-HZM?(L,N2 @(" @(" @("
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MOVC>$B28UA>?#YK'9W&P9;$SLN[&Y:'Q2QN!!KT'J(Z0=RL4/2600$! 0$!
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MLHX &ROG-CXGGHC?7A?MW;CX%.)5364E![" 0X$':*%21<J@[D! 0$! 0$!
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M1''A"T')W2\^G--":^C,.1R+S/-"\4<Q@V,:>D&FWRKZ7V79S@P:VC2UN/\
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MN=[CGEM?<6>ECK;=CN[+H2WX3?W-_?.Z?PC(6'R-;7^,LZ,=<MFM>0_*JV:
M-/MD<-[I;FZ>3XP9:>\LZ0CU2@KO%Z6T]I7,8&UT]CXL?;S6T[Y60@^<X2,
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MA^6<TU;!P]E#Q#I< 22/!55Y-Y:T:1PA?MNQX<<ZV]J?V)<@ABMXV0P,$<+
M&LC: &M W  = 7A=!#ZHR("#B_T2@A+G+RRDR7'JO3T''>1M'Z0M(FDNE:W_
M $C0-[@-XZ0MCM-QT^S/)S/=^W3ECXE.?C'FKX00:.%'-V$'800MQS]3B9X>
M"3]%<ZLYIN-EAF&NRV,;Z!<ZEPP=0>:U'@<O!FVE;\:\'1;+O5\7LWCJCS\4
MQ8;G%H7*L;QY$6$[Z5BO 8J&FWS_ $??6NMMLE?#5TV+NFWR1[T1Z^#W)=>Z
M*C89/VAQI VGANX7.^Y:\E5QAR?=GZE\[W;Q_KK_ %0U'.<]='XR-PQKI,M<
MC<V%IC97PO>![P*OIM,EN<:0\.?O&WQ\IZI0MJ7FKJW4-]'<B[=8VMN]LMM9
MVKBQC7,((+B-KC4=*V>/:TK&CE]SW;/EMK$],>2R^A]46VK].VN9MB&R/'9W
M45:]G.P#C;[]1X"M)EIT6TEW&UW%<^.+Q_XELJK>L0$! 0$! 0$%>.]1BW28
MC!9EH)]GN9+5YIN;,PO%3XV*%EE%8%!8NAW>LK^DN6MA$Y_%)82S6CATCA=Q
M-]YRLA3;FE921$! 0$! 0$! 0$! 0?*XECA@DFF<&11M+GO<:!K6[22? @HM
MS4U[=:]U3/?%Q;BK0NM\;!7S6Q-<?/IUO.TGJHJIG5?$:0U;"X;(:@REKAL5
M"Z>_O'B.*-HKOWD]0 VD]2"ZO+/E7@^7^/;PQQW6H'@^UY,M\\\6]C*UX6>+
M?TJ<0JFVJ0 P 4'0I(N2 @(" @(*L]ZOYP:=^*7'K&*%EM$#6/\ 7[3\?%\,
M**<\GZ/JUYQ 0$'%VX^)!^=NH/U_E?CEQZURI>A+/=B^?EY\GR^LC4HYH6Y+
M=C<K%0@(" @(" @(" @@#O5_-K ?*+_[.Y0LLIS58.XJM8O_ ,N?F'IWY/M_
M5A70HELZRP(" @(" @(" @("#!:';T'3R&)QN4M);')6T=W9S"DL$S1(QP\(
M=58T9U5CYL\@WX>*XU)HMCIL<RLEUBAQ/DA;M+G1':7,;]2=H4)A9%D!**:<
MN[MS#FPN<&CLE,3BLH[\@XSLANS]**[A(-GV5%*LHWA;)IXA56*7) 0$'YXZ
ML^=6<^4+OUSU4]'@DSNR_O(F^2KKUL"S"-^2X2L4B @(" @(" @H_P ]_P!Z
MF?\ LH/[/&JIYKZ\GG<H_P!Y6F?CT7T4CFQ;DOBK5(@(" @(" @(*E=Z'YZ8
M[X@WUCE7*ZG)#F%_7&.^-0>L:HIOT7;Z(\05SS,H"#YSRM@C=*\AK& N>X[@
MT"I*"D'.'F%/KW5,LL+R,)8$V^.AKYI -'RD;JO(]RBJF=5U8T:5B,3?YW)V
MF(QD)FOKV5L,,;>ESS2IZ@-Y*PDNCRMY3X;0&.9,]C+K4LK2+O(TVBOTD5?1
M;0[:;^E61"F9U2-P@4\"DBR@(" @(""KW>K/_F^G/B]S\-BA991 N+_6=E^/
MB^&%"5J^RL4(9UQR-S4-Q/E=.3NR44KG2S07#V^T@G::.V!^WQ+;X-Y$1I;@
MXW?=FOU3?'/5Z)0]>6=YC[AUK?6\EM<LV/AE:6.'D.U;.MJSRXN8R8K4G2\3
M$O@L\%<:^HWIH:ZLL8^1[8XVE[W&C6-%23X $F8\6:UFW"O%)6C^2^I=1.CN
M<FPXK%NVN?*/P[AL]&,[17K*\67>5K[O-OMIV7)ETF_LU_:L5IK2N'TGCVXS
M#P=E"#Q22$@RR.^J>Z@J5ILF2UYUL[3!MZ8:]-(X/>4'H$! 0$! 0$! 0$!
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M6*A 0$! 0$! 04?Y[_O4S_V4']GC54\U]>3SN4?[RM,_'HOHI'-BW)?%6J1
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M@5D*)>DLL" @_/'5GSJSGRA=^N>JGH\$F=V7]Y$WR5=>M@680OR7"5BH0$!
M0$! 0$%'^>W[U,_]E!_9XU5/-?7D\[E'^\K3/QZ+Z*1S8MR7Q5JD0$! 0$!
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M3ZE(-^T[STKIWR?77B(R()L[N;IOTMFH]OLQMXG.'1Q\9 ]ZJUF_CA'FZO\
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M<_CI/AE=/3W7RG)[\^N?M62[OOS/N?CC_@M6EWOXCN>Q_E_IE+:\3?" @("
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MVVH<G-=LXBYEN7%L#"?J(V^:/<6-5D0[NAN7.I-?7XM<-;\%HW^L9"8.;;Q
M;=K@#4]30FFK$VT;CSNT#AN7UGI;%8IA?++'=OO;R2G:SR Q"KB -@J>$="S
M:-$:SJBFQ_K]I^/B^&U82E^CRM4" @(.+MQ\2#\[=0?K_*_'+CUKE4]"6>[%
M\_+SY.E]9&LU0NMT-RL5,H" @(" @(" @(( [U?S:P'RB_\ L[E"RRG-5@[B
MJUD+_P#+GYAZ<^3[?U85T*)YMG66! 0$!!XFJM+X?5V&GPF:M^VLY^D;'QO
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M$=3Z]U;K&8R9[)S7$1<7,M XLMF'ZV)M&BG72JQJGH^NBN7^H]>9!MEA;>D
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M#MV(/A-96ER VY@9,T;A(T/ \5:H.4=O!"T,BC;'&-S& -:/($'U0$! 0$!
M0$!!\I+6WF9V<T396?4R .'N%8T'&&SM+=O#;PLA:=[8VA@]P461]T! 0$!
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MT4'I<T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!$.M.>6(PCY+#
M3K&Y3(L);),>(6S"-XJ""X_8[/"O;@VEK\9X0T&][SCPZQ3VK?L0AGN8&K=1
MS.?D<E*(CNMX'&*(#J#6G;Y5M*;>E>4.4W'<<^7G.GHAK3W/>[BD<7./2XDG
MWU?HU]IF?%@;-HV*4RQK.KU,9J//8:5LV,R$]L]IJ."1W#Y6[BJ[8J7CC#U8
MMWEQ3[-IU2UH_G]>0/99ZNMQ-!3A&0MVD2@]!>RM"/L0/$M=EV/C7ZG1[3OO
M&*Y8^F$[8O,6&:LHLAB[B.ZLYMK)HCQ ^#P'P+5VK-9TF.+J\>2N2O568F'?
M6$Q 0$!!@FE/"@R%C4%D$! 0$! 0$! 0$! 0":(.+G4W;4$<ZZYO8/2)DL+:
MF1SC?-]FC/X.(_[5_1]B-J]6';6R>B&HWO=,6WX>];RA 6I.96KM32/-Y?.M
MK5VZTM"Z*(#JWEQ\I6VQ[:E/#67'[CNF?-XZ1Y0U)[W/)<\ESCO)-3[Z].GF
MUEIF><L+.J/-](IY[=X?;R/B>-SHW%A]T46)B-.*RN2T<I;_ *5YR:NTV60W
M$HRM@W88;LESVMKMX) 00?LJA>+)M*7Y<);G:]YSXYTM[<?M6&T=KS$ZVL'W
MF*#V20\+;J"9A:Z-[A6G$/-/D*T^7'..=)=GM-W3<5ZJ_2VH;@JWL$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M'-K2T4JL#DL@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M)9! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MYW:;R\$,.;E_1F5+0)0\'V=SZ;2U^V@)Z'+5Y=I>D\.,.PVO=\.6(BT]-O\
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M0$! 0$! 0$! 0$! 0$! 6)%5>>_[P[KXI;?!<M[LOP_I<'WS\Q_M_BL-R_\
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M(" @(" @(" L2*J<]Z_XAW7Q2V^"Y;S9?A_2X/OOYC_;'[UA^7_S)P'Q*#X
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M']MO'A"]6VS?#OQY-1W/9?,XM(]Z.,($Y<ZYN]!YMSIFN=B[DB+(6U/.'"2
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M,VF\#-,Z>7%VLD\CN)\KH6%Q<36M2*U4^NVG-3.&DSKI&KUF@ 4 I107,H"
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; @(" @(" @(" @(" @(" @(" @(" @("#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>lg_mackenziepartners-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_mackenziepartners-bw.jpg
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M%!04%!04%!3_P  1" "R E<# 1$  A$! Q$!_\0 H  !  ,! 0$! 0$
M      <("08%! ," 0$! 0$!                  (! Q   0,# @,% P<'
M!P<)!@<  0(#!  %!A$'(1((,4%A(A-1,A1Q0E(CE!46@6)RTE16&)&",W/3
M%PFA0V,D1-09L=&24X.3-"6EHK(UY3=GH\-%574F)Q$! 0$! 0$
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M3K3SO\);//V*,X$W/+)"+8@ ^<1$?725#CV%*4M*_K*$9G46)2I2@E()43H
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M1C-.3'I2EN.$);2$MM-%1U.F@[?"ABXT[)9>)[?2,MS<,-S[3;%W&],PN9+
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M"D:C7MY60Z#I],496A=$JG=4G5(U@[4K;S;R4ES,W$EJ[79HA2;:E0T+;9'
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MZI"/RT&/D6-=<FOC$-@+FWN\2T--@G5;TJ6X$C4GO4M5'1L=@^*PL'P^QXC
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M[$('%1\-2#&JFV^V^+;5XM%Q3%(OHPV?/(D+T,B5(( 6\\L <RU:?(!HE(
M%$.NH% H*-=?F>>I)QK;:([Y&0J^71L'7ZQ?,Q%!]A"?641^<#144GHI;WH*
MP/[SS"^;@RV@8MBC"WV]2A_MD[7G4@^U#*5)/@Y1-1QU=Y[^.-Z+O'C.^I:L
M:2FQP]/=YXQ)DG3V^NIQ.O>$BC8@FC6CW0Y@7X;VMDY=*:";CELI3S:B-%?
M0BIAD'Y7/66/:%"B*L_1A0*!0*!0*!00=U:9X,&V6O26'0BZY%I8X(U\VDP'
MXA0 .O!A+G'N411L4HZ1,%&;;U6=Z2UZELQQ*[Y+U&J>>*4ICC7LU]=;:M.\
M)-%5J11!040_Q![8&K[@UY"1K*B3XA5PU_U5QEP \-?\^:*BF;33K[J&64*<
M><4$-MH!4I2E'0  <22:*:6]*_3NUM38QE>41TJW"N[(#J%:*^[XJ]%?#I[O
M45P+RAW^4< 2HBU8ZC"@C_>_+_P)M-EN3(6&Y4:WNLPEDZ:2Y>D=@^.CCB3I
M1L9!464&@W058V;7MMDN5R>5G[SNGHJ>60E/PUN82H*)/  *?=_DHFJ_]5._
M[N[.2G',<?4-O[&ZI,0I) GRDZI5*4/H=J60?FZJX%6@-D2CT5;#>NZWO'E<
M;ZEHJ1B<1T>\X"4KFD'N3H4,Z]^JNY!HRU>:B2@4%=.MO_Z%2_\ ^3@?^^JC
M8S-HMZV*R4P\GLDM0)3'GQ72$^]HAY*N'CPH-8M\=L6-W-M[MAY4AJY+"9=G
MDN>ZU/CZEHD\=$JU4VL@<$J-$1DK>;-=,>NTVQWN*N%=K>\N--B.C1;;K9Y5
M)/=V]XX'NHM\T63(A269D1U3$N.M+S#S9*5H<;(4E22.(((U!H-2=@.HO&-X
M+'$@3I3-OW!CM)1<K0XH-F0M"1S/Q0=.="_>*$^9'8>&BE$6)OHPH(YW"WVV
MLVQ:=&49!'%R:!TL\-0E7!2A\WT6R2C7VN<J?&C<0KMIOUN+U![I1H6%QCBV
MV6.K3/OLA:&Y,V6WY@U&<6M*D-^N1[C?F2D*5SD@4;CR^OC._@,8Q_;R(X!(
MO$A5TN*0?,(L/R-)4->Q;JRH>+="*#44]"PV6?D=[MN/VMOU;E=93,*(W])Z
M0X&T#^55!LKBF.0,/QBSXK;!I;[-#8@QR1H5(CMA',K\Y6G,KQ-'-[%!67K>
MP#\4;5-Y7$:Y[IB$D224CF48$LI9D)&GL5Z3A/<E!HV,W*+*#37HQSS\7[.1
M;/*="[IBCZ[4ZDG59BZ>K&4? (46D_U=$5PO7OGAMV*V';R(Z4R+W(-RN*4G
M_9(7E:0H:]BW5<P\6J-B@E%)KZ6;M@&,[J1\MW#N[-IMMDBO/V\O(==]6<Z
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M)[J-BF['2[OY(;]1O")@3KIHX[&:5P_-6\D_Y**U\T[IKWVMX)?P6Y+T /\
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MPK[_ /[DR?M$/^WH:?PK[_\ [DR?M$/^WH:?PK[_ /[DR?M$/^WH:?PK[_\
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M V_=+?$G.MI]U*Y+"'2!X JHYO8H% H% H% H% H% H% H% H% H% H% H%
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MW458ZCJIZF,NVMS"UXA@3T1$I$/XR\N261((5(7HRV 2.4A*"L^T+%"1 O\
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M65?I)GW!"3_L4'W$J'L6\I*AXMT5'E]!>$LVS'\GW/N82R):_NJ#(<\H1$B
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MXDVBZQVY<-X<"6W4Z@*'<H=BD]H.HHAZE H,P^LC._QCO-/MD=SGM>*M(L[
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M3JDR/Z62K](.*](_H47%C^A/!_N+;6XYG);Y9F4S"F.H]\&W<S*".\:NJ?\
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M';9%F)B>J_(Y77%.H6>>0XXLZ\FOO45$(4:VSMLE4VW1)BN7FD,MO'D]W5Q
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EC8LM1A0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
